

Cardiac abnormalities after aneurysmal subarachnoid hemorrhage

Ivo van der Bilt

ISBN: 978-90-9029705-7

Design: Ferdinand van Nispen tot Pannerden, *my-thesis.nl*

Printed by: GVO Drukkers en Vormgevers; Ede; The Netherlands

**Cardiac abnormalities after aneurysmal
subarachnoid hemorrhage**

**Cardiale dysfunctie na een aneurysmatische
subarachnoïdale bloeding**

(met een samenvatting in het Nederlands)

Proefschrift

ter verkrijging van de graad van doctor aan de
Universiteit Utrecht op gezag van de rector magnificus,
prof.dr. G.J. van der Zwaan, ingevolge het besluit van het
college voor promoties in het openbaar te verdedigen op
donderdag 19 mei 2016 des ochtends te 10.30 uur

door

Ivo Adriaan Cornelis van der Bilt

geboren op 1 augustus 1975 te Bergen op Zoom

Promotoren: Prof.dr. G.J.E. Rinkel
Prof.dr. A.A.M. Wilde

Copromotor: Dr. D. Hasan

Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged. Publication of this thesis was also financially supported by Actelion Pharmaceuticals Nederland, Bayer HealthCare, Boehringer Ingelheim BV, Chipsoft BV, Meda Pharma, Pfizer, Philips, Servier, Siemens and St. Jude Medical Nederland.

There is a tide in the affairs of men,
Which, taken at the flood, leads on to fortune;
Omitted, all the voyage of their life
Is bound in shallows and in miseries
On such a full sea are we now afloat,
And we must take the current when it serves,
Or lose our ventures.

Brutus, Shakespeare, Julius Caesar IV.3 210

Dank aan alle patiënten en familieleden
die in de moeilijke tijd na een SAB
toestemming hebben gegeven voor de SEASAH studie

Contents

Contents	Page
Chapter 1 General Introduction	9
Chapter 2 Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage	17
Chapter 3 Cardiac dysfunction after aneurysmal subarachnoid hemorrhage: relationship with outcome	37
Chapter 4 Time course and risk factors for myocardial dysfunction after aneurysmal subarachnoid hemorrhage	53
Chapter 5 Relationship between cardiac dysfunction and cerebral perfusion in patients with aneurysmal subarachnoid hemorrhage	69
Chapter 6 Myocarditis in patients with subarachnoid hemorrhage: a histopathological study	79
Chapter 7 General discussion	93
Summary	109
Samenvatting	115
Dankwoord	121
Curriculum Vitae	131
List of publications	134

CHAPTER 1

General Introduction

Adapted from: van der Bilt IA, Hasan D, Rinkel GJ, Wilde AA, Visser FC.

Rationale of the SEAS study: Serial Echocardiography After Subarachnoid hemorrhage, a prospective national, multicenter, multidisciplinary, cohort study to evaluate cardiac abnormalities following intracranial hemorrhage. *Neth Heart J.*

2006 Nov;14(11):366-371.

In 1902, Harvey Cushing reported that increased intracranial pressure due to cerebral tumors leads to cardiopulmonary dysfunction.¹ Since this early observation, it gradually became established that cardiac dysfunction may occur following several forms of physical,²⁻⁵ and emotional stress.^{6,7} This dysfunction typically occurs in the absence of coronary artery disease, is mostly reversible and consists of myocardial wall motion abnormalities (WMA), electrocardiographic (ECG) changes, elevated serum markers for myocardial damage (troponin, CK-MB, BNP), and histopathological changes.⁸

The last few years, reported incidence of- and interest in this stress induced cardiomyopathy have significantly increased. Especially cases of Takotsubo cardiomyopathy (TC) have been reported rather frequently. TC is a transient stress induced myocardial dysfunction typically affecting the apex of the left ventricle, with hyperkinesia of the basal segments. This leads to dyskinesia or “ballooning” of the apex. The characteristic left ventricular angiographic or echocardiographic image has similarities with the shape of a Japanese octopus trap. In Japanese “Tako” means octopus and “Tsubo” means trap, hence the term: “Takotsubo cardiomyopathy”. Other commonly used terms are apical ballooning, stress cardiomyopathy and broken heart syndrome.^{6,7} Furthermore, several authors have also reported stress induced wall motion abnormalities without the typical apical ballooning shape, but with diffuse WMA, midventricular ballooning, basal ballooning and other patterns. Typical ECG changes in stress cardiomyopathy are ST-segment changes, T wave changes, prominent U-waves and QTc prolongation.^{9,10} Transient Q-waves have also been reported.¹¹ In addition, arrhythmias consisting of ventricular tachycardia, ventricular fibrillation, atrial fibrillation, and atrial tachycardia have been described.^{12,13} Serum Troponin, N-terminal portion of proBrain Natriuretic Peptide (NT-pro-BNP) and CK-MB may be elevated,¹⁴⁻¹⁶ as the result of cellular degradation.

Stress induced cardiomyopathy has also been reported quite frequently after aneurysmal subarachnoid hemorrhage (aSAH), a devastating neurological disease which carries a poor prognosis. An aSAH is caused by rupture of an intracranial aneurysm, causing acute sympathetic stress. Following this rupture, blood spurts into the subarachnoid space under arterial pressure, continuing until increased local or generalized intracranial pressure stops the bleeding. The annual incidence of aSAH adjusted for age and sex, is 7.8-23.0 per 100,000 population.¹⁷ In a systematic review case fatality after aSAH was reported between 32 and 67%,¹⁸ mainly caused by the

initial bleeding and complications such as rebleeding or delayed cerebral ischemia. Apart from neurological complications, non-neurological complications occur after aSAH, of which pulmonary and cardiac complications are the most important. To further investigate the incidence and prognostic meaning of stress cardiomyopathy in aSAH we launched a nationwide, multicenter, multidisciplinary cohort study called Serial Echocardiography After SubArachnoid Hemorrhage (S.E.A.S.A.H.).

The study objectives were: first, to assess the incidence of cardiac abnormalities, defined as ECG changes, echocardiographic systolic and diastolic function abnormalities and cardiac specific enzyme and protein elevations in patients with aSAH. Second, to determine clinical variables that may predict the occurrence of cardiac abnormalities following aSAH. Third, to assess the impact of cardiac abnormalities on outcome at 3 months.

Patients who were admitted within 72 hours after an aSAH were eligible for inclusion in the study. An aneurysm had to be confirmed by angiography or CT angiography. On admission and at 4 and 8 days after onset of symptoms cardiac evaluation was performed using echocardiography, electrocardiography and blood sampling. Clinical parameters such as medical history, neurological condition on admission (Glasgow Coma Scale (GCS),¹⁹ World Federation of Neurosurgeons Score (WFNS),²⁰ amount of blood on CT-scan (Hijdra score), medication, intracranial- (delayed cerebral ischemia, rebleeding, hydrocephalus) and extracranial- or systemic complications (pulmonary edema, pneumonia, cerebral salt wasting), and type of treatment (surgical or endovascular) were obtained. Finally, outcome at 3 months by means of the Glasgow Outcome Scale (GOS)²¹ was assessed.

Transthoracic echocardiography was the standard examination. All echocardiographic examinations were performed according to the American Heart Association standards. The cross sections and the segments were recorded for off-line analysis. A minimum of three heart cycles was recorded. Two investigators (independent from each other and unaware from the clinical data of the patient) analyzed the echocardiogram for assessment of global and regional left ventricular function. Diastolic function was determined using E/A ratios and pulmonary vein flow.

All ECGs were analyzed by one investigator, who was unaware of the clinical data of the patient. Criteria for the ECG abnormalities were defined according to the

guidelines of the European Society of Cardiology. A Q-wave in two contiguous leads was considered pathological when $\geq 0.03s$ wide and $\geq 0.1mV$ deep. ST deviation was considered to represent myocardial ischemia when ST elevation occurred at the J-point in two contiguous leads with the cut-off points: ≥ 0.2 mV in men or ≥ 0.15 mV in women in leads V2–V3 and/or ≥ 0.1 mV in other leads. Horizontal or down-sloping ST depression ≥ 0.05 mV in two contiguous leads; and/or T inversion ≥ 0.1 mV in two contiguous leads with prominent R-wave or R/S ratio >1 were also considered ischemic changes. The Cornell voltage criteria ($RaVL+SV3 > 28$ mm (men) or > 20 mm (women)), or Sokolow-Lyon voltage index ($SV1+RV5/6 > 35$ mm for left ventricular hypertrophy) were used.

The diagnostic brain CT-scan was used for analysis. The amount of blood in 13 individual cerebral cisterns on each CT was scored: a score of 0 = no blood; 1 = cistern partially filled with blood; and 2 = completely filled with blood. Subsequently, the sum score (ranging from 0 to 26) for each CT was calculated. A sum score greater than 13 was regarded as a “high cisternal blood score”.

A neurological examination was conducted on admission, on a daily basis, and after every deterioration of clinical condition. The level of consciousness was assessed by means of the 15-point Glasgow Coma Scale.

Prognosis was defined as death or dependency using the GOS. The follow-up period was defined as the time interval between entering the study and 3 month after onset of the aSAH.

Before we conducted the SEASAH study, we first performed a meta-analysis of the available literature from 1960 to 2007 regarding cardiac dysfunction after aneurysmal subarachnoid hemorrhage. This meta-analysis can be found in **Chapter 2** of this thesis. As most of the included studies were of small sample size, different study design and retrospective, questions remained. Therefore, in **Chapter 3** we describe the results of the SEASAH study. In this chapter we describe the incidence and prognostic significance of cardiac abnormalities after aSAH. In **Chapter 4** we describe the time course and risk factors of the myocardial dysfunction after aSAH. We found that WMA may be present on admission or develop during the course of aSAH. In **Chapter 5** we describe a study where we found that aSAH patients with cardiac dysfunction have an impaired cerebral perfusion measured with perfusion CT. This

supports the hypothesis that aSAH patients with cardiac dysfunction have a higher risk of DCI. In **Chapter 6** we describe a histopathological study of myocardium of patients who died from aSAH. Finally, **Chapter 7** summarizes the findings of this thesis, places it into the context of current knowledge and literature and suggests direction of further research.

Reference List

1. Cushing H. The blood pressure reaction of acute cerebral compression illustrated by cases of intracranial hemorrhage. *Am J Med Sci* 1903;125:1017-1044.
2. Mayer SA, Fink ME, Homma S, Sherman D, LiMandri G, Lennihan L, Solomon RA, Klebanoff LM, Beckford A, Raps EC. Cardiac injury associated with neurogenic pulmonary edema following subarachnoid hemorrhage. *Neurology* 1994 May;44(5):815-820.
3. Cheung RT, Hachinski V. Cardiac Effects of Stroke. *Curr Treat Options Cardiovasc Med* 2004 June;6(3):199-207.
4. Oppenheimer SM. Neurogenic cardiac effects of cerebrovascular disease. *Curr Opin Neurol* 1994 February;7(1):20-24.
5. Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa M, Yoshiyama M, Miyazaki S, Haze K, Ogawa H, Honda T, Hase M, Kai R, Morii I. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. *J Am Coll Cardiol* 2001 July;38(1):11-18.
6. Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC. Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med* 2005;10(352):539-548.
7. Sharkey SW, Lesser JR, Zenovich AG, Maron MS, Lindberg J, Longe TF, Maron BJ. Acute and reversible cardiomyopathy provoked by stress in women from the united states. *Circulation* 2005;111(4):472-479.
8. van der Bilt IA, Hasan D, Vandertop WP, Wilde AA, Algra A, Visser FC, Rinkel GJ. Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis. *Neurology* 2009 February 17;72(7):635-642.
9. Brouwers PJ, Wijdicks EF, Hasan D, Vermeulen M, Wever EF, Frericks H, van Gijn J. Serial electrocardiographic recording in aneurysmal subarachnoid hemorrhage. *Stroke* 1989 September;20(9):1162-1167.
10. Mayer SA, LiMandri G, Sherman D, Lennihan L, Fink ME, Solomon RA, DiTullio M, Klebanoff LM, Beckford AR, Homma S. Electrocardiographic markers of abnormal left ventricular wall motion in acute subarachnoid hemorrhage. *J Neurosurg* 1995 November;83(5):889-896.
11. Bybee KA, Kara T, Prasad A, Lerman A, Barsness GW, Wright RS, Rihal CS. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. *Ann Intern Med* 2004 December 7;141(11):858-865.
12. Andreoli A, Di Pasquale G, Pinelli G, Grazi P, Tognetti F, Testa C. Subarachnoid hemorrhage: frequency and severity of cardiac arrhythmias. A survey of 70 cases studied in the acute phase. *Stroke* 1987 May;18(3):558-564.
13. Di Pasquale G, Pinelli G, Andreoli A, Manini G, Grazi P, Tognetti F. Holter detection of cardiac arrhythmias in intracranial subarachnoid hemorrhage. *Am J Cardiol* 1987 March 1;59(6):596-600.
14. Khush K, Kopelnik A, Tung P, Banki N, Dae M, Lawton M, Smith W, Drew B, Foster E, Zaroff J. Age and aneurysm position predict patterns of left ventricular dysfunction after subarachnoid hemorrhage. *Journal of the American Society of Echocardiography* 2005 February;18(2):168-174.
15. Tung P, Kopelnik A, Banki N, Ong K, Ko N, Lawton MT, Gress D, Drew B, Foster E, Parmley W, Zaroff J. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. *Stroke* 2004 February;35(2):548-551.
16. Miss JC, Kopelnik A, Fisher LA, Tung PP, Banki NM, Lawton MT, Smith WS, Dowd CF, Zaroff JG. Cardiac injury after subarachnoid hemorrhage is independent of the type of aneurysm therapy. *Neurosurgery* 2004 December;55(6):1244-1251.
17. van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and Management. *Brain* 2001;124:249-278.
18. Hop JW, Rinkel GJE, Algra A, vanGijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage - A systematic review. *Stroke* 1997 March;28(3):660-664.
19. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. *Lancet* 1974 July 13;2(7872):81-84.

20. Teasdale GM, Drake CG, Hunt W, Kassell N, Sano K, Pertuiset B, De Villiers JC. A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. *J Neurol Neurosurg Psychiatry* 1988 November;51(11):1457.
21. Jennett B, Bond M. Assessment of outcome after severe brain damage. *Lancet* 1975 March 1;1(7905):480-484.

CHAPTER 2

Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage.

van der Bilt IAC, Hasan D, Vandertop WP, Wilde AAM, Algra A, Visser FC, Rinkel GJE Impact of Cardiac Complications on Outcome after Aneurysmal Subarachnoid Hemorrhage. *Neurology*. 2009 Feb 17;72(7):635-42

Abstract

Impact of cardiac complications after aneurysmal subarachnoid hemorrhage (SAH) remains controversial. We performed a meta-analysis to assess whether ECG changes, myocardial damage, or echocardiographic wall motion abnormalities (WMAs), are related to death, poor outcome (death or dependency) or delayed cerebral ischemia (DCI) after SAH.

Methods: Articles on cardiac abnormalities after aneurysmal SAH that met predefined criteria, and were published between 1960 and 2007 were retrieved. We assessed quality of reports, and extracted data on patient characteristics, cardiac abnormalities, and outcome measurements. Poor outcome was defined as death or dependence by the Glasgow Outcome Scale (dichotomized at ≤ 3), or the modified Rankin scale (dichotomized at >3). If studies used another dichotomy or another outcome scale, we used the numbers of patients with poor outcome provided by the authors. We calculated pooled Relative Risks (RR) with corresponding 95% CI for the relation between cardiac abnormalities and outcome measurements.

Results: We included 25 studies (16 prospective), totaling 2690 patients (mean age 53 years; 35% men). Mortality was related with WMAs (RR:1.9), elevated troponin (RR:2.0) and BNP levels (RR:11.1), tachycardia (RR:3.9), Q waves (RR:2.9), ST-depression (RR:2.1), T-wave abnormalities (RR:1.8), and bradycardia (RR:0.6). Poor outcome was associated with elevated troponin (RR:2.3), CK-MB levels (RR:2.3), and ST-depression (RR:2.4). Occurrence of DCI was associated with WMAs (RR:2.1), elevated troponin (RR:3.2), CK-MB (RR:2.9), and BNP levels (RR:4.5) and ST-depression (RR:2.4). All RR were significant.

Conclusion: Markers for cardiac damage and dysfunction are associated with an increased risk of death, poor outcome, and DCI after SAH. Future research should establish whether these cardiac abnormalities are independent prognosticators and should be directed towards pathophysiological mechanisms and potential treatment options.

Introduction

Case fatality after aneurysmal subarachnoid hemorrhage (SAH) is reported from 30% to 50%.¹ The main causes of death are the impact of the initial bleeding and neurological complications, such as rebleeding and delayed cerebral ischemia (DCI). Apart from the neurological complications, cardiac abnormalities occur frequently after SAH. These abnormalities include ECG changes, elevated biochemical markers of myocardial damage and heart failure, and decreased left ventricular function.

We hypothesized that cardiac abnormalities following SAH are related to the occurrence of death, poor outcome, and DCI. Therefore, we performed a meta-analysis on observational studies to assess the associations of cardiac complications with death, poor outcome, and DCI following aneurysmal SAH.

Materials and Methods

Search Strategy

Three investigators (I.B., D.H., and F.V.) independently performed a systematic search for studies regarding SAH accompanied by cardiac abnormalities, published between January 1960 and January 2007, using the electronic search engine PubMed. The following keywords were used: SAH* OR SAB* OR subarachnoid haemorrhage* OR subarachnoid hemorrhage* OR subarachnoid bleed* OR subarachnoid blood* OR intracranial aneurysm* OR intracranial bleed*. All these keywords were combined with the keywords: ECG*, electrocardiographic*, electrocardiography*, echocardiography*, echocardiographic, stunning*, myocardial damage*, myocardial necrosis*, left ventricular dysfunction*, LV dysfunction*, takotsubo*, apical ballooning*, CK*, CPK*, CK-MB*, MB*, troponin, BNP*, brain natriuretic peptide*, NT-pro-BNP* in different combinations.

Reference lists were manually cross-checked for additional publications. This procedure was followed until no additional studies were found. Because many publications were more than ten years old, no efforts were made to contact authors in case of missing data.

Eligibility

Two investigators (I.B. and D.H.) assessed eligibility of studies independently. Criteria for inclusion of studies in this review were: publication after 1960 in the English, French or German language. All studies had to report on cardiac abnormalities and outcome following aneurysmal SAH. Cardiac abnormalities were defined as echocardiographic wall motion abnormalities (WMAs), diastolic dysfunction, or biochemical evidence of myocardial damage (defined as elevated troponin levels, or elevated CK-MB levels), or elevated brain natriuretic peptide levels (BNP and NT-pro-BNP), or ECG changes. SAH had to be documented by either CT scanning or cerebrospinal fluid examination. Studies with less than ten patients, case reports, and reviews were excluded.

To avoid selection bias, only studies that included consecutive patients were eligible. When a study group published more articles on the same dataset, only the report with the largest number of patients was eligible for data extraction.

Quality assessment of studies

To systematically assess the quality of the studies, we modified the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) checklist (<https://www.strobe-statement.org>). Although this checklist is designed to improve the reporting of observational studies for optimal data extraction and interpretation, we used the list as a quality assessment tool. For every article, each of the 22 STROBE items was assigned a zero or one by two independent observers (I.B. and F.V.), and summed as the STROBE score. Several STROBE items consist of sub-items. These sub-items were also scored as zero or one and averaged. Disagreement was solved by direct communication between the two observers. The following items were assessed: cohort identification in title or abstract possible (item 1a), abstract informative and addressing key items (item 1b), background/rationale reported (item 2), objectives given with hypothesis (item 3), study design given (item 4), setting, locations and data collection period given (item 5), in- and exclusion criteria given and sources and methods of selection of patients given (item 6a), period and methods of follow-up given (item 6b), variables of interest defined (cardiac data and outcome measures) (item 7), method of assessment of variable of interest given (item 8a), comparability of assessment methods across groups given (item 8b), sources of bias given (item 9), rationale for sample size given (item 10), statistical methods given (item 11a), missing data described (item 11b), subgroup- and sensitivity analysis given (item 11c), analysis of quantitative variables given (item 12a), continuous and grouped

analysis presented (item 12b), source of funding and role of funders presented (item 13), number of patients at each stage of the study given (14a), reasons for non-participation given (item 14b), period of recruitment defined (item 14c), baseline characteristics given (item 15a), completeness of data for each baseline variable given (item 15b), average and total amount of follow-up given (item 15c), number of outcome events presented (item 16), association between determinants and outcomes given (item 17a), categories of quantitative variables compared (item 17b), absolute outcome data given (item 17c), subgroup analysis performed (item 18), key results summarized (item 19), limitations discussed (item 20), external validity of study findings discussed (item 21), overall interpretation of the results given (item 22).

Data Extraction

The three investigators who assessed quality and eligibility reviewed the publications independently. In case of disagreement, the authors reviewed the article in question together until consensus was reached. The following data were extracted: author, year of publication, study design (prospective or retrospective), definition of inclusion and exclusion criteria, number of included patients, gender, mean age, and follow-up period. The neurological condition on admission was dichotomized as good or poor according to the scoring system used in the particular article: Hunt-Hess², World Federation of Neurosurgical Societies (WFNS)³, Glasgow Coma Scale (GCS)⁴, or Botterell⁵. A poor condition on admission was considered when Hunt-Hess ≥ 3 , or WFNS ≥ 3 , or GCS < 12 , or Botterell ≥ 3 . Additionally, if an article did not use any of these scoring systems or used different criteria for poor outcome, the clinical condition reported by the authors was recorded.

As determinants we extracted the incidence of WMAs, diastolic dysfunction, elevated troponin levels, elevated (NT-pro)-BNP levels, elevated CK-MB levels, atrial fibrillation, tachycardia, bradycardia, wandering P, extrasystoles, peaked P, P mitrale, short PR interval, long PR interval, bundle branch block (BBB), pathological Q waves, ST segment depression, ST segment elevation, T wave changes (inverted or flat), U wave changes (present, inverted or prominent), left ventricular hypertrophy (LVH), and prolonged QT time. Combined ECG criteria were disregarded, because the separate ECG abnormalities may harbor different prognostic value. For outcome measurements we recorded the number of deaths from any cause, the number of patients with poor outcome, and the number of patients with DCI. Poor outcome was defined as death or dependence on activities of daily living, preferably defined by means of a handicap scale such

as the Glasgow Outcome Scale (dichotomized at ≤ 3), or the modified Rankin scale (dichotomized at >3). If studies used another dichotomy or another outcome scale, we used the numbers of patients with poor outcome provided by the authors, without adjusting to our preferred definition of poor outcome.

Several studies used different definitions of DCI. Given this heterogeneity of definitions, we recorded the number of patients with DCI as given by the authors, without adjusting these numbers to a predefined definition of DCI.

Data analysis


The relation between the three outcome measures and the 22 determinants was analyzed. The crude proportions of the extracted variables were calculated. Cross-tables were made to calculate Risk Ratios (RR) for each determinant and outcome in each article. The pooled RRs with their corresponding 95% confidence intervals (95% CI) were calculated by means of Cochrane's Review Manager 4.2. Using the same program, statistical heterogeneity of the effects was tested. This is indicated as I^2 . A value greater than 50% may be considered substantial heterogeneity.⁶

Results

Study Characteristics

In the initial PubMed search 2169 studies were found that reported on cardiac abnormalities after aneurysmal SAH (figure 1).

Figure 1: Search strategy explained.



Pts: patients. WMAs: echocardiographic wall motion abnormalities, DCI: delayed cerebral ischemia, BNP: brain natriuretic peptide.

After title screening and detailed abstract evaluation, 86 studies were selected. After detailed full paper evaluation, 25 studies were included in this meta-analysis.

Baseline Characteristics

Table 1 presents the baseline characteristics of patients included in the analysis.

A total of 2690 patients were included. In the 21 studies where gender distribution was reported, the mean percentage of men was 35%. Mean age varied from 36 to 59 years, with a weighted mean of 53 years (21 studies).

Sixteen studies were prospective, nine were retrospective. The STROBE score varied from 11 to 20 with a median of 17. In 15 studies, data on the neurological condition on admission were available. The proportion of patients with a poor neurological condition on admission varied from 23% to 68%, with a mean of 49% (15 studies). The follow-up duration (for outcome assessment) varied from follow-up during hospital stay (14 studies) to six months follow-up. The proportion of patients who died during the observation period varied from 8% to 38% with a mean of 22% (18 studies). The percentage of patients with poor outcome varied from 16% to 63% with a mean of 46% (seven studies). Finally, the percentage of patients with DCI varied from 8% to 44% with a mean of 23% (ten studies). As stated earlier, the definition of DCI varied. ⁷scored temporary focal neurological signs as DCI, ⁸ equated imaging signs of vasospasm with DCI, ¹⁰used neurological deterioration with imaging evidence of spasms, ¹¹⁻¹⁴ used neurological deterioration with exclusion of other causes (using CT), ¹⁵ used neurological deterioration and imaging evidence of spasms or CT evidence of infarction. ¹⁶did not use a clear definition (clinical vasospasm).

Table 2 shows the proportions of patients with cardiac abnormalities: WMAs varied from 13% to 31% of the patients with a mean of 22% (nine studies). Diastolic dysfunction was reported in one study, in 71% of patients. Elevated troponin levels were reported in 21% to 50% of patients with a mean of 34% (six studies). CK-MB presence varied from 13% to 60% with a mean of 33% (six studies). Three studies reported elevated BNP levels, but each used different criteria for BNP elevation. Using these different criteria, elevated BNP levels were found between 9% and 100%.

Table 2: Prevalence of cardiac abnormalities.

<i>Reference</i>	<i>WMA n (%)</i>	<i>Diastolic dysfunction n(%)</i>	<i>↑ troponins n (%)</i>	<i>↑ CK-MB n (%)</i>	<i>↑ BNP n(%)</i>
31	-	-	-	-	-
32	-	-	-	-	-
33	-	-	-	-	-
7	-	-	-	7(44)	-
34	-	-	-	7(41)	-
35	-	-	-	-	-
20	-	-	-	7(30)	-
36	4(31)	-	-	-	-
8	-	-	-	30(60)	-
10	2(15)	-	-	-	13(100)
11	9(13)	-	-	15(21)	-
28	-	-	-	-	-
9	5(13)	-	8(21)	5(13)	-
27	-	-	-	-	-
16	7(16)	-	12(28)	-	-
37	-	-	-	-	-
12	-	-	-	-	17(45)*
29	-	-	-	-	-
38	-	146(71)	-	-	-
13	55(22)	-	126(50)	-	-
30	-	-	35(51)	-	-
39	48(28)	-	41(24)	-	-
40	79(26)	-	-	-	-
14	-	-	-	-	-
15	45(19)	-	52(22)	-	14(9) †
Total	254/1141(22)	146/223(71)	274/811(34)	71/217(33)	44/286(15)

*: BNP ratios were used. †: BNP levels > 600pg/ml was used as cut-off value.

Table 3 summarizes prevalence of any ECG abnormality that was reported in the studies. T wave changes were the most frequently observed ECG abnormality (22%), whereas pathological Q waves were present in 1%.

Relation of determinants with outcome


Figure 2A shows the pooled RRs and corresponding 95% CI of the defined cardiac abnormalities for death.

Table 3: Prevalence of ECG abnormalities.

Ref.	AF n(%)	Tachy n(%)	Brady n(%)	Wand P n(%)	Extrasys n(%)	Peaked P n(%)	P mitrale n(%)	Short PR n(%)	Long PR n(%)	BBB n(%)	Path. Q n(%)	ST depr. n(%)	ST elev.n(%)	ΔT wave n(%)	ΔU wave n(%)	LVH n(%)	ΔQT n(%)
31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11(10)	-
32	-	-	6(30)	2(10)	-	-	-	-	-	-	0(0)	-	-	10(50)	2(10)	-	5(25)
33	-	10(10)	32(32)	-	5(5)	2(2)	-	1(1)	3(3)	12(12)	3(3)	9(9)	7(7)	34(34)	28(28)	-	21(21)
7	1(6)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	7(9)	7(9)	21(28)	-	8(11)	2(3)	3(4)	4(5)	2(3)	9(12)	6(8)	15(20)	-	13(17)	3(4)	-	8(11)
20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	-	-	-	-	-	-	1(8)	-	-	1(8)	-	-	-	5(39)	-	-	-
8	4(8)	-	-	-	-	-	-	16(32)	-	-	-	18(36)	-	7(54)	4(8)	-	4(8)
10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2(15)
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	-	-	4(1)	-	-	-	-	-	-	-	8(3)	13(4)	9(3)	48(15)	-	-	-
9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6(15)
16	2(5)	7(16)	2(5)	-	-	-	-	-	-	8(7)	8(7)	35(29)	10(12)	21(17)	7(6)	-	-
37	-	-	26(27)	-	-	-	-	-	-	9(21)	5(12)	5(12)	1(2)	11(26)	4(9)	-	5(12)
12	-	-	-	-	-	-	-	-	-	-	-	5(5)	7(7)	15(16)	16(17)	27(28)	24(25)
29	-	9(6)	17(11)	-	-	2(1)	4(3)	-	2(1)	6(4)	16(10)	9(6)	21(13)	32(20)	28(18)	-	36(23)
38	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	-	-	-	-	-	-	-	-	-	-	-	17(14)	10(8)	38(31)	63(52)	-	16(13)
15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total	14/185(8)	33/378(9)	108/808(13)	2/20(10)	13/176(7)	6/335(2)	8/248(3)	21/226(9)	7/335(2)	37/391(9)	47/846(1)	126/1081(12)	65/872(7)	234/1077(22)	155/788(20)	38/203(19)	127/718(18)

AF: Atrial fibrillation. Tachy: tachycardia. Brady: Bradycardia. Wand P: Wandering P wave. Extrasys: Extrasystole. BBB: bundle branch block. Path. Q: Pathological Q wave. ST Depri.: ST segment depression. ST Elev.: ST segment elevation. ΔT wave: T wave abnormality. ΔU wave: U wave abnormality. LVH: left ventricular-hypertrophy. ΔQT : prolonged QT interval.

Figure 2: Presentation of Risk Ratios (RR) for outcome measures.



Literature references for the studies used are given next to the determinants. For some determinants no I² is given because data are derived from one study. Panel A shows RRs for cardiac abnormalities and the occurrence of death. Panel B shows RRs for cardiac abnormalities and poor outcome. Panel C shows RRs for cardiac abnormalities and the occurrence of delayed cerebral ischemia. * indicates that these data are derived from one study that only provided Hazard ratios (HR) without raw data. Therefore, we used the HR in approximation of the RR.

Additionally, heterogeneity of the data (I^2) is presented. WMAs, elevated troponin and (NT-pro-)BNP levels, tachycardia, Q waves, ST depression and T wave abnormalities were significantly associated with an increased risk of death. Bradycardia was significantly associated with a higher chance of survival. However, Q waves and ST depression had significantly heterogeneity.

Figure 2B shows the poor outcome data. Elevated troponin and CK-MB levels and ST depression were significantly associated with poor outcome.

Figure 2C presents the pooled RRs for cardiac abnormalities on DCI. WMAs, elevated troponin, CK-MB, and (NT-pro)BNP levels and ST depression were significantly associated with an increased risk of the development of DCI. Heterogeneity for the association of DCI and troponin and BNP levels was high.

Discussion

This meta-analysis patently indicates that cardiac abnormalities after SAH are related to death, poor outcome and DCI. Although the main causes of death and poor outcome after SAH are the initial hemorrhage and neurological complications, we found that also WMAs, troponins, CK-MB, BNP, Q waves, ST depression and T wave abnormalities are associated with death and poor outcome. These markers for cardiac damage and dysfunction are often present after SAH, and are similar to those observed in ischemic heart disease, but the underlying pathophysiological mechanism is probably different.

Several mechanisms for the occurrence of cardiac complications after SAH have been suggested, but none is proven. However, a generally accepted hypothesis is that sympathetic stimulation induces catecholamine release in the myocardium, which may lead to impaired systolic and diastolic function, repolarization abnormalities, and myocardial damage.

In ischemic heart disease, QT prolongation and ST segment elevation are associated with death. Against our expectations, these ECG abnormalities were not associated with death or poor outcome in patients with SAH. Possible explanations for the lack of association are that criteria used for QT prolongation in the articles were heterogeneous and arrhythmias as a cause of death were not reported in the studies. Bradycardia was associated with decreased risk of death. This corroborates with the results of several publications that suggest a beneficial effect of beta-blockade on outcome after SAH.¹⁷⁻²⁰ However, it is unclear whether this beneficial

effect was due to decrease of heart rate or due to systemic or neuroprotective effects of the beta-blockade. In contrast, tachycardia was associated with higher risk of death. Tachycardia may be a sign of poor hemodynamic condition or inotropic stimulation. Additionally, the presence of a P mitrale, a sign of left atrial dilatation, was associated with death. This abnormality may also represent a poor hemodynamic condition.

We also found a relation between cardiac abnormalities and DCI after SAH. DCI is a complication that occurs in around 30% of patients with SAH, usually between four to 12 days after the SAH,²¹ and is an important contributor to poor outcome. In contrast to thrombo-embolic stroke, which has a sudden onset, is unifocal, and usually does not affect consciousness, DCI usually has a gradual onset with often waxing and waning focal deficits, a decreasing level of consciousness, or both, and often is multifocal. The pathogenesis of DCI has not been elucidated yet, but is often attributed to vasospasm of the intracranial arteries. However, vasospasm cannot be the only initiator of DCI, as one third of patients severe vasospasm do not develop DCI, and one third of patients with DCI do not have vasospasm.²² Powerful and independent predictors are the duration of loss of consciousness at time of the ictus and the total amount of extravasated blood,²³ and the occurrence of hypovolemia and hypotension.²⁴ Because many patients with SAH have narrowed arteries and hypovolemia, and also because autoregulation of cerebral perfusion is disturbed after SAH,^{25, 26} left ventricular dysfunction may directly affect cerebral perfusion. This is a potential explanation for the finding that cardiac abnormalities are also related to DCI. With this respect, not only the presence but also the degree of the cardiac abnormality may influence outcome. This notion is supported by the finding of a linear relation between the BNP levels and vasospasm severity.¹² Additionally, the degree of troponin elevation has been associated with poor outcome.¹³

Although an association has been established, it remains unclear whether a definite causal relation exists between cardiac abnormalities and outcome after SAH. Several studies have found an independent effect of cardiac abnormalities on outcome, adjusted for clinical variables,^{11, 15, 27} whereas others did not.^{14, 28-30}

Caution should be perceived when interpreting these results due to shortcomings of the included studies. First, the included studies were published over a period of more than 40 years. During this period, diagnosis and treatment of SAH has improved with decreased case fatality rates,¹ possibly affecting prevalence and consequence of cardiac complications on outcome.

Second, reference values of cardiac markers were not given in all studies. Abnormal BNP levels were differently defined in the three studies that used BNP as prognosticator.

One study defined QT prolongation as more than 410 milliseconds, whereas others have used a cut-off value of more than 460 milliseconds. T wave abnormalities included both T wave inversion and T wave flattening. U waves were defined as present, greater than 1 mm or as negative U waves. Moreover, some studies did not provide criteria for abnormalities at all. This obviously might influence reported prevalence of cardiac abnormalities and influence effect of cardiac abnormalities on outcome.

Third, most studies investigated echocardiography, biochemical markers and ECG abnormalities separately. Therefore, the relative contribution and incremental prognostic value of the different cardiac abnormalities is uncertain. The combinations of several ECG abnormalities have been studied, and three studies found that the combination of different ECG abnormalities better predicts prognosis than the individual variables alone.

Fourth, as the cardiac abnormalities are reversible, with unknown time course, the timing of cardiac evaluation could influence results. Only a few of the included studies performed serial cardiac studies with predefined time intervals. The importance of the timing of cardiac investigations in relation to the outcome of SAH is highlighted in one study, in which the authors found a difference in prognostic value of elevated troponin levels on day four versus day nine after onset of SAH. LV dysfunction showed the same trend, although the criteria for LV dysfunction were different between these two days.

Fifth, the baseline characteristics of the included studies and the prevalence of the cardiac determinants and outcomes showed a large variation. Percentage of men varied from 22 to 62%, follow-up duration varied from in-hospital follow-up to six months, and poor condition on admission varied from 23 to 68%. This might indicate differences in study populations and therefore influences results.

Six, the quality of the included articles varied as reflected in the STROBE score, which varied between 11 and 20 points (out of 22 points) with a median of 17. This may also partly explain the heterogeneity of results.

Finally, the heterogeneity of the different clinical severity scores and the thresholds used to dichotomize the various scales and the timing of the assessment may be a factor.

The shortcomings of the included studies stress the need for large prospective, observational studies with clearly defined methodology, sufficient sample size, and long-term follow-up to assess whether cardiac abnormalities have independent prognostic value after SAH.

Future research should establish an independent prognostic value of cardiac abnormalities and be directed towards elucidating the pathophysiological mechanisms, and potential treatment options. In conclusion, our findings support the view that cardiac abnormalities following SAH are related to higher risk of death, poor prognosis, and DCI.

Reference List

- 1 Hop JW, Rinkel GJ, Algra A, Van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. *Stroke* 1997 Mar;28:660-664.
- 2 Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. *J Neurosurg* 1968 Jan;28:14-20.
- 3 Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. *J Neurosurg* 1988 Jun;68:985-986.
- 4 Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. *Lancet* 1974 Jul 13;2:81-84.
- 5 Botterell EH, Loughheed WM, Scott JW, Vanderwater SL. Hypothermia, and interruption of carotid, or carotid and vertebral circulation, in the surgical management of intracranial aneurysms. *J Neurosurg* 1956 Jan;13:1-42.
- 6 Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, UK: 2005.
- 7 Fabinyi G, Hunt D, McKinley L. Myocardial creatine kinase isoenzyme in serum after subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry* 1977 Aug;40:818-820.
- 8 Maiuri F, Benvenuti D, Carrieri P, Orefice G, Carbone M, Carandente M. Serum and cerebrospinal fluid enzymes in subarachnoid haemorrhage. *Neurol Res* 1989 Mar;11:6-8.
- 9 Parekh N, Venkatesh B, Cross D, et al. Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. *J Am Coll Cardiol* 2000 Oct;36:1328-1335.
- 10 Wijdicks EF, Schievink WI, Burnett JC, Jr. Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage. *J Neurosurg* 1997 Aug;87:275-280.
- 11 Mayer SA, Lin J, Homma S, et al. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. *Stroke* 1999 Apr;30:780-786.
- 12 Svirí GE, Shik V, Raz B, Soustiel JF. Role of brain natriuretic peptide in cerebral vasospasm. *Acta Neurochir (Wien)* 2003 Oct;145:851-860.
- 13 Naidech AM, Kreiter KT, Janjua N, et al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. *Circulation* 2005 Nov 1;112:2851-2856.
- 14 Schuiling WJ, Algra A, de Weerd AW, Leemans P, Rinkel GJ. ECG abnormalities in predicting secondary cerebral ischemia after subarachnoid haemorrhage. *Acta Neurochir (Wien)* 2006 Aug;148:853-858.
- 15 Yarlagadda S, Rajendran P, Miss JC, et al. Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage. *Neurocrit Care* 2006;5:102-107.
- 16 Deibert E, Barzilai B, Braverman AC, et al. Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage. *J Neurosurg* 2003 Apr;98:741-746.
- 17 Walter P, Neil-Dwyer G, Cruickshank JM. Beneficial effects of adrenergic blockade in patients with subarachnoid haemorrhage. *Br Med J (Clin Res Ed)* 1982 Jun 5;284:1661-1664.
- 18 Neil-Dwyer G, Walter P, Cruickshank JM. Beta-blockade benefits patients following a subarachnoid haemorrhage. *Eur J Clin Pharmacol* 1985;28 Suppl:25-29.
- 19 Cruickshank JM, Neil-Dwyer G, Degaute JP, et al. Reduction of stress/catecholamine-induced cardiac necrosis by beta 1-selective blockade. *Lancet* 1987 Sep 12;2:585-589.
- 20 Neil-Dwyer G, Cruickshank JM, Stratton C. Beta-blocker, Plasma Total Creatine Kinase and Creatine Kinase Myocardial Isoenzyme, and the Prognosis of Subarachnoid Hemorrhage. *Surg Neurol* 1986;25:163-168.
- 21 Brilstra EH, Rinkel GJ, Algra A, Van Gijn J. Rebleeding, secondary ischemia, and timing of operation in patients with subarachnoid hemorrhage. *Neurology* 2000 Dec 12;55:1656-1660.
- 22 Rabinstein AA, Friedman JA, Weigand SD, et al. Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. *Stroke* 2004 Aug;35:1862-1866.
- 23 Hop JW, Rinkel GJ, Algra A, Van Gijn J. Initial loss of consciousness and risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. *Stroke* 1999 Nov;30:2268-2271.
- 24 Chang HS, Hongo K, Nakagawa H. Adverse effects of limited hypotensive anesthesia on the outcome of patients with subarachnoid hemorrhage. *J Neurosurg* 2000 Jun;92:971-975.

- 25 Lang EW, Diehl RR, Mehdorn HM. Cerebral autoregulation testing after aneurysmal subarachnoid hemorrhage: the phase relationship between arterial blood pressure and cerebral blood flow velocity. *Crit Care Med* 2001 Jan;29:158-163.
- 26 Soehle M, Czosnyka M, Pickard JD, Kirkpatrick PJ. Continuous assessment of cerebral autoregulation in subarachnoid hemorrhage. *Anesth Analg* 2004 Apr;98:1133-1139.
- 27 Kawasaki T, Azuma A, Sawada T, et al. Electrocardiographic score as a predictor of mortality after subarachnoid hemorrhage. *Circ J* 2002 Jun;66:567-570.
- 28 Zaroff JG, Rordorf GA, Newell JB, Ogilvy CS, Levinson JR. Cardiac outcome in patients with subarachnoid hemorrhage and electrocardiographic abnormalities. *Neurosurgery* 1999 Jan;44:34-39.
- 29 Sakr YL, Lim N, Amaral AC, et al. Relation of ECG changes to neurological outcome in patients with aneurysmal subarachnoid hemorrhage. *Int J Cardiol* 2004 Sep;96:369-373.
- 30 Schuiling WJ, Dennesen PJ, Tans JT, Kingma LM, Algra A, Rinkel GJ. Troponin I in predicting cardiac or pulmonary complications and outcome in subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry* 2005 Nov;76:1565-1569.
- 31 Sarner M, Crawford MD. Ruptured intracranial aneurysm. Clinical series. *Lancet* 1965 Dec 18;2:1251-1254.
- 32 Hunt D, McRae C, Zapf P. Electrocardiographic and serum enzyme change in subarachnoid hemorrhage. *Am Heart J* 1969 Apr;77:479-488.
- 33 Page A, Boulard G, Guerin J, Pouyane H. [Electrocardiographic abnormalities during meningeal hemorrhage]. *Nouv Presse Med* 1976 May 29;5:1405-1408.
- 34 Kettunen P. Subarachnoid haemorrhage and acute heart injury. *Clin Chim Acta* 1983 Oct 31;134:123-127.
- 35 Melin J, Fogelholm R. Electrocardiographic findings in subarachnoid hemorrhage. A population study. *Acta Med Scand* 1983;213:5-8.
- 36 Pollick C, Cujec B, Parker S, Tator C. Left ventricular wall motion abnormalities in subarachnoid hemorrhage: an echocardiographic study. *J Am Coll Cardiol* 1988 Sep;12:600-605.
- 37 Lorscheid A, Simmers TA, Robles De Medina EO. The relationship between electrocardiographic abnormalities and location of the intracranial aneurysm in subarachnoid hemorrhage. *Pacing Clin Electrophysiol* 2003 Aug;26:1722-1728.
- 38 Kopelnik A, Fisher L, Miss JC, et al. Prevalence and implications of diastolic dysfunction after subarachnoid hemorrhage. *Neurocrit Care* 2005;3:132-138.
- 39 Banki N, Kopelnik A, Tung P, et al. Prospective analysis of prevalence, distribution, and rate of recovery of left ventricular systolic dysfunction in patients with subarachnoid hemorrhage. *J Neurosurg* 2006 Jul;105:15-20.
- 40 Kothavale A, Banki NM, Kopelnik A, et al. Predictors of left ventricular regional wall motion abnormalities after subarachnoid hemorrhage. *Neurocrit Care* 2006;4:199-205.

CHAPTER 3

Cardiac dysfunction after aneurysmal subarachnoid hemorrhage: relationship with outcome

van der Bilt IAC, Hasan D, van den Brink RBA, Cramer MJM, van der Jagt M, van Kooten F, Meertens JHJM, van den Berg MP, Groen RJ, ten Cate FJ, Kamp O, Götte MJW, Horn J, Groeneveld J, Vandertop WP, Algra A, Visser FC, Wilde AAM and Rinkel GJE, on behalf of the SEASAH (Serial Echocardiography After Subarachnoid Hemorrhage) Investigators. *Neurology*. 2014 Jan 28;82(4):351-8

Abstract

Objective: To assess whether cardiac abnormalities after aneurysmal subarachnoid hemorrhage (aSAH) are associated with delayed cerebral ischemia and clinical outcome, independent from known clinical risk factors for these outcomes.

Methods: In a prospective, multicenter cohort study we performed echocardiography, electrocardiography (ECG) and measured biochemical markers for myocardial damage in patients with aSAH. Outcomes were delayed cerebral ischemia (DCI), death and poor clinical outcome (death or dependency for activities of daily life) at three months. With multivariable Poisson regression analysis we calculated risk ratios (RR) with corresponding 95% confidence intervals (CI). We used survival analysis to assess cumulative percentage of death in patients with and without echocardiographic wall motion abnormalities (WMAs).

Results: We included 301 patients with an age of 57 years. 70% were women. A wall motion score index ≥ 1.2 had an adjusted RR 1.2(0.9-1.6) for DCI, 1.9(1.1-3.3) for death and 1.8(1.1-3.0) for poor outcome. Midventricular WMAs had adjusted RRs 1.1(0.8-1.4) for DCI, 2.3(1.4-3.8) for death and 2.2(1.4-3.5) for poor outcome. For apical WMAs adjusted RRs were 1.3(1.1-1.7) for DCI, 1.5(0.8-2.7) for death and 1.4(0.8-2.5) for poor outcome. Elevated Troponin T levels, ST-segment changes and low voltage on the admission ECGs had a univariable association with death, but were no independent predictors for outcome.

Conclusion: WMAs are independent risk factors for clinical outcome after aSAH. This relation is partly explained by a higher risk of DCI. Further study should aim at treatment strategies for these aSAH related cardiac abnormalities to improve clinical outcome.

Introduction

Subarachnoid hemorrhage from a ruptured aneurysm (aSAH) occurs at relatively young age (mean age 55 years) and carries a poor prognosis: one third of patients die within one month and of those who survive 10-15% remains dependent.¹ Several reports have described cardiac dysfunction following aSAH, and in a meta-analysis of these studies we found that cardiac abnormalities are associated with poor outcome.² However, it is uncertain whether this association is independent of known clinical risk factors of poor outcome. An important prognosticator for outcome is delayed cerebral ischemia (DCI).³ As cerebral autoregulation is disturbed after aSAH⁴, impaired cardiac performance may lead to reduced cerebral blood flow (CBF), and may contribute to the development of DCI.⁵

We conducted a prospective, multicenter cohort study to assess whether cardiac abnormalities independently influence the occurrence of DCI, death and poor outcome after aSAH.

Methods:

Design:

The study was designed as a prospective, observational, multicenter cohort study in the Netherlands. The number of patients to be included was 300, which was deemed to sufficiently answer the study objectives, based on the assumption that cardiac abnormalities would occur in 20% and DCI in 30%. With these assumptions an RR of 1.5 has a 95% confidence interval of 1.1 to 2.2. In a pre-specified interim analysis after 100 patients these assumptions were confirmed. From February 2005 to March 2008, 301 patients with aSAH were enrolled. Five tertiary referral university hospitals participated.

Standard Protocol Approvals, Registrations, and Patient Consents:

The study was approved by the national ethics committee and by all participating hospitals. Written informed consent was obtained from the patient or a legal representative.

Criteria for diagnosis of aSAH:

The diagnosis of aSAH was based on clinical signs and symptoms, presence of

subarachnoid blood on computer tomography (CT) scan or xanthochromia of the cerebrospinal fluid if the CT was non-diagnostic, and by the presence of an aneurysm on conventional or CT-angiography. Patients with aSAH presenting within 72 hours of the onset of symptoms were eligible for inclusion. Patients with cardiac abnormalities prior to the aSAH (i.e. ECG or echocardiographic abnormalities after myocardial infarction, CABG or PCI) were excluded. All investigations mentioned below were performed within 24 hours after admission.

Study procedure and data collection:

Clinical data were entered in case report forms (CRF) by local investigators. Periodically, the study coordinator (IB) checked all CRFs against patients' charts and entered these in an anonymized electronic database. The following data were collected: age, sex, loss of consciousness at ictus, seizures at ictus, angina pectoris, myocardial infarction, prior coronary artery bypass graft (CABG), prior angioplasty, known hypertension, hypercholesterolemia, peripheral vascular disease, cerebrovascular events (ischemic or hemorrhagic), diabetes mellitus, current cigarette smoking, family history of coronary artery disease, drug use. The clinical condition on admission was categorized according to the World Federation of Neurosurgical Societies (WFNS) grading scale for subarachnoid hemorrhage, where a WFNS ≥ 3 was considered a poor condition on admission.⁶

CT-scan:

The amount of blood on all admission CT scans was assessed according to the Hijdra score⁷ by one investigator (DH), who was unaware of the clinical condition of the patient. The amount of blood in 13 cerebral cisterns was scored from 0 (no blood) to 2 (completely filled with blood). The sum score (ranging from 0 to 26) for each CT scan was calculated.

Electrocardiography:

All ECGs were analyzed by one investigator (FV), who was unaware of the clinical data of the patient. Criteria for the ECG abnormalities were defined according to the guidelines of the European Society of Cardiology (ESC).⁸ A Q-wave in two contiguous leads was considered pathological when $\geq 0.03s$ wide and $\geq 0.1mV$ deep. ST deviation was considered to represent myocardial ischemia when ST elevation occurred at the J-point in two contiguous leads with the cut-off points: ≥ 0.2 mV in men or ≥ 0.15 mV in women in leads V2–V3 and/or ≥ 0.1 mV in other leads.

Horizontal or down-sloping ST depression ≥ 0.05 mV in two contiguous leads; and/or T inversion ≥ 0.1 mV in two contiguous leads with prominent R-wave or R/S ratio >1 were also considered ischemic changes. The Cornell voltage criteria ($R_{aVL} + S_{V3} > 28$ mm(men) or > 20 mm(women)), or Sokolow-Lyon voltage index ($S_{V1} + R_{V5/6}$) >35 mm for left ventricular hypertrophy were used.

Echocardiography:

Transthoracic echocardiography was performed according to the standards of the American Society of Echocardiography (ASE). Vingmed Medical Systems 7 were used, one center used a Philips Sonos 7500 for 30 examinations. For assessment of systolic function, three cardiologists (RB, MC, MG), independently from each other and unaware of the clinical data of the patients, reviewed all echocardiograms with the standard ASE 17-segment model for systolic function.⁹ All segments were scored based on contractility: 0 uninterpretable, 1 normal, 2 hypokinetic, 3 akinetic, 4 dyskinetic, 5 aneurysmal. A wall motion score index (WMSI) was calculated by dividing the sum of wall motion scores by the number of visualized segments. Diastolic function was assessed measuring pulsed wave Doppler of mitral valve peak velocity of early (E) and late (A) diastolic flow, early flow deceleration time, and duration of late flow. The E/A ratio was calculated from the mean E and A of three heart cycles. Pulmonary vein systolic (Ps) and diastolic (Pd) flow velocity, and atrial reversal flow duration (Adur) were also measured. Doppler tissue imaging (DTI) of the mitral annular motion was measured for early (E') and late diastolic annular velocity and the ratio of the mitral E to the DTI E' was calculated using the septal (E/E') velocities. These parameters were then checked with the criteria on diastolic dysfunction according to the guidelines of the European Society of Cardiology.¹⁰

Laboratory results:

On admission, serum Troponin levels were determined, as a marker for myocardial damage. Additionally, N-terminal prohormone of B-Type Natriuretic Peptide (NT-proBNP) was measured which is a natriuretic hormone that, although first identified in the brain, is released from the heart in response to high filling pressures. Finally, Creatinine as indication of renal function was measured on admission. The upper limits of normal as defined by the local laboratory were used as reference.

Assessment of outcome: Delayed cerebral ischemia:

The study coordinator (IB) entered all episodes of clinical deterioration in an electronic database. Following this procedure, two neurologists (FK,MJ), who had access to all clinical data except the cardiac data, assessed whether these clinical deteriorations fulfilled the criteria for probable or definite DCI. Probable DCI was defined as a focal deficit or deterioration of level of consciousness not explained by rebleeding, hydrocephalus, complication from aneurysm treatment, infection, or metabolic disturbances, but without new hypodensities on a repeated CT scan. Infection was defined as fever, leucocytosis, and increased C-reactive protein, or positive cultures along with clinical signs of infection for which antibiotic treatment was started.

Definite DCI was defined as development of focal neurological signs or deterioration of the level of consciousness, or both, with evidence of cerebral infarction on CT-scan or at autopsy. Any new hypodensity on the CT scan without an obvious explanation such as neurosurgical or endovascular intervention, or perihematomal edema were scored as definite DCI even in the absence of clinical symptoms. Probable and definite DCI were taken together as one event.

Poor outcome:

Patients were contacted by phone or in the outpatient clinic three months after admission and outcome was scored according to the Modified Rankin Scale (MRS).¹¹ Poor outcome was defined as a MRS score > 3.

Statistical analysis:

Baseline characteristics were analyzed using descriptive statistics. Univariable risk ratios (RR) for baseline determinants and outcomes at three months (DCI, death and poor outcome) with corresponding 95% CI were calculated with Poisson regression with robust standard errors.^{12, 13} For determinant-outcome combinations that yielded a significance level of 5%, multivariable adjustments were performed with Poisson regression. Adjustments are reported for those factors that changed the crude risk ratio by more than 5%. Missing values were excluded by casewise deletion. Hijdra score was dichotomized on the median, WMSI was dichotomized on one standard deviation above the median.

Additionally, we made Kaplan-Meier curves for cumulative percentages of death according to presence or absence of WMAs. Because rebleeding may increase the risk of DCI and poor outcome the chance of cardiac abnormalities, we performed a sensitivity analysis with exclusion of patients who had an episode of rebleeding after

Table 1: Baseline characteristics.

	Total	DCI	Death	Poor outcome
	(N=301)	(n=164)	(n=58)	(n=66)
Female sex	210(70%)	99(60%)	37(64%)	43(65%)
Mean age (in years)(\pm SD)	57(\pm 13)	58(\pm 13)	64(\pm 14)	63(\pm 14)
Coronary risk factors				
Hypertension	90(30%)	44(27%)	22(38%)	27(41%)
Hypercholesterolemia	26(9%)	13(8%)	5(9%)	5(8%)
Diabetes Mellitus	14(5%)	7(4%)	4(7%)	5(8%)
Smoking (previous and current)	115(38%)	52(32%)	15(26%)	16(24%)
Medical history				
Myocardial infarction*	8(3%)	4(2%)	1(2%)	2(3%)
Percutaneous Coronary Intervention (PCI)	7(2%)	2(1%)	0(0%)	0(0%)
Coronary Artery Bypass Graft (CABG)	4(1%)	1(1%)	0(0%)	0(0%)
Ischemic Stroke	16(5%)	8(5%)	7(12%)	7(11%)
Intracerebral Hemorrhage	7(2%)	2(1%)	1(2%)	1(2%)
Family history of cardiovascular disease	33(11%)	12(7%)	3(5%)	3(5%)
Location of aneurysm in Anterior circulation				
Anterior Communicating Artery	127(42%)	61(37%)	22(38%)	28(42%)
Anterior cerebral artery	12(4%)	6(4%)	1(2%)	1(2%)
Middle cerebral artery	61(20%)	31(19%)	13(22%)	15(23%)
Internal carotid artery	61(20%)	28(17%)	12(21%)	12(18%)
Location of aneurysm in Posterior circulation				
Posterior cerebral artery	11(4%)	5(3%)	2(3%)	2(3%)
Basilar artery	21(7%)	9(5%)	6(10%)	6(9%)
Vertebral artery	10(3%)	6(4%)	2(3%)	2(3%)
Aneurysm treatment				
Coiling	183(60%)	77(47%)	26(45%)	30(46%)
Clipping	95(31%)	58(35%)	10(17%)	14(21%)
None	25(8%)	11(7%)	22(38%)	22(33%)
Amount of blood > median (Hijdra =19 points)	142(47%)	84(51%)	35(60%)	38(58%)
Clinical condition on admission (WFNS)				
I	104(34%)	29(18%)	3(5%)	5(8%)
II	54(18%)	30(18%)	10(17%)	11(17%)
III	24(8%)	14(9%)	4(7%)	5(8%)
IV	64(21%)	40(24%)	20(35%)	23(35%)
V	57(19%)	33(20%)	21(36%)	22(33%)
Acute hydrocephalus	107(35%)	55(34%)	23(40%)	27(41%)

Baseline characteristics. N: number of patients; CABG: Coronary artery bypass graft; WFNS: World Federation of Neurosurgical Societies subarachnoid grading scale. SD: Standard Deviation; *: The patients with prior myocardial infarction, PCI or CABG that were included did not have ECG abnormalities or echocardiographic abnormalities prior to the SAH.

admission. Subanalyses were performed for patients that underwent the investigations within 48 hours of the bleed, for patients that underwent surgery or coiling and for the outcomes definite DCI, and probable and definite DCI combined.

Results

Participants:

320 patients were assessed for eligibility. Five patients were not included because no aneurysm was found; for 5 others informed consent was declined by next of kin. Nine were excluded: in 6 no cardiac examination could be performed and 3 were lost to follow-up. Finally, 301 subjects completed follow-up and were analyzed. Baseline characteristics are listed in table 1.

Cardiac data:

The prevalence of cardiac abnormalities on admission is shown in table 2.

The wall motion abnormalities did not correspond to a single coronary territory. Ten percent of patients showed hypokinesia of the apical segments with hypercontractility of the basal segments which is compatible with a Takotsubo cardiomyopathy (TTC).¹⁴ Due to this finding, a secondary analysis was done to analyze whether WMAs occurring in the basal, midventricular or apical segments were as such associated with outcome.

Outcome data:

Probable or definite ischemia occurred in 164(54%) patients. Of these patients 146(48%) had definite DCI. The median time from aSAH onset to DCI was 3.5; IQR 4.9 days. At the end of follow up 58(19%) patients had died (median time to death 10; IQR days) and 66(22%) had a poor outcome (8 patients had MRS 4 or 5). In 57 patients cause of death was poor neurological condition, and one patient died due to cardiogenic shock. Post mortem examination in the latter patient showed a rupture of the free wall of the right ventricle and thrombotic occlusion of the right coronary artery. During the clinical course 40(16%) patients had an episode of rebleeding. Median time to rebleeding was 3.6; IQR 10.1 days. 48(51%) of patients that underwent clipping had surgery within 24 hours. 121(66%) of patients that underwent coiling had it within 24 hours. Results were essentially the same if we restricted the analyses to patients investigated within 48 hours after onset of clinical symptoms.

Table 2: Prevalence of cardiac abnormalities on admission.

Cardiac parameters	Total (n=301)	DCI (n=164)	Death (n=58)	Poor outcome (n=66)
ECG				
Heart frequency (bpm)				
<60	62(21%)	28(17%)	6(10%)	8(12%)
60<>100	212(70%)	102(62%)	29(67%)	44(67%)
>100	29(10%)	16(10%)	13(22%)	14(21%)
Pathological Q-wave present	14(5%)	8(5%)	4(7%)	5(8%)
ST depression	26(9%)	12(7%)	8(14%)	8(12%)
ST elevation	10(3%)	7(4%)	4(7%)	4(6%)
Negative T-waves	79(26%)	47(29%)	18(31%)	22(33%)
ST segment "Ischemic"	33(11%)	17(10%)	10(17%)	10(15%)
QTc prolongation	145(48%)	83(51%)	33(57%)	38(58%)
LVH – Sokolow – Lyon	56(19%)	28(17%)	11(19%)	12(18%)
Strain pattern	14(5%)	5(3%)	3(5%)	3(5%)
Low voltage	8(3%)	6(4%)	4(7%)	4(6%)
Myocardial infarction pattern	13(4%)	7(4%)	3(5%)	4(6%)
Echocardiography (N=279)				
WMSI >1.0	59(20%)	31/139(22%)	16/52(28%)	19/60(29%)
Mean WMSI (±SD)	1.1(±0.2)	1.1(±0.3)	1.2(±0.4)	1.2(±0.4)
WMAs of Basal segments	28(9%)	13/139(9%)	6/52(10%)	8/60(12%)
WMAs of Midventricular segments	46(15%)	24/139(17%)	16/52(28%)	18/60(27%)
WMAs of Apical segments	39(13%)	26/139(19%)	10/50(17%)	11/57(17%)
Diastolic dysfunction	143(47%)	71/146(49%)	33(57%)	37(56%)
Laboratory findings				
Elevated Troponin T (µg/L)*	97/261(37%)	51/117(36%)	27/48(47%)	28/55(42%)
Elevated NT-proBNP (ng/L)*	159/225(71%)	78/101(53%)	31/39(53%)	37/45(56%)
Decreased GFR (ml/min)*	66/217(30%)	29/93(20%)	13/40(22%)	14/46(21%)

N: number of patients; LVH: Left ventricular hypertrophy. WMSI: wall motion score index, WMAs: wall motion abnormalities; GFR: glomerular filtration rate; SD: Standard Deviation. *The upper and lower limits of normal as defined by the local laboratory were used as reference. In case of missing data the number of patients with available data is given after the forward slash.

Main results:

Table 3 shows the adjusted RRs for the association of WMSI ≥ 1.2 and the three outcomes. A WMSI ≥ 1.2 is associated with death and poor outcome independent of known predictors for these outcomes. As NT-proBNP was the only variable that changed the RRs > 5%, the RRs for WMSI ≥ 1.2 and outcome, adjusted for elevated NT-proBNP is also given in table 3.


Table 3: Adjusted Risk Ratios (RR) for the three outcomes and wall motion abnormalities.

Determinants	DCI	Death	Poor outcome
WMSI > 1.1			
Crude RR	1.2(0.9-1.6)	1.9(1.1-3.4)	1.8(1.1-3.0)
Adjusted RR*	1.2(0.9-1.5)	1.9(1.1-3.3)	1.8(1.1-3.0)
Adjusted RR for NT-proBNP	1.2(0.9-1.7)	1.6(0.8-3.3)	1.6(0.8-3.0)
Basal WMAs			
Crude RR	1.0(0.7-1.4)	1.2(0.6-2.5)	1.4(0.7-2.6)
Adjusted RR*	0.9(0.7-1.4)	1.2(0.6-2.5)	1.4(0.7-2.6)
Adjusted RR for NT-proBNP	1.0(0.6-1.5)	0.8(0.3-2.5)	1.3(0.6-2.8)
Midventricular WMAs			
Crude RR	1.1(0.9-1.4)	2.3(1.4-3.7)	2.2(1.4-3.4)
Adjusted RR*	1.1(0.8-1.4)	2.3(1.4-3.8)	2.2(1.4-3.5)
Adjusted for NT-proBNP	1.1(0.8-1.5)	1.8(0.9-3.5)	1.9(1.0-3.4)
Apical WMAs			
Crude RR	1.4(1.1-1.7)	1.5(0.8-2.8)	1.4(0.7-2.6)
Adjusted RR*	1.3(1.1-1.7)	1.5(0.8-2.7)	1.4(0.8-2.5)
Adjusted for NT-proBNP	1.4(1.0-1.8)	1.4(0.6-3.2)	1.5(0.8-2.8)

Abbreviations; WMSI: wall motion score index. WMAs: wall motion abnormalities, LVH: left ventricular hypertrophy; *adjusted for WFNS, age, Hijdra score. Adjustment for elevated Troponin on admission, presence of Q-waves on ECG, low voltage on ECG, ST depression, ST elevation, Negative T-waves, prolonged QT interval (>500ms) yielded in a change of RR of < 5%.

As a secondary analysis, WMAs were subdivided in basal, midventricular and apical WMAs. Midventricular WMAs were associated with death, independent from clinical condition on admission, age or amount of blood on the CT-scan. Apical WMAs were an independent predictor for DCI. Adjustment for elevated Troponin, presence of Q-waves, low voltage, ST-segment deviation, and negative T-waves led to a change in the RR of < 5%. None of the other cardiologic determinants were associated with outcome. Diastolic dysfunction had a univariable RR for DCI of 1.0(0.8-1.2), for death of 1.5(0.9-2.3) and for poor outcome 1.4(0.9-2.2). Therefore we refrained from including diastolic dysfunction in the multivariable model. Results from the sensitivity analysis after exclusion of patients with rebleeding were comparable with those of the main analysis. Additionally, in the sensitivity analysis on patients with definite DCI only, the results are comparable to those of the main analysis. Figure 1 shows Kaplan-Meier curves for cumulative death according to presence or absence of wall motion abnormalities.

Figure 1: Fraction of death in patients with- or without WMAs.



Kaplan-Meier curves of fraction of death in patients with a wall motion score index(WMSI) > 1.0 or wall motion abnormalities in the basal, midventricular or apical segments of the heart.

Discussion

The main finding of the present study is that WMAs are a predictor for adverse clinical outcome in aSAH, independent from known clinical predictors. Since these WMAs are also an independent risk factor for the occurrence of DCI, the relation between cardiac abnormalities and outcome may therefore, at least in part, be explained by the contribution of cardiac abnormalities to the development of DCI.

We found cardiac abnormalities in a high proportion of patients; in particular prolonged QT-interval and elevated NT-proBNP. The elevated NT-proBNP weakened the relation between wall motion abnormalities and outcome. NT-proBNP is expressed predominantly in the ventricles in response to cardiac overload.¹⁵ This weakening of the relation between wall motion abnormalities and outcome by

NT-proBNP is therefore probably explained by the secretion of NT-proBNP by the cardiac ventricles in response to increased wall stress of the myocardium when WMAs occur after aSAH. This is supported by the finding that NT-proBNP levels in stress cardiomyopathy or TTC are elevated and correlate with catecholamine increase and severity of LV dysfunction.¹⁶ Other studies also found an elevated NT-proBNP in patients with SAH.¹⁷⁻²⁰ However, these studies had relatively small sample size, used different cut-off values for elevated NT-proBNP, or had not defined outcome.

The cause of cardiac abnormalities after SAH cannot be answered by the present study. The generally accepted pathway is that due to massive sympathetic activation a catecholamine burst causes myocardial dysfunction by epicardial spasm, microvascular dysfunction, hyperdynamic contractility with midventricular or outflow tract obstruction, or that it is caused by direct effects of catecholamines on cardiomyocytes.²¹ Myocardial ischemia is an unlikely cause of the dysfunction as myocardial perfusion was reported to be normal.²²

Although in the univariable analysis several ST-segment changes were associated with outcome, none of the ECG parameters predicted outcome in the multivariable analyses. Possibly, ST-segment changes in aSAH are caused by changes in wall stress due to catecholaminergic stress after the aSAH. Another likely explanation is that ECG abnormalities, Troponin and NT-proBNP elevation, together with WMAs represent the same phenomenon; cardiac dysfunction after aSAH. Furthermore, we considered only the admission ECG whereas we know from earlier studies that serial ECG changes after SAH occur frequently, and have been linked to outcome.²³⁻²⁵ Earlier studies found similar proportions of patients with WMAs as the present study.²⁶⁻²⁹ However, these studies did not find a relation between WMAs and outcome, although an association with elevated troponin and outcome was reported.³⁰ In our study all examinations were performed within 96 hours of the aSAH, which was usually not the case in other studies. Also, our study was appropriately powered and had considerable follow-up duration.

We found that the distribution of the WMAs did not correspond with the territory of a single coronary artery, which has been described before in aSAH.³¹ Some patients showed a diffusely disturbed systolic function and of the patients who had apical wall motion abnormalities, almost all also showed basal hyperdynamic contractility, consistent with a TTC. Although it has widely been accepted that TTC is a benign condition which carries an excellent prognosis³², in our secondary analysis the patients with apical WMAs had more risk of DCI whereas midventricular WMAs were associated with death. This finding might be explained by an impaired cardiac

output in combination with disturbed cerebral autoregulation after aSAH. However, since these analyses were not part of the original protocol and sample sizes were small, these observations need further explorations. Second, we did not have hemodynamic data to support cerebral hypoperfusion. Nevertheless, as DCI is a multifactorial entity, WMAs may play a role in the pathophysiology of DCI and may, if treated, improve outcome.

Some studies have suggested that β -sympathomimetics such as dobutamine or phosphodiesterase inhibitors such as milrinone recruit inotropic reserve in patients with aSAH.^{17, 33} The aforementioned drugs could be effective in restoring myocardial function, but whether this improves outcome in patients with aSAH and WMA should be investigated.

Our study included a high number of patients with poor clinical condition compared to other studies. This might explain why we found a high proportion of patients with DCI. Another explanation for the relative high incidence of DCI lies in the criteria we used for DCI, including both clinical episodes not confirmed with new hypodensities on CT as well as any new hypodensity on CT. This definition has been proposed earlier.³⁴ We found a high number of patients with a rebleed. This is probably due to the inclusion of a high number of patients in whom occlusion of the aneurysm was postponed because of poor clinical condition.

As this was an observational study we could only assess associations and neither pathophysiological pathways nor therapeutic hypotheses were evaluated.

The strength of the present study is the structured, prospective, and multicenter approach with a 90 day follow-up duration. We included a representative series of patients, including a considerable proportion of patients in poor clinical condition on admission.

Cardiac abnormalities occur frequently after aSAH. Echocardiographic WMAs are associated with clinical outcome after aSAH, regardless of the severity of the aSAH. This relation may partly be explained by a higher chance of DCI.

Reference List

1. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol* 2009 July;8(7):635-642.
2. van der Bilt IA, Hasan D, Vandertop WP, Wilde AA, Algra A, Visser FC, Rinkel GJ. Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis. *Neurology* 2009 February 17;72(7):635-642.
3. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. *Lancet* 2007 January 27;369(9558):306-318.
4. Jaeger M, Soehle M, Schuhmann MU, Meixensberger J. Clinical Significance of Impaired Cerebrovascular Autoregulation After Severe Aneurysmal Subarachnoid Hemorrhage. *Stroke* 2012 May 22.
5. Mayer SA, Lin J, Homma S, Solomon RA, Lennihan L, Sherman D, Fink ME, Beckford A, Klebanoff LM. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. *Stroke* 1999 April;30(4):780-786.
6. Anonymous. Report of World Federation on Neurological Surgeons committee on a universal subarachnoid hemorrhage grading scale. *J Neurosurg* 1988;68:985-986.
7. Hijdra A, Brouwers PJ, Vermeulen M, van Gijn J. Grading the amount of blood on computed tomograms after subarachnoid hemorrhage. *Stroke* 1990 August;21(8):1156-1161.
8. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal definition of myocardial infarction. *Circulation* 2007 November 27;116(22):2634-2653.
9. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 2002 January 29;105(4):539-542.
10. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwinger J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Jung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2012 August;14(8):803-869.
11. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* 1988 May;19(5):604-607.
12. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004 April 1;159(7):702-706.
13. Knol MJ, Le CS, Algra A, Vandenbroucke JP, Groenwold RH. Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression. *CMAJ* 2012 May 15;184(8):895-899.
14. Akashi YJ, Goldstein DS, Barbaro G, Ueyama T. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. *Circulation* 2008 December 16;118(25):2754-2762.
15. Magga J, Vuolteenaho O, Tokola H, Marttila M, Ruskoaho H. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. *Ann Med* 1998 August;30 Suppl 1:39-45.

16. Nguyen TH, Neil CJ, Sverdlow AL, Mahadavan G, Chirkov YY, Kucia AM, Stansborough J, Beltrame JF, Selvanayagam JB, Zeitz CJ, Struthers AD, Frenneaux MP, Horowitz JD. N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy. *Am J Cardiol* 2011 November 1;108(9):1316-1321.
17. Yarlagadda S, Rajendran P, Miss JC, Banki NM, Kopelnik A, Wu AH, Ko N, Gelb AW, Lawton MT, Smith WS, Young WL, Zaroff JG. Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage. *Neurocrit Care* 2006;5(2):102-107.
18. Wijdicks EF, Schievink WI, Burnett JC, Jr. Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage. *J Neurosurg* 1997 August;87(2):275-280.
19. Sviri GE, Shik V, Raz B, Soustiel JF. Role of brain natriuretic peptide in cerebral vasospasm. *Acta Neurochir (Wien)* 2003 October;145(10):851-860.
20. Tung PP, Olmsted E, Kopelnik A, Banki NM, Drew BJ, Ko N, Lawton MT, Smith W, Foster E, Young WL, Zaroff JG. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. *Stroke* 2005 July;36(7):1567-1569.
21. Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy--a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. *Nat Clin Pract Cardiovasc Med* 2008 January;5(1):22-29.
22. Banki NM, Kopelnik A, Dae MW, Miss J, Tung P, Lawton MT, Drew BJ, Foster E, Smith W, Parmley WW, Zaroff JG. Acute neurocardiogenic injury after subarachnoid hemorrhage. *Circulation* 2005 November 22;112(21):3314-3319.
23. Galloon S, Rees GA, Briscoe CE, Davies S, Kilpatrick GS. Prospective study of electrocardiographic changes associated with subarachnoid haemorrhage. *Br J Anaesth* 1972 May;44(5):511-516.
24. Brouwers PJ, Wijdicks EF, Hasan D, Vermeulen M, Wever EF, Frericks H, van Gijn J. Serial electrocardiographic recording in aneurysmal subarachnoid hemorrhage. *Stroke* 1989 September;20(9):1162-1167.
25. Schuiling WJ, Algra A, de Weerd AW, Leemans P, Rinkel GJ. ECG abnormalities in predicting secondary cerebral ischemia after subarachnoid haemorrhage. *Acta Neurochir (Wien)* 2006 August;148(8):853-858.
26. Miss JC, Kopelnik A, Fisher LA, Tung PP, Banki NM, Lawton MT, Smith WS, Dowd CF, Zaroff JG. Cardiac injury after subarachnoid hemorrhage is independent of the type of aneurysm therapy. *Neurosurgery* 2004 December;55(6):1244-1251.
27. Naidech AM, Kreiter KT, Janjua N, Ostapkovich ND, Parra A, Commichau C, Fitzsimmons BF, Connolly ES, Mayer SA. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. *Circulation* 2005 November 1;112(18):2851-2856.
28. Banki N, Kopelnik A, Tung P, Lawton MT, Gress D, Drew B, Dae M, Foster E, Parmley W, Zaroff J. Prospective analysis of prevalence, distribution, and rate of recovery of left ventricular systolic dysfunction in patients with subarachnoid hemorrhage. *J Neurosurg* 2006 July;105(1):15-20.
29. Kothavale A, Banki NM, Kopelnik A, Yarlagadda S, Lawton MT, Ko N, Smith WS, Drew B, Foster E, Zaroff JG. Predictors of left ventricular regional wall motion abnormalities after subarachnoid hemorrhage. *Neurocrit Care* 2006;4(3):199-205.
30. Zaroff JG, Leong J, Kim H, Young WL, Cullen SP, Rao VA, Sorel M, Quesenberry CP, Jr., Sidney S. Cardiovascular predictors of long-term outcomes after non-traumatic subarachnoid hemorrhage. *Neurocrit Care* 2012 December;17(3):374-381.
31. Zaroff JG, Rordorf GA, Ogilvy CS, Picard MH. Regional patterns of left ventricular systolic dysfunction after subarachnoid hemorrhage: evidence for neurally mediated cardiac injury. *J Am Soc Echocardiogr* 2000 August;13(8):774-779.
32. Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC. Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med* 2005;10(352):539-548.
33. Naidech A, Du Y, Kreiter KT, Parra A, Fitzsimmons BF, Lavine SD, Connolly ES, Mayer SA, Commichau C. Dobutamine versus milrinone after subarachnoid hemorrhage. *Neurosurgery* 2005;56(1):21-61.
34. Vergouwen MD, Vermeulen M, van GJ, Rinkel GJ, Wijdicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringner MN, Broderick JP, Dreier JP, Roos YB. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. *Stroke* 2010 October;41(10):2391-2395.

CHAPTER 4

Time course and risk factors for myocardial dysfunction after aneurysmal subarachnoid hemorrhage.

van der Bilt IAC, Hasan D, van den Brink RBA, Cramer MJM, van der Jagt M,
van Kooten F, Regtien JG, van den Berg MP, Groen RJ, ten Cate FJ, Kamp O,
Götte MJW, Horn J, Girbes ARJ, Vandertop WP, Algra A, Rinkel GJE,
Wilde AAM; SEASAH (Serial Echocardiography After Subarachnoid Hemorrhage)
Investigators. *Neurosurgery*. 2015 Jun;76(6):700-5

Abstract

Background: Myocardial wall motion abnormalities (WMA) are independent risk factors for poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH).

Objective: To study the time course of WMA during the initial phase after aSAH, and to investigate which clinical, electrocardiographic or myocardial serum markers are predictors for early or late development of WMA.

Methods: In a prospective, multicenter cohort study in patients with aSAH we performed serial electrocardiography (ECG), echocardiography, and measured Troponin T and NT-proBNP. WMA present on admission were considered early WMA; those that developed during the clinical course were considered late WMA. With multivariable regression analysis we calculated odds ratios (OR) with corresponding 95% confidence intervals (CI) for clinical parameters, ECG, and myocardial serum makers with early or late occurrence of WMA.

Results: We included 301 patients (mean age 57(SD±13) years). Multivariable ORs for early WMA were: poor clinical condition 2.7(95%CI: 1.1-6.8), sinus tachycardia 5.0(1.3-19.9), ST-depression 3.7(1.02-13.1), ST-elevation 16.6 (1.5-178.9) and elevated troponin T 2.8(1.1-7.3). Multivariable ORs for late development of WMA were 6.8 (1.6-30) for myocardial infarct pattern on admission ECG and 3.4 (1.4-8.5) for elevated troponin T on admission.

Conclusions: WMA may be present on admission or develop during the course of aSAH. Poor neurological condition on admission, sinus tachycardia, ST-depression and ST-elevation at the admission ECG and elevated troponin T, are independent predictors for early WMA, a myocardial infarct pattern on the admission ECG and elevated troponin T independently predict late WMA.

Introduction

Aneurysmal subarachnoid hemorrhage (aSAH) is a subset of stroke that occurs at young age (mean age 55 years), with an incidence of 5-20/100,000 and carries a poor prognosis: 30% of patients die within one month and of those who survive 10-15% remain dependent.¹ In patients with aSAH, myocardial wall motion abnormalities (WMA) are associated with poor outcome, independently of other well-known clinical predictors.²⁻⁶ WMA are reported in up to 25% of patients and are usually reversible.⁷⁻¹⁰ To early identify patients at risk for poor outcome due to cardiac dysfunction, the objective of this study was to investigate the time course of WMA after aSAH and to identify predictors for WMA using clinical parameters, ECGs and myocardial serum markers that are available on admission.

Methods

Design:

The Serial Echocardiography After SubArachnoid Hemorrhage (SEASAH) study was a prospective multicenter cohort study conducted in 5 tertiary referral centers in the Netherlands. The study design was published earlier; the major finding of the study was that WMA are associated with poor outcome independent of other clinical parameters.⁶ Three hundred and one patients with aSAH were included. The Dutch national ethics committee and all local ethics committees of the participating hospitals approved the study. Written informed consent was obtained for all patients.

Criteria for diagnosis of aSAH:

The diagnosis of aSAH was based on clinical signs and symptoms, presence of subarachnoid blood on computer tomography(CT) scan or xanthochromia of the cerebrospinal fluid if the CT was non-diagnostic, and by the presence of an aneurysm on conventional or CT-angiography. Patients with aSAH presenting within 72 hours of the onset of symptoms were eligible for inclusion. Patients with known electrocardiographic or echocardiographic abnormalities were excluded.

Study procedure and data collection:

The World Federation of Neurosurgical Societies (WFNS) grading scale for subarachnoid hemorrhage was used for grading clinical condition, where a WFNS ≥ 3 was considered a poor condition.¹¹

Echocardiography, ECG and testing for myocardial serum markers (N-terminal prohormone of B-Type Natriuretic Peptide (NT-proBNP) and troponin T) was performed as soon as possible after admission and 4 and 8 days after onset of symptoms. The upper limits of normal as defined by the local laboratory were used as reference.

CT-scan:

The amount of blood on the admission CT scans was assessed according to the Hijdra score¹² by one investigator (DH), who was unaware of the clinical condition of the patient or the results of the cardiologic examinations. Hydrocephalus was defined as the bicaudate index (=BCI, width of the frontal horns at the level of the foramina of Monro, divided by the corresponding diameter of the brain) on the CT, exceeding the 95th percentile for age. The upper limits are: <36 years of age, 0.16; 36-45 years, 0.17; 46-55 years, 0.18; 56-65 years, 0.19; 66-75 years, 0.20; 76-85 years, 0.21.¹³

Cardiac examinations:

The investigators who scored the echocardiograms, ECGs or blood results, were unaware of the clinical data of the patient. Criteria for the ECG abnormalities were defined according to the guidelines of the European Society of Cardiology¹⁴ and are described earlier.⁶ ST segment deviation is frequent in aSAH, but often does not represent myocardial ischemia.¹⁵ ST deviation was considered suggestive for myocardial ischemia when ST elevation occurred at the J-point in two contiguous leads. Horizontal or down-sloping ST depression in two contiguous leads; and/or T inversion in two contiguous leads with prominent R-wave or R/S ratio >1 were also considered ischemic changes. Transthoracic echocardiography was performed according to the standards of the American Society of Echocardiography (ASE).¹⁶ For assessment of systolic function, three cardiologists, independently from each other and unaware of the clinical data of the patients, reviewed all echocardiograms. All segments were scored based on contractility: 0 uninterpretable, 1 normal, 2 hypokinetic, 3 akinetic, 4 dyskinetic, 5 aneurysmal. A wall motion score index (WMSI) was calculated by dividing the sum of wall motion scores by the number of visualized segments. A WMSI > 1 means that WMA were present.

Statistical analysis:

Baseline characteristics were analyzed using descriptive statistics. WMSI was dichotomized on one standard deviation above the median. WMA were divided in early WMA, which were present on admission and late WMA, which were present on the echocardiograms on day 4 and/or day 8 after the onset of the aSAH but with a normal admission echocardiogram. Univariable odds ratios (OR) with corresponding 95% confidence intervals (CI) were calculated using logistic regression for baseline determinants and early and late WMA. For determinant-outcome combinations that yielded a significance level of 5% in the univariable analysis, multivariable adjustments were performed. Missing values were excluded by casewise deletion. Hijdra score was dichotomized on the median. Because rebleeding of the aneurysm may cause late WMA we performed a sensitivity analysis with exclusion of patients with a rebleed.

Results:

Participants:

Three hundred and twenty patients were assessed for eligibility. Five patients were not included because no aneurysm was found; for 5 others informed consent was declined by next of kin. Nine were excluded: in 6 no cardiac examination could be performed and 3 were lost to follow-up. Three hundred and one patients with aSAH were included and underwent the cardiac examinations. Table 1 shows the baseline characteristics.

Table 1: shows the baseline characteristics.

	N=301
Female sex	210(70%)
Mean age (in years)(\pm SD)	57(\pm 13)
Coronary risk factors	
Hypertension	90(30%)
Hypercholesterolemia	26(9%)
Diabetes Mellitus	14(5%)
Smoking (previous and current)	115(38%)
Family history of CVD	33(11%)
Medical history	
Myocardial infarction*	8(3%)
PCI	7(2%)
CABG	4(1%)
Ischemic Stroke	16(5%)
Intracerebral Hemorrhage	7(2%)
Location of aneurysm in Carotid circulation	
Anterior Communicating Artery	127(42%)
Anterior cerebral artery	12(4%)
Middle cerebral artery	61(20%)
Internal carotid artery	61(20%)
Location of aneurysm in Posterior circulation	
Posterior cerebral artery	11(4%)
Basilar artery	20(7%)
Vertebral artery	9(3%)
Hijdra score >19	142(47%)
Acute hydrocephalus	107(35%)
Clinical condition on admission (WFNS)	
I	103(34%)
II	54(18%)
III	24(8%)
IV	64(21%)
V	56(19%)

Abbreviations: N: number, SD: standard deviation, WFNS: World Federation of Neurosurgical Societies. CVD: cardiovascular disease. PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft *: The patients with prior myocardial infarction, PCI or CABG who were included did not have ECG abnormalities or echocardiographic abnormalities prior to the SAH.

Cardiac abnormalities:

The prevalence of cardiac abnormalities during the study period is shown in table 2.

Table 2: shows the course of the determinants.

Cardiac parameters	Admission n=301* (298 ECGs)	Day 4 n=283* (264 ECGs)	Day 8 n=272* (224 ECGs)
Sinusbradycardia	41(14%)	39(15%)	18(8%)
Sinustachycardia	19(6%)	13(5%)	21(9%)
Low voltage	8(3%)	16(6%)	6(3%)
Pathologic Q wave	14(5%)	7(3%)	10(5%)
ST-depression	26(9%)	10(4%)	5(2%)
ST-elevation	10(3%)	3(1%)	3(1%)
Negative T-waves	90(30%)	134(51%)	61(27%)
Prominent U-waves	99(33%)	85(32%)	60(27%)
QTc prolongation >500ms	43(14%)	29(11%)	11(5%)
LVH on ECG	56(19%)	37(14%)	39(17%)
Strain pattern on ECG	14(5%)	11(4%)	8(4%)
Myocardial infarction pattern	13(4%)	5(2%)	9(4%)
Elevated Troponin T	97/261 (37%)	65/244(27%)	29/190(15%)
Elevated NT-proBNP	159/225 (71%)	85/207(41%)	49/150(33%)

LVH: Left ventricular hypertrophy. *The difference between the number of alive patients and the smaller number of ECGs can be explained because patients were discharged (largest effect at 8 days) or because of study logistics.

Of the individual ECG abnormalities, a prominent U-wave was the most common with a prevalence of 33% (27% on 8th day) together with negative T-waves in 30% (27% on 8th day). Twenty percent of patients had a normal ECG on admission versus 31% at the 8th day after the aSAH. Thirty seven percent had elevated troponin T on admission and 71% had elevated NT-proBNP.

Course of WMA over time:

WMA were present in 58/277 (21%) patients on admission and in 29/187(16%) of those who were still alive and not yet discharged from hospital on day 8 (26 patients had died on the 8th day after the aSAH). Of the 58 patients with WMA on admission, 14 had a normal LV function on the 8th day(see Figure 1 which demonstrates the dynamic nature of the WMA. In this figure only the patients with complete follow up (3 echocardiograms) are shown).




Figure 1: shows the dynamic nature of wall motion abnormalities by depicting the course of the wall motion score index (WMSI) over time. Panel A shows patients with WMSI > 1 on the admission echo. Panel B shows patients that had a normal WMSI on admission but developed a WMSI > 1 on the 4th day after the aSAH. NOTE: Only patients that completed follow-up are shown in this figure. 28 patients had WMSI>1 on admission but died or were discharged before the 4th or 8th day after the aSAH, these but are not shown in panel A.

Of the 58 patients with WMA on admission 36 had positive troponin T. Of the 16 patients with WMA on day 4 but no WMA on admission 7 had positive troponin T. Results from the sensitivity analysis after exclusion of patients with an episode of rebleeding were comparable with those of the main analysis. The WMA did not correspond to a single coronary territory. A pattern of WMA of the apical segments with hypercontractility of the basal segments, compatible with Takotsubo cardiomyopathy, was found in 25/271(9%) of patients.

Risk factors for early and delayed WMA:

Table 3 shows the univariable associations of the determinants and early and late WMA.

Table 3: shows the univariable ORs with determinants for early and late WMA.

Determinants*	Early WMA	Late WMA
Age > 50 years	1.7(0.9-3.4)	0.6(0.3-1.5)
Female sex	0.6(0.3-1.2)	0.9(0.4-2.2)
Poor WFNS	3.0(1.6-5.5) [‡]	1.1(0.5-2.6)
Hijdra >19	1.4(0.8-2.4)	0.9(0.4-2.2)
Acute hydrocephalus	0.6(0.3-1.1)	0.5(0.2-1.1)
Aneurysm in carotid circulation [†]	1.1(0.6-2.1)	1.9(0.8-4.4)
Sinusbradycardia	0.4(0.1-1.3)	0.5(0.1-2.4)
Sinustachycardia	3.3(1.3-8.9) [‡]	2.9(0.9-9.9)
Low voltage	3.2(0.8-11.8)	9.6(1.8-50.7) [‡]
Pathologic Q wave	1.0(0.99-1.0)	1.0(0.99-1.0)
ST depression	5.8(2.4-14.4) [‡]	2.5(0.7-9.8)
ST elevation	31.8(3.8-264.5) [‡]	NE
Negative T-waves	2.4(1.3-4.8) [‡]	1.5(0.6-3.6)
Prominent U-waves	0.6(0.3-1.1)	1.1(0.5-2.7)
QTc prolongation > 500ms	1.7(0.8-3.7)	1.8(0.6-5.3)
LVH on ECG	0.7(0.5-1.1)	0.8(0.5-1.2)
Strain pattern on ECG	0.8(0.2-3.7)	0.9(0.1-7.8)
Myocardial infarction pattern	3.6(1.0-12.1) [‡]	8.0(2.0-32.2) [‡]
Elevated Troponin T	4.2(2.2-7.9) [‡]	3.9(1.6-9.7) [‡]
Elevated NT-proBNP	2.6(1.04-6.7) [‡]	1.6(0.5-5.2)
Decreased GFR	0.96(0.9-1.0)	0.99(0.9-1.1)

*The ORs of medical history (angina pectoris, myocardial infarction, prior coronary artery bypass graft(CABG), prior angioplasty, known hypertension, hypercholesterolemia, peripheral vascular disease, cerebrovascular events(ischemic or hemorrhagic), diabetes mellitus, current cigarette smoking or family history of coronary artery disease) with early and late WMA are not shown as they were not significantly associated. [†] includes anterior communicating artery, anterior cerebral artery, middle cerebral artery and internal carotid artery. [‡]These determinants were included in the multivariable analyses. Abbreviations: LVH: Left ventricular hypertrophy; WMA: wall motion abnormalities; GFR: glomerular filtration rate. NE: not estimable.

In the multivariable analyses (determinants marked in table 3), poor WFNS OR 2.7 (1.1-6.8), sinus tachycardia OR 5.0 (1.3-19.9), ST-depression OR 3.7 (1.02-13.1), ST-elevation OR 16.6 (1.5-178.9) and elevated troponin T OR 2.8 (1.1-7.3) predicted early WMA. Myocardial infarct pattern on the admission ECG with an OR 6.8(1.6-30) and elevated troponin T on admission with an OR 3.4 (1.4-8.5) predicted late WMA.

Discussion

WMA after aSAH may be present on admission, but can also develop during the course of the aSAH without a preceding rebleeding. Abnormal admission ECG (sinus tachycardia, ST-segment elevation or –depression) and positive troponin T are risk factors for early WMA, and a myocardial infarct pattern on the admission ECG and positive troponin T also predicts late WMA. The generally accepted hypothesis is that following the initial bleed a catecholamine release by the sympathetic nerve endings in the myocardium is responsible for the observed cardiac abnormalities.^{8, 17-19} Myocardial ischemia or infarction as a cause for the abnormalities is unlikely as normal myocardial perfusion was reported after aSAH.¹⁷ Risk factors for CAD such as smoking and hypertension were not associated with WMA in the univariable analyses, nor were the WMA associated with the perfusion territory of a single coronary artery. Nevertheless, we cannot exclude that at least in some patients the cardiac abnormalities were related to myocardial ischemia as some of the included patients, with risk factors for cardiovascular disease, may have had asymptomatic coronary artery disease (CAD). This is supported by our finding that an ECG compatible with an acute myocardial infarction predicts late WMA.

Our study is not unique in investigating prognostic significance of cardiac abnormalities after SAH. However, it distinguishes from other studies as only few studies investigated the time course of the WMA,^{7, 10} and we could not find any studies that investigated risk factors for late WMA. The studies published so far have given contradicting results on the associations between troponin release,^{3, 10, 20} BNP release²¹ and WMA on admission. Differences in study design, definitions of determinants and outcomes, and also assay (e.g. NT-proBNP versus of BNP) might explain the discrepant findings between studies. Moreover, most of the previous studies were retrospective, monocenter, or had a smaller sample size than our study. The prospective studies that have been performed used admission determinants disregarding the dynamic nature of the WMA.

Although our study was prospective, multicenter, and used predefined definitions for the clinical determinants, it still has some potential limitations. The number of patients with late development of WMA is rather small, which limits the power for analysis on risk factors for late development of WMA. This is partly due to missing data of the last investigation, mostly because patients had died or were discharged. Another potential limitations lies in the study design as observational studies are prone for several forms of bias.²² However, by using strict definitions for all determinants

and using liberal inclusion criteria we are confident we minimized potential bias. Another possible limitation of observational studies is the generalizability to large population cohorts. By designing this study as a multicenter national project in which the majority of the Dutch aSAH treatment centers participated, we are confident we minimized this limitation. Finally, we have no information on coronary arteries in our patients as coronary angiograms or cardiac CT scans were not routinely performed. The potential clinical benefit of our study is that troponin T may allow us to early identify patients with a risk of developing early and late WMA. As delayed cerebral ischemia(DCI), an important prognosticator for poor outcome, usually occurs 4-7 days after the aSAH,²³ the occurrence of late WMA may play an important role in the development of DCI. However, this needs further investigation. We suggest that patients with troponin T elevation after an aSAH are closely monitored and that cardiac evaluation is performed to evaluate presence of WMA. Our data suggest that therapy aimed at restoring LV function if the troponins are increased but WMA are not (yet) present may be beneficial. However, the present study does not answer the pathophysiologic question why positive troponins are risk factors for early and late WMA. We hypothesize that cardiac abnormalities may manifest as a spectrum with some patients having ECG changes, troponin release and a severe impaired left ventricular function. Others may present with only ECG changes and they may develop troponin release or WMA in a later phase of the disease. Furthermore, we cannot exclude that treatment such as triple H therapy, Nimodipine or vasopressors also plays a role. These questions warrant more research.

Indeed, some studies have suggested that the use of β -sympaticomimetics, phosphodiesterase inhibitors or calcium sensitizers can improve LV function.²⁴ ²⁵ As calcium overload due to the sympathetic catecholamine surge is suggested to be the mechanism of the WMA,²⁶ these drugs should be effective in recruiting inotropic reserve. However, a drop in blood pressure and left ventricular outflow tract obstruction is reported after the use of for example dobutamine which may be especially harmful in patients with aSAH as cerebral perfusion must be optimized. Furthermore, the cardiac effects of aSAH treatment, for example administration of nimodipine, a calcium antagonist to prevent cerebral vasospasm, are also unknown. Therefore, before implementing such strategies, it is critical that large randomized clinical trials are performed to evaluate any potential therapeutic consequence of our findings.

Conclusion:

We found that WMA may be present on admission or develop during the course of aSAH. Poor neurological condition on admission, sinus tachycardia, ST-depression and ST-elevation at the admission ECG and elevated troponin T, are independent predictors for early WMA, a myocardial infarct pattern on the admission ECG and elevated troponin T independently predict late WMA. This allows the treating physicians to identify patients at higher risk, possibly influencing clinical management. More research should be directed towards treatment option of WMA after aSAH.

Reference List

1. van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and Management. *Brain* 2001;124:249-278.
2. Zaroff JG, Leong J, Kim H, Young WL, Cullen SP, Rao VA, Sorel M, Quesenberry CP, Jr., Sidney S. Cardiovascular predictors of long-term outcomes after non-traumatic subarachnoid hemorrhage. *Neurocrit Care* 2012 December;17(3):374-381.
3. Naidech AM, Janjua N, Kreiter KT, Ostapkovich ND, Fitzsimmons BF, Parra A, Commichau C, Connolly ES, Mayer SA. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. *Archives of Neurology* 2005 March;62(3):410-416.
4. Yarlagadda S, Rajendran P, Miss JC, Banki NM, Kopelnik A, Wu AH, Ko N, Gelb AW, Lawton MT, Smith WS, Young WL, Zaroff JG. Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage. *Neurocrit Care* 2006;5(2):102-107.
5. Crago EA, Kerr ME, Kong Y, Baldisseri M, Horowitz M, Yonas H, Kassam A. The impact of cardiac complications on outcome in the SAH population. *Acta Neurol Scand* 2004 October;110(4):248-253.
6. van der Bilt I, Hasan D, van den Brink R, Cramer MJ, van der Jagt M, van KF, Meertens J, van den Berg M, Groen R, Ten CF, Kamp O, Gotte M, Horn J, Groeneveld J, Vandertop P, Algra A, Visser F, Wilde A, Rinkel G. Cardiac dysfunction after aneurysmal subarachnoid hemorrhage: Relationship with outcome. *Neurology* 2014 January 28;82(4):351-358.
7. Banki N, Kopelnik A, Tung P, Lawton MT, Gress D, Drew B, Dae M, Foster E, Parmley W, Zaroff J. Prospective analysis of prevalence, distribution, and rate of recovery of left ventricular systolic dysfunction in patients with subarachnoid hemorrhage. *J Neurosurg* 2006 July;105(1):15-20.
8. Mayer SA, Lin J, Homma S, Solomon RA, Lennihan L, Sherman D, Fink ME, Beckford A, Klebanoff LM. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. *Stroke* 1999 April;30(4):780-786.
9. Zaroff JG, Rordorf GA, Ogilvy CS, Picard MH. Regional patterns of left ventricular systolic dysfunction after subarachnoid hemorrhage: evidence for neurally mediated cardiac injury. *J Am Soc Echocardiogr* 2000 August;13(8):774-779.
10. Deibert E, Barzilai B, Braverman AC, Edwards DF, Aiyagari V, Dacey R, Diringner M. Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage. *J Neurosurg* 2003 April;98(4):741-746.
11. Anonymous. Report of World Federation on Neurological Surgeons committee on a universal subarachnoid hemorrhage grading scale. *J Neurosurg* 1988;68:985-986.
12. Hijdra A, Brouwers PJ, Vermeulen M, van Gijn J. Grading the amount of blood on computed tomograms after subarachnoid hemorrhage. *Stroke* 1990 August;21(8):1156-1161.
13. Vermeij F.H., Hasan D, Bijvoet H.W.C., Avezaat C.J.J. Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. *Stroke* 1998;29:924-930.
14. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal definition of myocardial infarction. *Circulation* 2007 November 27;116(22):2634-2653.
15. Som margren CE. Electrocardiographic abnormalities in patients with subarachnoid hemorrhage. *Am J Crit Care* 2002 January;11(1):48-56.
16. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 2002 January 29;105(4):539-542.

17. Zaroff JG, Rordorf GA, Titus JS, Newell JB, Nowak NJ, Torchiana DF, Aretz HT, Picard MH, Macdonald RL. Regional myocardial perfusion after experimental subarachnoid hemorrhage. *Stroke* 2000 May;31(5):1136-1143.
18. Samuels MA. Neurogenic heart disease: a unifying hypothesis. *Am J Cardiol* 1987 December 28;60(18):15J-19J.
19. Banki NM, Kopelnik A, Dae MW, Miss J, Tung P, Lawton MT, Drew BJ, Foster E, smith w, Parmley WW, Zaroff JG. Acute neurocardiogenic injury after subarachnoid hemorrhage. *Circulation* 2005 November 22;112(21):3314-3319.
20. Kothavale A, Banki NM, Kopelnik A, Yarlagadda S, Lawton MT, Ko N, Smith WS, Drew B, Foster E, Zaroff JG. Predictors of left ventricular regional wall motion abnormalities after subarachnoid hemorrhage. *Neurocrit Care* 2006;4(3):199-205.
21. Tung PP, Olmsted E, Kopelnik A, Banki NM, Drew BJ, Ko N, Lawton MT, smith w, Foster E, Young WL, Zaroff JG. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. *Stroke* 2005 July;36(7):1567-1569.
22. Hammer GP, du Prel JB, Blettner M. Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. *Dtsch Arztebl Int* 2009 October;106(41):664-668.
23. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. *Lancet* 2007 January 27;369(9558):306-318.
24. Naidech A, Du Y, Kreiter KT, Parra A, Fitzsimmons BF, Lavine SD, Connolly ES, Mayer SA, Commichau C. Dobutamine versus milrinone after subarachnoid hemorrhage. *Neurosurgery* 2005;56(1):21-6l.
25. Busani S, Rinaldi L, Severino C, Cobelli M, Pasetto A, Girardis M. Levosimendan in cardiac failure after subarachnoid hemorrhage. *J Trauma* 2010 May;68(5):E108-E110.
26. Wittstein IS. Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? *Cell Mol Neurobiol* 2012 July;32(5):847-857.

CHAPTER 5

Relationship between cardiac dysfunction and cerebral perfusion in patients with aneurysmal subarachnoid hemorrhage.

Cremers CH, van der Bilt IAC, van der Schaaf IC, Vergouwen MD, Dankbaar JW, Cramer MJ, Wilde AA, Rinkel GJ, Velthuis BK.
Neurocrit Care. 2015 Aug 12 *epub ahead of print.*

Abstract

Introduction: Cardiac dysfunction may occur after aneurysmal subarachnoid hemorrhage (aSAH). Although it is associated with poor outcome, the pathophysiological mechanism of this association remains unclear. We investigated the relationship between cardiac function and cerebral perfusion in patients with aSAH.

Methods: We studied 72 aSAH patients admitted within 72 hours after ictus with echocardiography and cerebral CT perfusion within 24 hours after admission. Cardiac dysfunction was defined as myocardial wall motion abnormalities or positive troponin. In patients with and without cardiac dysfunction, we calculated mean perfusion (cerebral blood flow (CBF) and time to peak (TTP)) in standard regions of interest and calculated differences with 95% confidence intervals (95%CI).

Results: In 35 patients with cardiac dysfunction minimal CBF was 15.83 mL/100g/min compared to 18.59 in 37 without (difference of means: -2.76; 95%CI:-5.43 to -0.09). Maximal TTP was 26.94 seconds for patients with and 23.10 seconds for patients without cardiac dysfunction (difference of means: 3.84; 95%CI:1.63 to 6.05). Mean global CBF was 21.71 mL/100g/min for patients with cardiac dysfunction and 24.67 mL/100g/min for patients without cardiac dysfunction (-2.96; 95%CI:-6.19 to 0.27). Mean global TTP was 25.27 seconds for patients with cardiac dysfunction and 21.26 for patients without cardiac dysfunction (4.01; 95%CI:1.95 to 6.07).

Conclusion: aSAH patients with cardiac dysfunction have decreased focal and global cerebral perfusion. Further studies should evaluate whether this relation is explained by a direct effect of cardiac dysfunction on cerebral circulation or by an external determinant, such as a hypercatecholaminergic or hypometabolic state, influencing both cardiac function and cerebral perfusion.

Introduction

Cerebral perfusion can be affected shortly after aneurysmal subarachnoid hemorrhage (aSAH).¹ Cardiac dysfunction, consisting of echocardiographic wall motion abnormalities (WMAs), ECG changes and positive troponins suggestive of myocardial damage, may also occur after aSAH. The WMAs are independently associated with poor outcome after aSAH.² The pathophysiology behind this finding is unclear. To investigate whether the increased risk of poor functional outcome in patients with cardiac dysfunction² is explained by lower cerebral perfusion, a first step is to identify whether a relationship between cardiac function and cerebral perfusion exists. Therefore the aim of this study was to investigate the relationship between cardiac dysfunction and cerebral perfusion in patients with aSAH.

Methods

Design

Patients were retrieved from a prospectively collected series of aSAH patients who were admitted to the University Medical Center Utrecht between 2005 and 2008 and participated in the SEASAH (Serial Echocardiography After SubArachnoid Hemorrhage) study.² Patients enrolled in the SEASAH study had to be admitted within 72 hours after ictus and underwent echocardiography and blood testing within 24 hours after admission. As part of routine care in our institution all patients with aSAH undergo non-contrast CT (NCCT), CT perfusion (CTP) and CT-angiography (CTA) on admission, unless contrast contraindications exist. The SEASAH study was approved by the national and local hospital medical ethics committees. Informed consent was obtained from the patient or next of kin.

Echocardiography and troponin release

Transthoracic echocardiography was performed within 24 hours after admission. Two cardiologists, unaware of clinical and cerebral perfusion data, independently assessed the presence or absence of WMAs according to American Society of Echocardiography standards.³ More details on the scoring of WMAs are published earlier.² For assessment of troponin release, the upper limits of normal as defined by the local laboratory were used as reference. Patients were dichotomized in “cardiac dysfunction” (with WMAs or positive troponins) or “no cardiac dysfunction” (no WMAs and negative troponins).


CT imaging

CT imaging was performed on 16- or 64-multidetector CT scanners (Philips Healthcare). For CTP, 40 mL of non-ionic contrast agent (Iopromide, Ultravist, 300 mg iodine/mL, Schering) followed by 40 mL saline was injected intravenously at a rate of 5 mL/s. One image per 2 seconds was acquired during 60 seconds, with 512x512 matrix, 160-220 mm field-of-view, and UB filter. Scan parameters were: 16 slice, 90 kVp, 150 mAs, 8x3 mm collimation; 64 slice, 80 kVp, 150 mAs, 64x0.625 mm collimation. Depending on the multidetector type CT scanner, for the CTA scan another 60-80 mL of contrast was injected at a rate of 5 mL/s, followed by a 40 mL saline flush at a rate of 5 mL/s. Imaging was performed with: 90-120 kVp, 150–300 mAs, 512x512 matrix, 200 mm field of view, 0.9–1 mm slice thickness, and 0.45–0.5 mm reconstruction increment.

CTP post-processing

CTP maps were evaluated on a workstation (Intellispace Portal, Philips Healthcare). A tracer delay insensitive algorithm was used to calculate the perfusion maps. Twelve regions of interest (ROIs) were drawn in the peripheral (cortical) and deep (basal ganglia) flow territories of the anterior (ACA), middle (MCA) and posterior cerebral artery (PCA) (Figure 1).

Figure 1: Standard regions of interest in the peripheral (cortical) and deep (basal ganglia) flow territories of the anterior, middle and posterior cerebral artery.



Quantitative values for cerebral blood flow (CBF) and time to peak (TTP) were obtained for each ROI. We chose CBF as a measure of cerebral perfusion and TTP to represent contrast delay. The ROI with the lowest CBF value and the ROI with the highest TTP value of the 12 ROIs was selected, as this represents the brain tissue with the lowest perfusion. In addition, we calculated the mean global CBF and TTP of all the ROIs.

CTA imaging

All admission CTAs were evaluated in consensus by two experienced radiologists (IvdS, BKV). Early vasospasm was interpreted as none to mild (<25%), moderate (25-50%) or severe (>50%) arterial narrowing that could not be attributed to atherosclerosis.⁴

Analyses

In patients with and without cardiac dysfunction we compared minimal CBF and maximal TTP values on CTP to compare focal perfusion deficits and mean CBF and TTP values to compare global perfusion. Differences of means with 95% confidence intervals (95%CI) were calculated.

Results

We included 72 aSAH patients, of whom 35 had cardiac dysfunction; 11 with both WMAs and positive troponins, 5 had WMAs but negative troponins, and 19 had positive troponins and no WMAs (Table 1). Patients with cardiac dysfunction had a worse clinical condition on admission compared to patients without cardiac dysfunction. The amount of extravasated blood on admission was comparable between patients with and without cardiac dysfunction (Table 1).

Table 1: Patient characteristics

	Cardiac dysfunction (n=35)	No cardiac dysfunction (n=37)
Women	29 (83%)	28 (76%)
Age (mean, range)	61.9 (41.1 – 85.7)	58.1 (26.9 – 87.6)
Amount of extravasated blood (Hijdra score*) on admission (median, range)	17 (0 – 29)	19 (0 – 32)
Clinical condition (WFNS-score) on admission		
I	8 (23%)	24 (65%)
II	7 (20%)	5 (14%)
III	5 (14%)	2 (5%)
IV	7 (20%)	4 (11%)
V	8 (23%)	2 (5%)
Aneurysm location		
Internal carotid artery	3 (9%)	2 (5%)
Anterior communicating and cerebral arteries	18 (51%)	19 (51%)
Middle cerebral artery	4 (11%)	6 (16%)
Posterior communicating artery	3 (9%)	8 (22%)
Vertebrobasilar circulation**	7 (20%)	2 (5%)
Aneurysm treatment		
Clip	7 (20%)	14 (38%)
Coil	25 (71%)	23 (62%)
None	3 (9%)	0 (0%)

n = number; WFNS = World Federation of Neurological Surgeons.

* Hijdra score describes the amount of blood in the cisternal and ventricular spaces.¹⁰

** Including vertebral, basilar, cerebellar and posterior cerebral arteries.

Mean CBF of the ROI with the lowest value was 15.83 mL/100g/min for patients with cardiac dysfunction and 18.59 mL/100g/min for patients without cardiac dysfunction (difference of means: -2.76; 95%CI:-5.43 to -0.09). Mean global CBF was 21.71 mL/100g/min for patients with cardiac dysfunction and 24.67 mL/100g/min for patients without cardiac dysfunction (-2.96; 95%CI:-6.19 to 0.27). Mean TTP of the ROI with the highest value was 26.94 seconds for patients with and 23.10 seconds for patients without cardiac dysfunction (difference of means 3.84; 95%CI:1.63 to 6.05). Mean global TTP was 25.27 seconds for patients with cardiac dysfunction and 21.26 for patients without cardiac dysfunction (4.01; 95%CI:1.95 to 6.07) (Table 2).

Table 2: Perfusion values (with 95% confidence intervals)

	Cardiac dysfunction (n=35)			No cardiac dysfunction (n=37)	
	All	WMAs and positive troponins (n=11)	WMAs only (n=5)	Positive troponins only (n=19)	
Focal perfusion					
Minimal CBF (mL/100g/min)	15.83 (14.17-17.49)	16.13 (12.22-20.03)	17.14 (10.16-24.11)	15.32 (13.30-17.34)	18.59 (16.47-20.72)
Maximal TTP (s)	26.94 (25.56-28.32)	28.39 (26.10-30.67)	24.81 (20.14-29.48)	26.66 (24.60-28.72)	23.10 (21.34-24.85)
Global perfusion					
Mean CBF (mL/100g/min)	21.71 (19.87-23.55)	22.47 (18.05-26.88)	23.03 (15.63-30.42)	20.93 (18.72-23.13)	24.67 (21.99-27.35)
Mean TTP (s)	25.27 (23.97-26.56)	26.56 (24.71-28.42)	22.98 (18.23-27.73)	25.12 (23.14-27.10)	21.26 (19.63-22.88)

n = number; WMAs = wall motion abnormalities; CBF = cerebral blood flow; TTP = time-to-peak.

Early vasospasm was seen in only two patients (2.8%) on admission CTA. One patient had severe (>50%) arterial narrowing of the right MCA bifurcation in the presence of a MCA aneurysm, substantial SAH and a large intracerebral hematoma. The lowest perfusion values were also seen in the right MCA territory. The other patient had more diffuse bilateral moderate (25-50%) narrowing of both MCA and ACA in the presence of an anterior communicating artery aneurysm. In this patient lowest perfusion values were seen in the right thalamus and the right PCA territory. Both patients with early vasospasm were in the subgroup with cardiac dysfunction, one had increased troponins and one patient had WMAs. Excluding these two patients did not change the results.

Discussion

The results of our study show that aSAH patients with cardiac dysfunction have an impaired cerebral perfusion, both on a focal and global level.

Cardiac complications following central nervous system events such as ischemic or hemorrhagic stroke, brain tumors and even emotional stress have been described extensively.⁵⁻⁶ In recent years there has been increasing interest in this “heart-brain axis” and its clinical implications. Early onset cardiac and cerebral dysfunction are both related to poor outcome after aSAH.^{2,7} Understanding the pathophysiology

of this early heart-brain dysfunction may have implications for preventing cerebral hypoperfusion after aSAH and therefore for better outcome.

The clinical impact of lower cerebral perfusion is not well understood, as it is unknown at what perfusion value thresholds patients develop cerebral ischemia in the context of aSAH. We could not study the influence of elevated intracranial pressure as a possible cause of cerebral hypoperfusion, as ICP measurements are not part of routine care in all aSAH patients in our hospital. Moderate to severe early vasospasm ($\geq 25\%$ arterial luminal narrowing) was only seen in 2 patients on CT angiography that was performed on admission in all patients.

The worse clinical condition in patients with cardiac dysfunction might therefore be explained by a lower cerebral perfusion caused by cardiac dysfunction, or by a systemic determinant that influences both cardiac dysfunction and cerebral perfusion, such as the hypercatecholaminergic response. Excessive release of norepinephrine from myocardial sympathetic nerve terminals may lead to denervation of both the myocytes and the nerve terminals and thereby to focal WMAs and cardiac dysfunction.⁸ In addition, this systemic hypercatecholaminergic response might also cause dysfunction of the cerebral autoregulation and thereby lead to perfusion deficits in the brain. Other potential mechanisms underlying early cerebral hypoperfusion after aSAH are endothelial dysfunction resulting from both the initial hypoperfusion insult as well as the pro-inflammatory, pro-thrombotic and pro-vasoconstriction properties of extravasated subarachnoid blood. Another possible explanation is a hypometabolic state, which was also found to be associated with the early cerebral hypoperfusion in a PET study in SAH patients.⁹

In this study we investigated whether a relationship between cardiac function and cerebral perfusion exists in patients with aSAH. We were unable to determine whether this is a causal relationship.

Further studies need to evaluate whether cerebral hypoperfusion occurring soon after aSAH is explained by cardiac dysfunction or by an external determinant, such as a hypercatecholaminergic reaction or hypometabolic state, influencing both cardiac function and cerebral perfusion. Future studies could also investigate whether treatment of cardiac dysfunction or a systemic response, improves cerebral perfusion and thereby prognosis.

Reference List

1. Schubert GA, Seiz M, Hegewald AA, Manville J, Thome C. Acute hypoperfusion immediately after subarachnoid hemorrhage: a xenon contrast-enhanced CT study. *J Neurotrauma* 2009; 26: 2225-2231.
2. Van der Bilt I, Hasan D, van den Brink R, et al. Cardiac dysfunction after aneurysmal subarachnoid hemorrhage: relationship with outcome. *Neurology* 2014; 82: 351-358.
3. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 2002; 105: 539-542.
4. Baldwin ME, Macdonald RL, Huo D, et al. Early vasospasm on admission angiography in patients with aneurysmal subarachnoid hemorrhage is a predictor for in-hospital complications and poor outcome. *Stroke* 2004; 35: 2506-2511.
5. Kallmunzer B, Breuer L, Kahl N, et al. Serious cardiac arrhythmias after stroke: incidence, time course, and predictors—a systematic, prospective analysis. *Stroke* 2012; 43: 2892-2897.
6. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Eng J Med* 2005; 352: 539-548.
7. Kamp MA, Heiroth HJ, Beseoglu K, Turowski B, Steiger HJ, Hanggi D. Early CT perfusion measurement after aneurysmal subarachnoid hemorrhage: a screening method to predict outcome? *Acta Neurochir Suppl* 2012; 114: 329-332.
8. Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy – a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. *Nat Clin Pract Cardiovasc Med* 2008; 5: 22-29.
9. Frykholm P, Andersson JL, Langstrom B, Persson L, Enblad P. Haemodynamic and metabolic disturbances in the acute stage of subarachnoid haemorrhage demonstrated by PET. *Acta Neurol Scand* 2004; 109: 25-32.
10. Hijdra A, Brouwers PJ, Vermeulen M, van Gijn J. Grading the amount of blood on computed tomograms after subarachnoid hemorrhage. *Stroke* 1990; 21: 1156-1161.

CHAPTER 6

Myocarditis in patients with subarachnoid hemorrhage: a histopathological study

van der Bilt IAC, Vendeville JP, van de Hoef TP, Begieneman MPV,
Lagrand WK, Kros JM, Wilde AAM, Rinkel GJE, Niessen HWM. *J Crit Care.*
2015 Dec 11 *epub ahead of print.*

Abstract:

Introduction: Cardiac abnormalities after subarachnoid hemorrhage (SAH) such as ECG changes, echocardiographic wall motion abnormalities and elevated troponin levels, are independently associated with a poor prognosis. They are caused by catecholaminergic stress coinciding with influx of inflammatory cells into the heart. These abnormalities could be a sign of a myocarditis, potentially giving insight in pathophysiology and treatment options. These inflammatory cells are insufficiently characterized, and it is unknown whether myocarditis is associated with SAH.

Methods: Myocardium of 25 patients who died from SAH and 18 controls was stained with antibodies identifying macrophages (CD68), lymphocytes (CD45) and neutrophil granulocytes (MPO). Myocytolysis was visualized using complement staining (C3d). CD31 was used to identify putative thrombi. We used Mann-Whitney-U testing for analysis.

Results: In the myocardium of SAH patients the amount of MPO ($p < 0.005$), CD45 ($p < 0.0005$), and CD68 ($p < 0.0005$) positive cells was significantly higher compared to controls. Thrombi in intramyocardial arteries were found in 22 SAH patients and 1 control. Myocytolysis was found in 6 SAH patients but not in controls.

Conclusion: Myocarditis, consisting of an influx of neutrophil granulocytes, lymphocytes and macrophages, coinciding with myocytolysis and thrombi in intramyocardial arteries, occurs in patients with SAH but not in controls. These findings might explain the cardiac abnormalities after SAH, and may have implications for treatment.

Introduction

Cardiac dysfunction following subarachnoid hemorrhage (SAH), such as ECG changes, wall motion abnormalities and troponin release, occurs frequently and is associated with poor prognosis.¹ The massive sympathetic activation following the SAH leads to a catecholamine release in the myocardium which is thought to cause these cardiac abnormalities.² On a cellular level, catecholamine release has been associated with myocardial damage.²⁻⁶ Literature is limited and early pathology studies that reported on myocardial cellular infiltration and myocytolysis following SAH, using immunohistochemical staining⁷, did not classify the inflammatory response nor did they specify the types of inflammatory cells in the heart. According to the Dallas criteria, myocardial infiltration of inflammatory cells and myocytolysis qualifies as a myocarditis.⁸ Myocarditis after SAH has never been established but is a plausible explanation in the pathway from catecholamine release; it may explain the cardiac abnormalities and may have important clinical implications for treatment and prognosis. Therefore, the objectives of the present study were to characterize the infiltration of inflammatory cells in the heart after SAH compared to controls, to investigate whether this cellular infiltration meets criteria for the diagnosis myocarditis and to search for other myocarditis stigmata such as myocytolysis and intra-arterial thrombi.

Methods

Patients' Selection

Myocardium of patients who died from SAH between 1994 and 2004 was obtained from the departments of Pathology of the VU University Medical Center Amsterdam, the Netherlands and the Erasmus Medical Center Rotterdam, the Netherlands. The pathology databases were searched for cases in which SAH was documented as cause of death, as indicated by the clinician requesting autopsy, in concomitance with the presence of subarachnoid blood documented in the autopsy report. As a control group, myocardium of oncologic patients without cardiac involvement of the disease whom did not receive cardiotoxic chemotherapy or radiotherapy in the cardiac region was obtained. Control patients who died from a neurological disease or potentially suffered from an underlying disease associated with cardiac inflammation, e.g. sepsis, were excluded. The study was approved by and performed according to the guidelines

of the local medical ethics committee, and in accordance with the Declaration of Helsinki. Use of material for research after completion of a pathological examination is part of the patient contract in the participating hospitals.

Immunohistochemistry

The heart tissue samples of both the SAH patients and the control subjects were fixed in 4% buffered formaldehyde solution and embedded in paraffin for the preparation of 4 μm sections. Sections were then dewaxed, dehydrated, and antigen retrieval was performed by boiling in 10 mM sodium citrate buffer, pH 6.0, for 10 minutes in a microwave oven. Sections were pre-incubated with normal serum for 10 minutes. Rabbit serum was used for monoclonal antibodies; swine serum was for polyclonal antibodies. Pre-incubation was followed by incubation with primary antibodies for 1 hour.

The primary antibodies that we used are: Myeloperoxidase (MPO), mouse anti-human CD68, mouse anti-human CD45, rabbit anti-human Complement C3d and mouse anti-human CD31, all from Dako Cytomation, Denmark.

Sections were subsequently rinsed in Phosphate Buffered Saline (PBS), and incubated with a biotin-labeled secondary antibody (Rat-anti-Mouse-biotin (R α M-biotin) or Swine-anti-Rabbit-biotin (S α R-biotin)) for 30 minutes. After washing in PBS, sections were incubated with streptavidin-biotin complex/HRP (sABC/HRP) for 1 hour. After the sABC/HRP incubation, sections were rinsed with PBS, followed by visualization with 3,3'-diaminobenzidine (DAB 0.1 mg/mL, 0.02% H2O2). Sections were subsequently counterstained with hematoxylin, dehydrated and covered. As a control, the same staining procedure was used, but instead of primary monoclonal or polyclonal antibody, PBS was used.

Morphometric analysis

Two observers (I.B., W.L) scored the number of extravascular neutrophil granulocytes (MPO positive), lymphocytes (CD45 positive) and macrophages (CD68 positive). This was done by counting the number of positive cells within a fixed grid drawn on the microscopic slide with the specimen. To minimize inter-observer variability, some of the slides were scored on a two person multi-viewing microscope, some were done separately. Additionally a third observer, an experienced pathologist, checked samples at random. Both observers were blinded with respect to the origin of the slides (SAH versus controls). In case of significant differences in scoring results between the 2 observers, both observers examined the same myocardial slides simultaneously.

After this, consensus was achieved by the 2 observers. The number of extravascular inflammatory cells per 100 mm² was then calculated. Myocytolysis was defined as Complement (C3d) positivity of cardiomyocytes. Finally, the number of putative thrombi (CD31 positive) in intramyocardial arteries was scored and calculated per 100 mm². Myocarditis was classified according the Dallas criteria as “myocarditis”: an aggregation of inflammatory cells in the myocardium coincided with areas of myocytolysis, or “borderline myocarditis”: when aggregation of inflammatory cells in the myocardium was documented without myocytolysis.

Statistical analysis

Distribution of data was checked using Kolmogorov-Smirnoff analyses. After that, non-parametric testing using Mann-Whitney U was used for differences between groups. A sensitivity analysis was performed for patients with a proven aneurysm on autopsy and the patients with SAH without an aneurysm. A p-value <0.05 was considered statistically significant.

Results

Myocardial tissue samples of 25 patients were retrieved from the pathology databases. Baseline characteristics could be retrieved for 23 patients. Mean age was 59(±SD15) years of age, and 11 patients (44%) were female. In 16 patients (64%) a culprit aneurysm was reported on autopsy. Duration from hospital admission to death ranged from 2 hours to 21 days. As depicted in Figure 1, there was a large spread in the number of cells per individual patient.

Myocardial tissue of 18 control patients was used as a control group. Figure 2 shows the mean number of cells in SAH patients compared to controls. Compared to the control group, the amount of MPO, CD45, and CD68 positive cells was significantly higher in SAH patients (p<0.005 for all).

Figure 1: Number of myeloperoxidase (MPO), CD45 and CD68 positive cells per individual patient. The horizontal axis represents individual patients with SAH.





Figure 2: Mean number of myeloperoxidase (MPO), CD45 and CD68 positive cells in SAH and to controls with standard deviations. Compared to the control group, in SAH patients the amount of MPO ($p < 0.005$), CD45 ($p < 0.0005$), and CD68 ($p < 0.0005$) positive cells was significantly higher.



In six patients with SAH (24%) spots with C3d positive cells, indicating myocytolysis, were documented, and these patients consequently fulfilled the Dallas criteria for myocarditis. In contrast, no C3d positive cells were documented in the controls. Intramyocardial thrombi were found in 22 SAH patients (88%), and in only

one control patient. Sensitivity analyses showed no difference in the number of inflammatory cells or myocytolysis in patients with- or without proven aneurysm.

Discussion

In the present autopsy study we documented an influx of neutrophil granulocytes, lymphocytes and macrophages into the myocardium of patients who died following SAH. In some this coincided with myocytolysis and thrombi in intramyocardial arteries. According to the Dallas criteria this finding suggests that patients with SAH have a borderline myocarditis and some have a myocarditis.

Although other studies have reported on myocardial cellular infiltration and myocytolysis after SAH, classification of the inflammatory cells is not described before and we could not find previous studies establishing myocarditis after SAH. Most studies focused on the myocardial cell damage after SAH, only a few studies used immunohistochemical staining methods which were not specific for the type of cell.

There is overwhelming evidence from clinical and experimental studies that catecholaminergic stress after acute cerebral lesions causes myocardial cell damage.^{3, 9-16} However, influx of inflammatory cells in the myocardium was not investigated.

Intramyocardial catecholamine release by sympathetic nerve endings has been suggested as the primary source of the catecholamines, since experimental SAH studies showed no myocardial damage following SAH in sympathectomized baboons, while extensive myocardial damage was documented in adrenalectomized dogs.¹⁷ This hypothesis is supported by the finding that cardiomyocytolysis after SAH is more prevalent in the direct surrounding of the sympathetic nerve terminals.¹⁸

We found evidence of thrombi in the intramyocardial arteries. It is known that myocarditis may cause vasospasm which may cause the formation of thrombi. Thrombi might cause obstruction of the microarteries thus causing myocardial infarction.^{19, 20} Several other studies reported patchy subendocardial infarction after SAH, suggesting that thrombi, and likely myocarditis, were present in these cases as well.^{6, 12, 21}

The clinical relevance of our study is that treatment of cardiac abnormalities after SAH may improve outcome as they are associated with poor outcome independent of other clinical parameters.²² Our finding that myocarditis with microvascular thrombosis occurs in patients who die from SAH, has some potential clinical

implications. As treatment with inotropics, or sometimes even immunosuppressives may be beneficial in infectious myocarditis, we speculate that these treatments can be beneficial in SAH patients as well. Additionally, the myocardial microthrombosis found in this study suggests that antithrombotic therapy is an interesting treatment option in SAH patients. This suggestion is further supported by the finding that intracranial microthrombosis probably plays a role in the pathogenesis of DCI after SAH.²³ However, this is speculative and more research should be done to substantiate this.

Other conditions with acute catecholaminergic stress such as pheochromocytoma²⁴ or pulmonary embolism²⁵ have also been associated with myocarditis. Moreover, stress cardiomyopathy also known as Takotsubo cardiomyopathy, which is caused by acute sympathetic stress, has been linked to myocarditis using cardiac magnetic imaging that showed edema and late gadolinium enhancement indicating inflammation.²⁶ However, whether the catecholamine myocarditis is a reaction to cell damage or that catecholamines trigger another pathway (e.g. apoptosis of endothelial cells) that attracts the inflammatory cells is unknown.

Although we feel our study sufficiently shows evidence of a myocarditis in patients with SAH compared to controls, our study has shortcomings. Because we performed a retrospective search of the pathology database, detailed clinical data were unavailable to us. Because the reason of the clinician to request an autopsy was often unknown, this includes the risk of bias. Thus, we cannot draw conclusions on the proportion of SAH patients that have myocarditis. A prospective histopathology study is needed to answer these questions. Another limitation is that autopsy did not confirm the presence of an aneurysm in all patients. Brain autopsy was not performed in all patients, because it requires additional consent, which is often not given by the family if the cause of death obviously was an intracranial one. For these patients we had only information provided by the clinicians written on the autopsy form, which is often rather limited. However, if neurologists or neurosurgeons write SAH as clinical information, they usually mean SAH from an aneurysm and not traumatic SAH invariably. Given the fact that these patients had died from SAH, an aneurysm, or other arterial course of the SAH such as intracranial artery dissection is likely. Moreover, the sensitivity analysis excluding the patients without an aneurysm found similar results as in the main analysis.

Conclusion

Myocardial infiltration by macrophages, lymphocytes and neutrophil granulocytes coinciding with intramyocardial thrombi occurs frequently in patients with SAH. This indicates the presence of a myocarditis. Cardiac involvement after SAH expressed as myocarditis could explain the cardiac abnormalities observed following SAH. As cardiac abnormalities in SAH result in a worse prognosis, in consideration of the potential therapeutic and prognostic implications, further research aimed at recognition and treatment of myocarditis such as anti-inflammatory drugs, antithrombotic therapy or inotropics after SAH is warranted.

Reference List

1. van der Bilt IA, Hasan D, Vandertop WP, Wilde AA, Algra A, Visser FC, Rinkel GJ. Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis. *Neurology* 2009 February 17;72(7):635-642.
2. Masuda T, Sato K, Yamamoto S, Matsuyama N, Shimohama T, Matsunaga A, Obuchi S, Shiba Y, Shimizu S, Izumi T. Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. *Stroke* 2002 June;33(6):1671-1676.
3. Haft JI. Cardiovascular injury induced by sympathetic catecholamines. *Prog Cardiovasc Dis* 1974 July;17(1):73-86.
4. Eliot RS, Todd GL, Pieper GM, Clayton FC. Pathophysiology of catecholamine-mediated myocardial damage. *J S C Med Assoc* 1979 November;75(11):513-518.
5. Eliot RS, Todd GL, Clayton FC, Pieper GM. Experimental catecholamine-induced acute myocardial necrosis. *Adv Cardiol* 1978;25:107-118.
6. Kolin A, Norris JW. Myocardial damage from acute cerebral lesions. *Stroke* 1984 November;15(6):990-993.
7. Greenhoot JH, Reichenbach DD. Cardiac injury and subarachnoid hemorrhage. A clinical, pathological, and physiological correlation. *J Neurosurg* 1969 May;30(5):521-531.
8. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, Jr., Olsen EG, Schoen FJ. Myocarditis. A histopathologic definition and classification. *Am J Cardiovasc Pathol* 1987 January;1(1):3-14.
9. Connor RC. Myocardial damage secondary to brain lesions. *Am Heart J* 1969 August;78(2):145-148.
10. Koskelo P, Punsar S, Sipila W. Subendocardial hemorrhage and ECG changes in intracranial bleeding. *Br Med J* 1964;1:1479-1480.
11. Cropp GJ, Manning G.W. Electrocardiographic changes simulating myocardial ischemia and infarction associated with spontaneous intracranial hemorrhage. *Circulation* 1960;22:25-38.
12. Greenhoot J.H., Reichenbach D.D. Cardiac injury and subarachnoid hemorrhage. A clinical, pathological, and physiological correlation. *Neurosurgery* 1988;30:521-531.
13. Hersch C. Electrocardiographic changes in subarachnoid hemorrhage, meningitis, and intracranial space-occupying lesions. *Br Heart J* 1964;26:785-793.
14. Tung P, Kopelnik A, Banki N, Ong K, Ko N, Lawton MT, Gress D, Drew B, Foster E, Parmley W, Zaroff J. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. *Stroke* 2004 February;35(2):548-551.
15. Kettunen P. Subarachnoid haemorrhage and acute heart injury. *Clin Chim Acta* 1983 October 31;134(1-2):123-127.
16. Mayer SA, Lin J, Homma S, Solomon RA, Lennihan L, Sherman D, Fink ME, Beckford A, Klebanoff LM. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. *Stroke* 1999 April;30(4):780-786.
17. Novitzky D, wicomb W.N., Cooper DK, Rose AG, Reichart B. Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. *Ann Thorac Surg* 1986;41(5):520-524.
18. Hammermeister KE, Reichenbach DD. QRS changes, pulmonary edema, and myocardial necrosis associated with subarachnoid hemorrhage. *Am Heart J* 1969 July;78(1):94-100.
19. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. *Circulation* 1999 March 2;99(8):1091-1100.
20. Spodick DH. Infection and infarction. Acute viral (and other) infection in the onset, pathogenesis, and mimicry of acute myocardial infarction. *Am J Med* 1986 October;81(4):661-668.
21. Norris JW. Cardiovascular Manifestations of Acute Neurological Lesions. In: Aminoff M, editor. *Neurology and General Medicine*. San Francisco: Churchill Livingstone Inc.; 1989. p. 159-63.
22. van der Bilt I, Hasan D, van den Brink R, Cramer MJ, van der Jagt M, van KF, Meertens J, van den Berg M, Groen R, Ten CF, Kamp O, Gotte M, Horn J, Groeneveld J, Vandertop P, Algra A, Visser F, Wilde A, Rinkel G. Cardiac dysfunction after aneurysmal subarachnoid hemorrhage: Relationship with outcome. *Neurology* 2014 January 28;82(4):351-358.

23. Boluijt JC, Meijers C, Rinkel GJ, Vergouwen MD. Hemostasis and fibrinolysis in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a systematic review. *J Mol Cell Cardiol* 2015;35(5):724-733.
24. Roghi A, Pedrotti P, Milazzo A, Bonacina E, Bucciarelli-Ducci C. Adrenergic myocarditis in pheochromocytoma. *J Cardiovasc Magn Reson* 2011;13:4.
25. Begieneman MP, van de Goot FR, van der Bilt IA, Vonk NA, Spreeuwenberg MD, Paulus WJ, van Hinsbergh VW, Visser FC, Niessen HW. Pulmonary embolism causes endomyocarditis in the human heart. *Heart* 2008 April;94(4):450-456.
26. Eitel I, Lucke C, Grothoff M, Sareban M, Schuler G, Thiele H, Gutberlet M. Inflammation in takotsubo cardiomyopathy: insights from cardiovascular magnetic resonance imaging. *Eur Radiol* 2010 February;20(2):422-431.

CHAPTER 7

General Discussion

This thesis centers on the cardiac abnormalities that are associated with aneurysmal subarachnoid hemorrhage (aSAH). It is based on two observations: 1. The notion that cardiac abnormalities occur frequently after aneurysmal subarachnoid hemorrhage (aSAH) and that they might worsen clinical outcome; 2. The notion that stress cardiomyopathy, “The broken heart syndrome” or Tako-tsubo cardiomyopathy is increasingly being reported after several forms of acute physical or emotional stress and that it has striking similarities with the cardiac abnormalities observed after aSAH.

Stress induced cardiac abnormalities, which may mimic an acute coronary syndrome and predominantly occur in postmenopausal women, present with ECG changes, left ventricular dysfunction and cardiac specific serum enzyme- and protein elevation (CK-MB, Troponins, and NT-proBNP). Typically, there is absence of obstructive coronary artery disease. The characteristic echocardiographic finding is an aneurysmal apex with a hyperdynamic base, which resembles the shape of a Japanese octopus trap called Tako-tsubo (in Japanese Tako means octopus and Tsubo means trap, see figure 1), hence the name Tako-Tsubo cardiomyopathy.

Figure 1: Japanese octopus trap or Takotsubo. The octopus swims into the pot that lies on the ocean floor with food in it. The octopus cannot swim out because of the narrow neck. Courtesy of prof. Yoshihiro Akashi, Hiroshima for providing the Takotsubo. Photo made by me.




However, other distributions of wall motion abnormalities may occur as well. These WMA are not related to the perfusion territory of a single coronary artery. The abnormalities are reversible after 1-2 weeks and prognosis is reported to be excellent. Although reports and studies on stress cardiomyopathy are rapidly expanding, not much is known about this fascinating phenomenon. It is difficult to design reliable studies and estimate the sample size in a heterogeneous patient group with unknown prevalence and incidence of the disease that is subject of study. Most reports on stress cardiomyopathy are case reports or case series. Reports on incidence, predisposing factors, pathophysiology, prognosis or treatment are scarce and equivocal. Because aSAH is a disease with a poor outcome that is often complicated by cardiac abnormalities, we decided to use aSAH as a model for acute sympathetic stress and study the incidence, clinical characteristics and impact on outcome of stress cardiomyopathy after aSAH.

Aneurysmal subarachnoid hemorrhage

Aneurysmal subarachnoid hemorrhage is caused by rupture of a saccular aneurysm usually in the circle of Willis. Blood enters the subarachnoid (spider web) space under high pressure. The subarachnoid space is the anatomic space between the dura mater and the pia mater (figure 2).

Figure 2: Schematic drawing of the layers of the skull and subarachnoid space. From Wikipedia, usage under creative commons license (CCM)



This space is filled with trabeculae, giving it its spider web appearance, and contains cerebrospinal fluid. Typical symptoms of aSAH are acute onset “thunderclap” headache described as the worst headache patients have ever experienced. In the

acute phase there may be an altered- or loss of consciousness, nausea or vomiting. Coma and seizures are associated with poor outcome. The annual incidence of aSAH adjusted for age and sex, is 7.5-12.9 per 100,000 population per year. This devastating neurological disorder accounts for 22-25% of cerebrovascular deaths¹. Improvement of medical treatment has led to an improvement of outcome in patients with aSAH², although the mainstay of treatment remains obliteration of the aneurysm. Postoperative care is based on optimizing cerebral oxygenation, which is dependent on oxygenation of blood, oxygen transport capacity of the blood, and cerebral perfusion. A common complication with a negative impact on outcome is delayed cerebral ischemia (DCI) which usually occurs 4-7 days after the aSAH. This may be caused by multiple factors among which are vasospasm and hydrocephalus. Cerebral perfusion may be influenced by a number of other factors, among which, importantly, are cardiac output and blood pressure. The cardiac abnormalities after aSAH are sometimes accompanied by a drop in cardiac output and blood pressure, hence influencing patients' condition and neurological outcome unfavorable. In **Chapter 2** of this thesis we describe the results of our meta-analysis on the literature. We found that reported incidence varies widely. Furthermore, we found that cardiac abnormalities may be associated with poor outcome independent of other clinical variables. However, due to the limitation of the studies, no definitive conclusions could be made. We therefore launched the consecutive and prospective cohort study Serial Echocardiography After SubArachnoid Hemorrhage (SEASAH). The results of SEASAH are described in **Chapter 3** and **Chapter 4**. Most literature focuses on electrocardiographic abnormalities and/or echocardiographic abnormalities and/or biochemical changes. We analyzed and describe these cardiac investigations separately, although they all reflect on the same disease.

Electrocardiographic Changes and Cardiac Arrhythmia's

The first report of neurogenic electrocardiographic changes following a Central Nervous System (CNS) event occurred in 1938 when Aschenbrenner and Bodechtel³ stated that intracranial lesions may be responsible for ECG changes. Byer⁴ et al, in 1947, and Burch⁵ et al in 1954, found that these ECG abnormalities occur frequently in association with SAH. Since then, the majority of studies focused on ECG changes in aSAH. However, several other acute CNS events have also been reported to cause such abnormalities.⁶⁻²⁰

The frequency of ECG changes in association with SAH ranges between 50% and 90%²¹⁻²⁵. This large interval may largely be explained by the different monitoring

methods used in these studies and difference in study population. Brouwers et al.²¹ found that all patients with aSAH, monitored with serial ECG's, had ECG abnormalities. In the same study the authors found that poor outcome in patients with aSAH was associated with fast rhythm disturbances and/or electrocardiographic signs of cardiac ischemia. Arrhythmias occurred in 91% of patients monitored by 24 hour ECG monitoring after the onset of aSAH²⁶. Common ECG changes in aSAH are sinus bradycardia (50%), ST-segment changes (50%), T-wave abnormalities (48%), prominent U-wave (44%), QT interval abnormalities (39%), signs of left ventricular hypertrophy (36%), and sinus tachycardia (20%).^{21, 23, 27} Recent studies show that ECG changes after aSAH are correlated with echocardiographic abnormalities and biochemical markers of myocardial damage. Studies on the predictive value of ECG changes on impaired left ventricular systolic dysfunction are conflicting. Mayer et al.²³, in 1995, found that the presence of T waves or QT interval prolongation on any ECG was associated with 100% sensitivity and 81% specificity for echocardiographic left ventricular dysfunction. Davies et al.²² stated 15 years earlier that ECG changes have poor relation with echocardiographic abnormalities but are related to the severity of neurological injury. The latter is confirmed in a paper of Zaroff et al.²⁸, who also found that ECG changes have no independent predictive value for all-cause mortality. This is in accordance with a recent retrospective study of 159 patients²⁹ where ST depression was found to be more common in patients with poor outcome, but ECG changes were not independently related to outcome. The electrophysiological mechanism of the ECG changes seen in SAH remains unclear. Serum magnesium levels have been proposed as a possible factor. Van den Bergh et al.³⁰ found that lower serum magnesium levels are related to a long QTc interval.

In our meta-analysis which is described in **Chapter 2**, we found that Q waves, ST-segment depression, and T-wave abnormalities are associated with worsened clinical outcome. However in the multivariable analysis of the SEASAH study (**Chapter 3**) we found no independent clinical association of the ECG abnormalities with outcome, which indicated that they may be used as an indicator of cardiac dysfunction only. Patients with a normal ECG did not have cardiac dysfunction (unpublished). In conclusion, ECG changes occur frequently following aSAH, are related to a more severe neurological injury, but cannot be used as an independent predictor of outcome.

Left ventricular dysfunction

In addition to the ECG abnormalities described above, left ventricular systolic dysfunction has been described in patients with aSAH. Pollick et al.³¹ provided the first evidence for this in an echocardiographic study. However, as with de ECG data, epidemiological data on the occurrence of the LV dysfunction are conflicting. This may be due to the retrospective nature of most echocardiographic studies, the timing of the echocardiogram, and the difference in study population. Cardiac dysfunction not only occurs immediately after the onset of aSAH, but may also present several days after the aSAH. Pathophysiological data are lacking but this late dysfunction may be provoked by the initial aSAH as troponin may be elevated in patients with late onset dysfunction. Another possibility is that late cardiac dysfunction is caused by delayed cerebral ischemia, or recurrent bleeding ('rebleeds'). The largest prospective study to date was done by Sato et al.³² who performed echocardiography in 715 patients with aSAH. They found left ventricular dysfunction in 9.4% of the patients. This percentage might be underestimated because the authors only included patients with echocardiographic abnormalities on presentation to hospital. Patients with a normal LV function were not included in the study thus introducing selection bias. Another interesting observation is that the distribution of the wall motion abnormalities may vary. Typically, the apex is dyskinetic with a hyperdynamic base (typical Tako-Tsubo), but reversed Tako-Tsubo (hyperkinetic apex and akinetic base), midventricular Tako-Tsubo (hyperdynamic apex and base but hypokinetic midventricular portion of the myocardium), global hypokinesia or other segmental wall motion abnormalities have also been observed. The wall motion abnormalities usually do not correspond with the perfusion territory of one coronary artery. This makes coronary insufficiency as a cause unlikely. Furthermore, patients that underwent coronary angiograms indeed did not show any occlusion of a coronary artery. Several other studies showed that the wall motion abnormalities are reversible, thus suggesting supportive management in patients with aSAH and myocardial dysfunction. An important strength of the SEAS study is the prospective and consecutive nature and the serial echocardiography. We found that left ventricular dysfunction occurs frequently and that it is reversible. It presents at different time intervals after the onset of the aSAH and it is associated with poor outcome independent of other clinical variables (**Chapters 3 and 4**).

Myocardial damage and biochemical changes

Although many of the electrocardiographic and echocardiographic abnormalities following aSAH are typically those seen with myocardial ischemia from coronary

artery disease, pathological studies^{31, 33-35} and coronary angiography^{32, 36-39} have repeatedly failed to demonstrate this form of injury in such patients. In contrast to the belief that neurogenic changes on ECGs reflect purely electrical phenomena, affected patients frequently show evidence of structural cardiac damage, such as subendocardial infarctions, contraction band necrosis and myofibrillar lesions. These were first reported in the early 1960's after acute cerebral lesions.^{33, 35, 40-42} Focal myocardial necrosis was seen in animals after traumatic brain injury as early as the 1970s.⁴³ Elrifai et al.⁴⁴ performed electron microscopy on the myocardium of dogs with experimental SAH. Individual myocardial cell lesions with a swollen and loose appearance were described. The myocardial fibers appeared distorted and separated. Remarkably an unusual infiltration of fibroblasts and macrophages were present, indicating some form of inflammation. Several other authors describe the same microscopic finding.

Biochemical markers of myocardial damage are also frequently elevated and enzyme release seems to be related with the severity of the neurological injury.⁴⁵ We found that troponins are frequently elevated, are associated with poor outcome and that positive troponins on admission predict the occurrence of left ventricular dysfunction during admission (**Chapter 4**). Furthermore, in **Chapter 6** we describe myocarditis after aSAH. Data on troponins were lacking in that study, however it is plausible that the source of the troponins after aSAH is caused by an aseptic, catecholamine induced myocarditis. Clinical presentation of myocarditis consists of ECG changes, left ventricular dysfunction and positive troponins and this is similar to the changes observed after aSAH. Future studies are needed to elucidate not only the incidence and prevalence of this phenomenon, but also the identification of possible clinical predictive variables of myocardial damage and treatment options.


Etiology

Innervation of the heart

This thesis focusses on incidence and clinical relevance of cardiac abnormalities after aSAH, but not on pathophysiology. However, some data are available on potential etiologic factors. As already stated in the introduction of this thesis, Cushing⁴⁶ first reported that increased intracranial pressure due to cerebral tumors might lead to a substantial increase in blood pressure, a drop in heart rate, and slow irregular respiration. This is called the Cushing reflex. The Central Nervous System, consisting of a parasympathetic and a sympathetic pathway, innervates the heart through a

central autonomic network, consisting of the insular cortex, amygdala, hypothalamus, periaqueductal gray matter, parabrachial complex, nucleus of the tractus solitarius, and ventrolateral medulla (figure 3).

Figure 3: Schematic drawing of the anatomy and distribution of the cardiac nervous system. Adapted from: Kensuke Kimura et al. *Circulation Research*. 2012;110:325-336



It is known that stimulation of, epileptic seizures or stroke in particularly the insular cortex and amygdala may cause cardiac arrhythmias and other autonomic manifestations of cardiopulmonary dysfunction.^{47, 48}

In addition to the cardiopulmonary control of the above described anatomical structures, the nucleus of the vagus nerve contains, among others, neurons that innervate the heart and the lungs. The preganglionic fibers of the right vagus nerve supply mostly the sinoatrial node, whereas the left vagus fibers are concentrated at the atrioventricular node. Consequently, stimulation of the right vagus influences the heart rate; the atrioventricular conduction is affected by the left vagus. Moreover, it was recently shown that parasympathetic nerve fibers innervate both atria and ventricles. The nerve density is higher on the ventricular endocardium, but nerve thickness is greater on the epicardium. The right ventricle (RV) is more densely innervated than the LV, whereas the LV endocardium is more densely innervated than the RV endocardium.⁴⁹

The cardiac sympathetic nerves extend from the sympathetic neurons in stellate ganglia, which are located bilateral to the thoracic vertebra. Sympathetic nerve fibers project from the base of the heart into the myocardium, and are located predominantly in the subepicardium of the ventricle.

Sympathetic nervous activity is increased in patients with aSAH according to Naredi et al.⁵⁰ Plasma catecholamine concentrations are accepted as an index of sympathetic nervous activity in cardiovascular and neurological disorders and they are caused by a neurotransmitter spillover. Elrifai et al.⁴⁴ found that plasma catecholamine levels rose in their animal model with SAH and Sato et al.³² found elevated plasma catecholamine levels in their study with patients suffering from aSAH. Increased local release of catecholamines from the local nerve endings in the heart might mediate the cardiac abnormalities following acute CNS stress. Rona et al.⁵¹ first provided evidence that administration of high systemic doses of isoproterenol produced focal necrotic lesions in normal rat hearts. A transient severe coronary vasoconstriction causing ischemia, post ischemic left ventricle failure, and myocardial damage has been posed to be a consequence of the catecholamine release. This might cause a “neurogenic stunned myocardium”, referring to the post ischemic reperfusion injury. However, Zaroff et al.⁵² found no evidence of myocardial hypoperfusion in his experimental SAH study on dogs. A more plausible hypothesis is that a direct cardiotoxic effect of catecholamines leads to development of myofibrillar degeneration and subsequent myocardial dysfunction. Catecholamines may act on the β -adrenoreceptor, inducing reversible injury through excessive cellular Ca^{2+} -influx.

Also, autopsy on hearts of cerebrally injured patients revealed massive infiltration of inflammatory cells and contraction band necrosis or coagulative myocytolysis, both signs of myofibrillar degeneration.^{40, 42} Identical cardiac lesions were found in animal models with catecholamine infusion and in patients with pheochromocytoma.^{53, 54} As these lesions may also be induced in adrenalectomized animals⁴⁴, but not in brain dead sympathectomized baboons⁵⁵, it is concluded that a neurogenic mechanism is plausible. Furthermore, in **Chapter 6** we describe a study that suggests a myocarditis in patients with aSAH. Myocarditis would be a plausible explanation for the cardiac abnormalities that are observed after aSAH.

Another approach to neurogenic myocardial dysfunction may be constructed using purinergic signaling. This non-adrenergic, non-cholinergic neurotransmission was discovered by Burnstock et al. in the early 1960's.⁵⁶ The neurotransmitter appeared to be extracellular Adenosine-5'-triphosphate (ATP) and was found to be an indispensable co-transmitter for the sympathetic nervous system.⁵⁷ Mammalian cells have large quantities of the ATP molecule stored in secretory and synaptic vesicles of the sympathetic nerve endings.⁵⁸ ATP in the CNS triggers pro-inflammatory reactions, predominantly by activation of the P2X7 receptor, which results in production and release of pro-inflammatory cytokines. Concomitantly with massive sympathetic activation, ATP is secreted in high quantities before being converted into extracellular adenosine. In ischemic heart disease, adenosine is known to protect the myocardium from reperfusion damage and massive infarction.⁵⁹ Adenosine acts by opening ATP dependent potassium (KATP) channels, leading to membrane hyperpolarization, shortening of the cardiac action potential, and reduction of contractility.^{60, 61}

Conclusions, clinical implications and future perspectives

This thesis shows that cardiac abnormalities after aSAH occur often, that they are associated with prognosis, independently of other clinical variables, that they are transient, that they may occur days after the onset of the aSAH and disappear several days/weeks after the aSAH, and that their occurrence may be predicted using troponin. Most likely, cerebral perfusion is impaired because of cardiac dysfunction which is a possible the pathway through which prognosis is influenced. Finally, catecholamine induced myocarditis seems to occur after aSAH and would be a plausible explanation for the observed cardiac abnormalities.

The observed cardiac abnormalities after aSAH show striking similarities with stress cardiomyopathy or Tako-tsubo syndrome and they are reversible. Clinical implications of this thesis are: first, it may help physicians that are confronted with

a patient with aSAH and cardiac dysfunction to better understand it and to avoid invasive investigations such as coronary angiography and associated anticoagulation because of suspected myocardial infarction. Second: potential donor hearts in neurologically injured patients could be rejected, because structural heart disease cannot be excluded. However, as stress cardiomyopathy is reversible, these hearts could be used for transplantation although data is not available. Third: this thesis helps in understanding the cardiac dysfunction after aSAH and may guide clinicians in treatment as management of patients stress cardiomyopathy after aSAH has not been established. Because of the potential reversible nature, supportive management may be sufficient. Evidence for prophylaxis is not yet provided, although α - and β -receptor blockers have been suggested. Early studies have shown a possible beneficial effect on prevention of cardiac abnormalities after aSAH. In rabbits, an α -blocker prevented death and pulmonary edema after they had been infused with epinephrine.⁶² 90 patients with aSAH received orally the non-selective α -receptor blocker Phentolamine and the non-selective β -blocker Propranolol. Of the 12 patients that underwent autopsy, no myocardial lesions were found in the group that received drugs when they died. In the placebo group all patients had necrotic myocardial lesions.⁶³ Clinical use however, is still under discussion. Calcium antagonists, in particular nimodipine, have proven to have a beneficial effect on neurological outcome. The calcium channel blocker prevents delayed cerebral events (although incidence of vasospasm did not decrease) and improves clinical outcome, but may induce hypotension and the effect on cardiac dysfunction or myocarditis in aSAH is unclear. Furthermore, decreased cardiac output in the acute phase of aSAH may impair cerebral perfusion as is described in **Chapter 5**. Inotropic support, for example dobutamine and milrinone, has been effective in restoring cardiac function, although evidence is weak.^{64, 65}

The SEASAH paper in **Chapter 3** describes the results of a prospective multicenter study in the Netherlands in third line referral university centers. Clinical meaning of our study in other settings such as different healthcare logistics or hospitals with other aSAH protocols should be interpreted with caution. Since SEASAH was an observational study and although associations could be made, sound conclusions on pathophysiology or therapeutic options should be perceived with caution.

Future studies in patients with aSAH and cardiac dysfunction should be directed towards therapeutic studies such as inotropic therapy or immunosuppressives to improve outcome. Also, further understanding of the purinergic signaling is an important topic of study. Inhibition of purinergic signaling by the administration

of nucleotides receptors (for example the ATP receptor P2X7 or the ADP receptor P2Y12) and the inhibition of the different nucleotide ecto-enzymes which leads to a decrease in tissue adenosine level may prevent or decrease the cardiac abnormalities after aSAH and perhaps also in ischemic stunning. Finally, further insights in the catecholaminergic myocarditis which is described in **Chapter 6**, are needed. By using immunohistochemistry and for example investigating presence of adhesion molecules such as ICAM and VCAM in the myocardium of patients with aSAH, our knowledge on neurogenic myocardial dysfunction will be enriched.

Reference List

1. Brown RD, Whisnant JP, Sicks JD, Ofallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. *Stroke* 1996;27:373-380.
2. Vermeij F.H., Hasan D, Bijvoet H.W.C., Avezaat C.J.J. Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. *Stroke* 1998;29:924-930.
3. Aschenbrenner R, Bodechtel G. Uber EKG-Veränderungen bei Hirntumorkranken. *Klin Wochenschr* 1938;17:298-302.
4. Byer E, Ashman R, Toth LA. Electrocardiograms with large upright T waves and long Q-T intervals. *Am Heart J* 1947;33:796-806.
5. Burch GE, Meyers R, Abildskov JA. A new electrocardiographic pattern observed in cerebrovascular accidents. *Circulation* 1954;9:719-723.
6. Bernstein R, Mayer SA, Magnano A. Neurogenic stunned myocardium in Guillain-Barre syndrome. *Neurology* 2000 February 8;54(3):759-762.
7. Iga K, Himura Y, Izumi C, Miyamoto T, Kijima K, Gen H, Konishi T. Reversible left ventricular dysfunction associated with Guillain-Barre syndrome--an expression of catecholamine cardiotoxicity? *Jpn Circ J* 1995 April;59(4):236-240.
8. Brander L, Weinberger D, Henzen C. Heart and brain: a case of focal myocytolysis in severe pneumococcal meningoenzephalitis with review of the contemporary literature. *Anaesth Intensive Care* 2003 April;31(2):202-207.
9. Fu YC, Chi CS, Chiu YT, Hsu SL, Hwang B, Jan SL, Chen PY, Huang FL, Chang Y. Cardiac complications of enterovirus rhombencephalitis. *Arch Dis Child* 2004 April;89(4):368-373.
10. Botez MI, Gagea A. Electrocardiographic changes in intracranial expanding processes. *Psychiatr Neurol Neurochir* 1969 May;72(3):269-277.
11. Syverud G. Electrocardiographic changes and intracranial pathology. *AANA J* 1991 June;59(3):229-232.
12. Vogelín HP, Jutzi H, Gertsch M. [ECG and cardiac changes in acute brain injury]. *Schweiz Med Wochenschr* 1989 April 15;119(15):461-466.
13. Bozluolcay M, Ince B, Celik Y, Harmanci H, Ilerigelen B, Pelin Z. Electrocardiographic findings and prognosis in ischemic stroke. *Neurol India* 2003 December;51(4):500-502.
14. Aygun D, Altintop L, Doganay Z, Guven H, Baydin A. Electrocardiographic changes during migraine attacks. *Headache* 2003 September;43(8):861-866.
15. Dash M, Bithal PK, Prabhakar H, Chouhan RS, Mohanty B. ECG changes in pediatric patients with severe head injury. *J Neurosurg Anesthesiol* 2003 July;15(3):270-273.
16. Leutmezer F, Scherthaner C, Lurger S, Potzelberger K, Baumgartner C. Electrocardiographic changes at the onset of epileptic seizures. *Epilepsia* 2003 March;44(3):348-354.
17. Opherck C, Coromilas J, Hirsch LJ. Heart rate and EKG changes in 102 seizures: analysis of influencing factors. *Epilepsy Res* 2002 December;52(2):117-127.
18. Zijlmans M, Flanagan D, Gotman J. Heart rate changes and ECG abnormalities during epileptic seizures: prevalence and definition of an objective clinical sign. *Epilepsia* 2002 August;43(8):847-854.
19. Owa M, Aizawa K, Urasawa N, Ichinose H, Yamamoto K, Karasawa K, Kagoshima M, Koyama J, Ikeda S. Emotional stress-induced 'ampulla cardiomyopathy': discrepancy between the metabolic and sympathetic innervation imaging performed during the recovery course. *Jpn Circ J* 2001 April;65(4):349-352.
20. Melin J, Usenius JP, Fogelholm R. Left ventricular failure and pulmonary edema in acute multiple sclerosis. *Acta Neurol Scand* 1996 May;93(5):315-317.
21. Brouwers PJ, Wijdicks EF, Hasan D, Vermeulen M, Wever EF, Frericks H, van Gijn J. Serial electrocardiographic recording in aneurysmal subarachnoid hemorrhage. *Stroke* 1989 September;20(9):1162-1167.
22. Davies KR, Gelb AW, Manninen PH, Boughner DR, Bisnaire D. Cardiac function in aneurysmal subarachnoid haemorrhage: a study of electrocardiographic and echocardiographic abnormalities. *Br J Anaesth* 1991 July;67(1):58-63.
23. Mayer SA, LiMandri G, Sherman D, Lennihan L, Fink ME, Solomon RA, DiTullio M, Klebanoff LM, Beckford AR, Homma S. Electrocardiographic markers of abnormal left ventricular wall motion in acute subarachnoid hemorrhage. *J Neurosurg* 1995 November;83(5):889-896.

24. Rudehill A, Gordon E, Sundqvist K, Sylven C, Wahlgren NG. A study of ECG abnormalities and myocardial specific enzymes in patients with subarachnoid haemorrhage. *Acta Anaesthesiol Scand* 1982 August;26(4):344-350.
25. Stober T, Kunze K. Electrocardiographic alterations in subarachnoid haemorrhage. Correlation between spasm of the arteries of the left side on the brain and T inversion and QT prolongation. *J Neurol* 1982;227(2):99-113.
26. Di Pasquale G, Pinelli G, Andreoli A, Manini G, Grazi P, Tognetti F. Holter detection of cardiac arrhythmias in intracranial subarachnoid hemorrhage. *Am J Cardiol* 1987 March 1;59(6):596-600.
27. Lanzino G, Kongable GL, Kassell NF. Electrocardiographic abnormalities after nontraumatic subarachnoid hemorrhage. *J Neurosurg Anesthesiol* 1994 July;6(3):156-162.
28. Zaroff JG, Rordorf GA, Newell JB, Ogilvy CS, Levinson JR. Cardiac outcome in patients with subarachnoid hemorrhage and electrocardiographic abnormalities. *Neurosurgery* 1999 January;44(1):34-39.
29. Sakr YL, Lim N, Amaral AC, Ghosn I, Carvalho FB, Renard M, Vincent JL. Relation of ECG changes to neurological outcome in patients with aneurysmal subarachnoid hemorrhage. *Int J Cardiol* 2004 September;96(3):369-373.
30. van den Bergh W.M., Algra A., Rinkel GJ. Electrocardiographic abnormalities and serum magnesium in patients with subarachnoid hemorrhage. *Stroke* 2004;35(3):644-648.
31. Pollick C, Cujec B, Parker S, Tator C. Left ventricular wall motion abnormalities in subarachnoid hemorrhage: an echocardiographic study. *J Am Coll Cardiol* 1988 September;12(3):600-605.
32. Sato K, Masuda T, Izumi T. Subarachnoid hemorrhage and myocardial damage clinical and experimental studies. *Jpn Heart J* 1999 November;40(6):683-701.
33. Connor RC. Myocardial damage secondary to brain lesions. *Am Heart J* 1969 August;78(2):145-148.
34. Doshi R, Neil-Dwyer G. A clinico-pathological study of patients following subarachnoid hemorrhage. *J Neurosurg* 1980;52:295-301.
35. Koskelo P, Punsar S, Sipilä W. Subendocardial hemorrhage and ECG changes in intracranial bleeding. *Br Med J* 1964;1:1479-1480.
36. Kono T, Morita H, Kuroiwa T, Onaka H, Takatsuka H, Fujiwara A. Left ventricular wall motion abnormalities in patients with subarachnoid hemorrhage: neurogenic stunned myocardium. *J Am Coll Cardiol* 1994 September;24(3):636-640.
37. Ono Y, Kawamura T, Ito J, Kanayama S, Miura T, Kikuchi F. Ampulla (takotsubo) cardiomyopathy associated with subarachnoid hemorrhage worsening in the late phase of vasospasm—case report. *Neurol Med Chir (Tokyo)* 2004 February;44(2):72-74.
38. Abe Y, Kondo M, Matsuoka R, Araki M, Dohyama K, Tanio H. Assessment of clinical features in transient left ventricular apical ballooning. *J Am Coll Cardiol* 2003 March 5;41(5):737-742.
39. Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa M, Yoshiyama M, Miyazaki S, Haze K, Ogawa H, Honda T, Hase M, Kai R, Morii I. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. *J Am Coll Cardiol* 2001 July;38(1):11-18.
40. Cropp GJ, Manning G.W. Electrocardiographic changes simulating myocardial ischemia and infarction associated with spontaneous intracranial hemorrhage. *Circulation* 1960;22:25-38.
41. Greenhoot J.H., Reichenbach D.D. Cardiac injury and subarachnoid hemorrhage. A clinical, pathological, and physiological correlation. *Neurosurgery* 1988;30:521-531.
42. Hersch C. Electrocardiographic changes in subarachnoid hemorrhage, meningitis, and intracranial space-occupying lesions. *Br Heart J* 1964;26:785-793.
43. King JM, Roth L, Haschek WM. Myocardial necrosis secondary to neural lesions in domestic animals. *J Am Vet Med Assoc* 1982 January 15;180(2):144-148.
44. Elrifai AM, Bailes JE, Shih SR, Dianzumba S, Brillman J. Characterization of the cardiac effects of acute subarachnoid hemorrhage in dogs. *Stroke* 1996 April;27(4):737-741.
45. Tung P, Kopelnik A, Banki N, Ong K, Ko N, Lawton MT, Gress D, Drew B, Foster E, Parmley W, Zaroff J. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. *Stroke* 2004 February;35(2):548-551.
46. Cushing H. The blood pressure reaction of acute cerebral compression illustrated by cases of intracranial hemorrhage. *Am J Med Sci* 1903;125:1017-1044.

47. Oppenheimer SM, Gelb A, Girvin JP, Hachinski VC. Cardiovascular Effects of Human Insular Cortex Stimulation. *Neurology* 1992;42:1727-1732.
48. Elrifai AM, Dureza C BJ. Cardiac and Systemic Medical Complications of Subarachnoid Hemorrhage. *Subarachnoid Hemorrhage: Pathophysiology and Management*. Illinois: The American Association of Neurological Surgeons; 1997. p. 87-116.
49. Ulphani JS, Cain JH, Inderyas F, Gordon D, Gikas PV, Shade G, Mayor D, Arora R, Kadish AH, Goldberger JJ. Quantitative analysis of parasympathetic innervation of the porcine heart. *Heart Rhythm* 2010 August;7(8):1113-1119.
50. naredi S., Lambert G, Eden E, Zall S., Runnerstam M., Rydenhag B., Friberg P. Increased sympathetic nervous activity in patients with nontraumatic subarachnoid hemorrhage. *Stroke* 2000;31(901):906.
51. Rona G. Catecholamine cardiotoxicity. *J Mol Cell Cardiol* 1985;17(4):291-306.
52. Zaroff JG, Rordorf GA, Titus JS, Newell JB, Nowak NJ, Torchiana DF, Aretz HT, Picard MH, Macdonald RL. Regional myocardial perfusion after experimental subarachnoid hemorrhage. *Stroke* 2000 May;31(5):1136-1143.
53. Rosenbaum J, Billingham M.E., Ginsburg R, Tsujimoto G., Lurie K.G., Hoffman BB. Cardiomyopathy in a rat model of pheochromocytoma. Morphological and functional alterations. *Am J Cardiovasc Pathol* 1988;1(3):389-399.
54. Prichard BN, Owens CW, Smith CC, Walden RJ. Heart and catecholamines. *Acta Cardiol* 1991;46(3):309-322.
55. Novitzky D, wicomb W.N., Cooper DK, Rose AG, Reichart B. Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. *Ann Thorac Surg* 1986;41(5):520-524.
56. Burnstock G, Campbell G, Bennett M, Holman ME. Inhibition of the smooth muscle cell on the taenia coli. *Nature* 1963 November 9;200:581-582.
57. Su C, Bevan JA, Burnstock G. [3H]adenosine triphosphate: release during stimulation of enteric nerves. *Science* 1971 July 23;173(3994):336-338.
58. Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. *Trends Neurosci* 2009 January;32(1):19-29.
59. Yetgin T, Uitterdijk A, Te Lintel HM, Merkus D, Krabbendam-Peters I, van Beusekom HM, Falotico R, Serruys PW, Manintveld OC, van Geuns RJ, Zijlstra F, Duncker DJ. Limitation of Infarct Size and No-Reflow by Intracoronary Adenosine Depends Critically on Dose and Duration. *JACC Cardiovasc Interv* 2015 December 28;8(15):1990-1999.
60. Sato T, Sasaki N, O'Rourke B, Marban E. Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: a key step in ischemic preconditioning? *Circulation* 2000 August 15;102(7):800-805.
61. Brennan S, Jackson R, Patel M, Sims MW, Hudman D, Norman RI, Lodwick D, Rainbow RD. Early opening of sarcolemmal ATP-sensitive potassium channels is not a key step in PKC-mediated cardioprotection. *J Mol Cell Cardiol* 2015 February;79:42-53.
62. Siwadlowski W., Aravanis C., Worthen M., Luisada A.A. Mechanism of adrenalin pulmonary edema and its prevention by narcotics and autonomic blockers. *Chest* 1970;57:554-557.
63. Neil-Dwyer G, Walter P, Cruickshank J, Doshi B., O'Gorman P. Effect of propranolol and phentolamine on myocardial necrosis after subarachnoid haemorrhage. *Br Med J* 1978;2(6143):990-992.
64. Parr MJ, Finfer SR, Morgan MK. Reversible cardiogenic shock complicating subarachnoid haemorrhage. *Br Med J* 1996;313:681-683.
65. Schell AR, Shenoy MM, Friedman SA, Patel AR. Pulmonary edema associated with subarachnoid hemorrhage. Evidence for a cardiogenic origin. *Arch Intern Med* 1987;147:591-592.

Summary

Summary

Aneurysmal subarachnoid hemorrhage (aSAH), caused by rupture of an intracranial aneurysm, is a devastating neurological disease that accounts for approximately 5% of all strokes. It occurs at a relative young age (50% of patients are younger than 55 years of age), women are predominantly affected and prognosis is poor. Treatment is based primarily on aneurysm obliteration by either coiling or clipping of the aneurysm, the latter requiring craniotomy. However, during the course of the aSAH several neurological and medical complications may occur. The most important neurological complications are rebleeding of the aneurysm, hydrocephalus and delayed cerebral ischemia. Other complications are cardiac dysfunction, pulmonary dysfunction and renal dysfunction. Other common complications of a general Intensive Care Unit population such as infection, SIRS, etc. of course might also threaten this vulnerable patient group.

Of the non-neurological complications after aSAH, cardiac complications occur rather frequently and treatment options are unclear. Stress cardiomyopathy or Tako-tsubo cardiomyopathy is a fascinating phenomenon that has been described after acute stress. It is a reversible cardiac dysfunction with distinct imaging features (the echocardiographic or left ventricular angiographic image resembles a Tako-Tsubo which is a Japanese octopus trap) that is also observed after aSAH. Additionally, ECG abnormalities and biochemical changes occur. This thesis was based on the question how often cardiac dysfunction occurs in aSAH, what the clinical characteristics are and whether it influences outcome. Second we sought to further investigate Tako-Tsubo cardiomyopathy in a disease where it seemed to occur often: aSAH.

We designed a multicenter cohort study (Serial Echocardiography After Subarachnoid Hemorrhage (S.E.A.S.A.H.)) to observe the frequency of cardiac dysfunction, characteristics of the cardiac dysfunction and to investigate prognostic meaning in patients with aSAH.

In **Chapter 1** the outline of this thesis is described with an introduction and background. Furthermore we elaborate on the study design of the SEASAH study and explain the study protocol. The SEASAH was a multicenter cohort study in which serial ECG's, echocardiography and laboratory testing was performed in patients with aSAH. A follow-up took place at 3 months. Outcome was defined as death, occurrence of delayed cerebral ischemia (DCI) or poor functional status.

In **Chapter 2** the results of our meta-analysis are presented which we performed prior to conducting the SEASAH study. From this meta-analysis on literature from 1960-2007 we included 25 studies with a total of 2690 patients. We concluded that troponin and/or NT-proBNP and abnormal echocardiographic findings are associated with an increased risk of death, poor outcome, and delayed cerebral ischemia after subarachnoid hemorrhage (relative risk for death and wall motion abnormalities on echocardiography was 1.9). However, multi-variate analysis was not possible and many questions remained. So we decided to go forward with the SEASAH study.

In **Chapter 3** we describe the results of the SEASAH study. In this study we included 301 patients in which we performed serial ECGs, echocardiography and measured troponin and NT-proBNP. We performed a 3 months follow up for death, occurrence of DCI and poor outcome. We found that echocardiographic wall motion abnormalities were associated with death, DCI and poor outcome, independent of other clinical predictors for outcome. This finding was in line with the meta-analysis but answered the important question whether wall motion abnormalities were independent predictor for poor outcome. We also found that elevated troponin T levels, ST-segment changes, and low voltage on the admission ECGs had a univariable association with death but were not independent predictors for outcome.

In **Chapter 4** a sub-analysis of the SEASAH is described. Because of the reversible nature of the wall motion abnormalities we wanted to investigate the time course of WMA during the initial phase after aSAH. Furthermore we investigated which clinical, electrocardiographic or myocardial serum markers are predictors for early or late development of WMA. We found that WMA may be present on admission or develop during the course of aSAH. Poor neurological condition on admission, sinus tachycardia, ST-depression and ST-elevation at the admission ECG and elevated troponin T, are independent predictors for early WMA, a myocardial infarct pattern on the admission ECG and elevated troponin T in patients with aSAH predict late WMA independent of other clinical predictors.

In **Chapter 5** we investigated our hypothesis that cardiac dysfunction impairs cerebral perfusion and thus influences outcome. Data of cerebral CT perfusion was correlated with cardiac data from the SEASAH. We found an association between decreased cerebral blood flow in patients with impaired cardiac function compared

to patients with normal cardiac function. Although decreased autoregulation could be an explanation, pathophysiological conclusions cannot be drawn.

In **Chapter 6** we describe the results of a histopathological study. In this study we sought for evidence that the mononuclear cellular infiltration that is found in the myocardium of patients with aSAH might be a myocarditis. We compared post-mortem myocardium of patients who died from aSAH with controls. We found a markedly increase in inflammatory cells in patient with aSAH. Furthermore, we found evidence of thrombi and myocytolysis. This study supports the theory that catecholaminergic stress causes a myocarditis and gives direction to future research.

Finally, in **Chapter 7** we summarize the main conclusions of this thesis and put the findings into perspective of literature. We elaborate on available literature, put the findings of the thesis into context and describe possible etiologic factors for stress induced cardiac dysfunction. We describe clinical implications of this thesis, limitations of the studies and suggest direction for future research.

Samenvatting

Samenvatting

Een aneurysmatische subarachnoïdale bloeding (SAB) is een zeer ernstige neurologische aandoening die veroorzaakt wordt door ruptuur van een intracraniël aneurysma, een zwakke plek in een slagader. Het komt voor op een relatief jonge leeftijd (50% van de patiënten zijn jonger dan 55 jaar), vrouwen worden vaker getroffen dan mannen en de prognose is slecht. De behandeling is in eerste instantie gebaseerd op het uit de circulatie nemen van het aneurysma door “coiling” (het opvullen van het aneurysma met een soort veertje, een coil, door middel van een catheter via een bloedvat) of door “clipping” (het aanbrengen van een clip op de hals van het aneurysma via een craniotomie welke wordt uitgevoerd door de neurochirurg). Tijdens het klinische beloop van de SAB kunnen verschillende neurologische en medische complicaties optreden. De belangrijkste neurologische complicaties zijn: een recidief bloeding van het aneurysma, hydrocephalus en secundaire cerebrale ischemie (dit treedt meestal 4-7 dagen na de SAB op). Een aantal andere mogelijke complicaties zijn cardiale dysfunctie, longoedeem en nierfunctiestoornissen. Tenslotte kunnen veel voorkomende complicaties van een algemene Intensive Care populatie zoals bijvoorbeeld infectie een bedreiging vormen voor deze kwetsbare patiëntengroep. Van de niet-neurologische complicaties na SAB, komen de cardiale complicaties frequent voor, maar hoe ze te behandelen is niet duidelijk.

Stress cardiomyopathie of Tako-subo cardiomyopathie is een fascinerend fenomeen wat steeds vaker wordt beschreven. Het is vooral geassocieerd met acute emotionele stress en bestaat uit een reversibele cardiale disfunctie (met name wandbewegingsstoornissen (WBS)) met een kenmerkend echocardiografisch of angiografisch beeld. Dit beeld lijkt op een Tako-Tsubo, een Japanse octopus val. De cardiale afwijkingen na een SAB hebben grote overeenkomsten met die van een stress cardiomyopathie.

Dit proefschrift is gebaseerd op de vraag hoe vaak cardiale disfunctie optreedt na een SAB, wat de klinische kenmerken zijn en wat het effect is op de prognose. Om dit te onderzoeken is de multicentrum cohort studie (Seriële Echocardiography na subarachnoïdale bloeding (S.E.A.S.A.H.)) ontworpen. Ten tweede wilden we stress cardiomyopathie verder onderzoeken in een ziektebeeld waar het vaak voorkomt: een aneurysmatische subarachnoïdale bloeding.

In **Hoofdstuk 1**, worden de contouren van dit proefschrift wordt beschreven, met een inleiding en een achtergrond van de literatuur. Tevens wordt de opzet van de SEASAH studie en het studieprotocol beschreven. De SEASAH was een multicenter

cohort studie waarin seriële ECG's, echocardiografie en laboratoriumtests werd uitgevoerd bij patiënten met SAB om te onderzoeken hoe vaak cardiale dysfunctie optreedt na SAB, of er klinische variabelen zijn die de dysfunctie kunnen voorspellen en of de cardiale dysfunctie een afhankelijke voorspeller is voor klinische uitkomst. Een follow-up vond plaats op 3 maanden. De primaire uitkomst werd gedefinieerd als dood, het optreden van secundaire cerebrale ischemie (DCI) of een slechte functionele status.

In **Hoofdstuk 2** worden de resultaten van de meta-analyse gepresenteerd, die voorafgaand aan de SEASAH studie werd verricht. Uit deze meta-analyse van literatuur van 1960 tot en met 2007, naar de prognostische betekenis van cardiale dysfunctie bij patiënten met een SAB, zijn 25 studies geïncludeerd met in totaal 2690 patiënten. De conclusie was dat troponine en/of NT-proBNP en abnormale echocardiografische bevindingen geassocieerd zijn met een verhoogd risico op overlijden, een slechte uitkomst, en secundaire cerebrale ischemie na een SAB (het relatieve risico op overlijden en WBS op echocardiografie was 1,9). Echter, multivariate analyse was niet mogelijk en een aantal wetenschappelijke vragen bleven onbeantwoord. Daarom werd besloten de SEASAH studie uit te voeren.

In **Hoofdstuk 3** worden de resultaten van de SEASAH studie beschreven. In deze prospectieve studie werden 301 patiënten geïncludeerd die seriële ECG, echocardiografie en troponine en NT-proBNP bepalingen ondergingen. Na 3 maanden werd een follow-up uitgevoerd voor dood, het optreden van secundaire cerebrale ischemie en een slechte uitkomst. We vonden dat echocardiografische WBS geassocieerd waren met dood, secundaire cerebrale ischemie en een slechte uitkomst, onafhankelijk van andere klinische voorspellers voor deze uitkomsten. Deze bevinding was in lijn met de meta-analyse, en bevestigde de belangrijke klinische vraag of WBS onafhankelijke voorspellers zijn voor een slechte afloop. We vonden ook dat verhoogde troponine T, ST-segment veranderingen en lage QRS voltages een univariabele associatie hadden met dood, maar het waren geen onafhankelijke voorspellers voor uitkomst.

In **Hoofdstuk 4** wordt een sub-analyse van de SEASAH beschreven. Vanwege de reversibele aard van de WBS werd het tijdsverloop van WBS onderzocht tijdens de eerste fase na de SAB. Verder werd onderzocht welke klinische, electrocardiografische of bloedwaarden voorspellers zijn voor vroeg of laat optreden van WBS. We vonden

dat WBS aanwezig kunnen zijn bij opname of ze kunnen zich later ontwikkelen. Slechte neurologische conditie bij opname, sinus tachycardie, ST-depressie en ST-elevatie bij het opname ECG en verhoogde troponine T, zijn onafhankelijke voorspellers voor het vroeg optreden van WBS, een myocard infarct patroon op het opname ECG en verhoogde troponine T bij patiënten met een SAB voorspellen het laat optreden van WBS, onafhankelijk van andere klinische voorspellers.

In **Hoofdstuk 5** onderzochten we de hypothese dat cardiale dysfunctie na een SAB cerebrale perfusie kan verminderden. De data van cerebrale CT perfusie werden gecorreleerd aan de cardiale gegevens van de SEASAH. We vonden een verband tussen verminderde bloedtoevoer naar de hersenen bij patiënten met een verminderde hartfunctie in vergelijking met patiënten met een normale hartfunctie. Verminderde autoregulatie van de cerebrale vaten zou een potentiële verklaring kunnen zijn, maar pathofysiologische conclusies kunnen niet worden getrokken uit deze studie.

In **Hoofdstuk 6** worden de resultaten van een histopathologisch onderzoek beschreven. In deze studie hebben we gezocht naar bewijs dat de mononucleaire cellulaire infiltratie die wordt gevonden in het myocardium van patiënten na een SAB aan de criteria van een myocarditis voldoet. We vergeleken post-mortem myocard van de patiënten die overleden aan een SAB met een controlegroep. We vonden een duidelijke verhoging van ontstekingscellen bij patiënten met een SAB en niet bij de controle groep. Verder vonden we trombi en myocytolysis, een andere aanwijzing voor een myocarditis. Dit onderzoek ondersteunt de theorie dat catecholaminerge stress een myocarditis kan veroorzaken en geeft richting aan toekomstig onderzoek. Tenslotte worden in **Hoofdstuk 7** de belangrijkste conclusies van dit proefschrift samengevat en worden de resultaten in de context van de literatuur gezet. De klinische implicaties van dit proefschrift worden beschreven alsmede de beperkingen. Tenslotte wordt er een richting voor toekomstig onderzoek gesuggereerd.

Dankwoord

Een promotie is een eenzame weg die de promovendus zelf zal moeten afleggen. Gelukkig staan er aan de kant supporters die toejuichen en ondersteunen. Dat is maar goed ook want promoveren is een bipolaire activiteit. Er zijn hoge pieken en diepe dalen. Mijn promotie is er bij uitstek één geweest van de lange adem waar ik enorm veel steun heb mogen ontvangen van enorm veel mensen. Het idee wat ik samen met Djo Hasan had, om eens te gaan kijken naar het hart bij mensen met een hersenbloeding, is uitgegroeid tot een multicentrum, multidisciplinaire studie. Dit resulteert nu dus, eindelijk, in een promotie. Het is een unicum dat een grote studie als de SEASAH ongesponsord en zonder beurs of andere vorm van financiële ondersteuning toch tot stand heeft kunnen komen. Ik ben er trots op dat we door de inzet en het enthousiasme van de SEASAH onderzoeksgroep in staat zijn geweest een dergelijke studie te verrichten in Nederland. Enkel en alleen door de medewerking van heel veel gemotiveerde collegae die allen belangeloos en uit pure wetenschappelijke interesse (en omdat ik maar bleef zeuren) wilden meewerken heb ik de SEASAH kunnen uitvoeren. Ik voel me bevoorrecht om in zoveel Centra de afdelingen Cardiologie, Neurologie, Neurochirurgie en Intensive Care te hebben mogen bezoeken, een kijkje in de keuken te hebben mogen nemen en om zoveel mensen te hebben mogen ontmoeten. Het heeft me veel geleerd en in zekere mate ook gevormd als dokter. Om iedereen een persoonlijk dankwoord te schrijven zou een proefschrift op zichzelf zijn. Toch wil ik enkele mensen in het bijzonder bedanken met bij voorbaat excuses als uw naam niet genoemd wordt.

Prof. Dr. G.J.E. Rinkel, beste Gabriel, ik weet nog precies dat ik je voor de eerste keer een e-mail stuurde over een plan om onderzoek te doen bij SAB's. Dit was nog voor mijn co-schappen. De reactie die ik toen van je kreeg is tekenend voor hoe ik je heb leren kennen. Correct, enthousiast, welwillend, to-the-point en ook precies en kritisch. Je bent vanaf het eerste uur bij SEAS betrokken geweest en ik heb altijd je steun gevoeld om dit avontuur (want dat was het ook voor jou) tot een goed einde te brengen. Ook als het even anders liep dan gepland. Je hebt me veel geleerd over wetenschap, epidemiologie en Neurologie en dat ondersteunt mij ook in de dagelijkse praktijk.

Prof. Dr. A.A.M. Wilde, beste Arthur. Jij haakte iets later aan dan Gabriel maar ook jij was meteen open voor de gedachte van de SEAS. Je zag kansen op gebied van QT en Cardiogenetica. Helaas komen deze passies van jou niet in dit proefschrift naar voren. Je hebt me alle kansen en mogelijkheden gegeven die ik me maar kan wensen

en zonder jouw nooit aflatende steun en vertrouwen was dit nooit gelukt. Je was vaak op afstand aanwezig maar bij vragen altijd bereid mee te denken. Hoe je toch altijd die e-mails zo snel kan beantwoorden naast de drukke agenda snap ik niet, evenmin hoe je tussen al die stapels papier op je bureau niks kwijt raakt...Ik ben er trots op dat jij mijn promotor en opleider bent.

Dr. D. Hasan, beste Djo. Er zijn geen woorden die recht kunnen doen aan wat jij voor mij betekend hebt. Zowel op professioneel als persoonlijk vlak. Van een wild plan om een beademingsmachine naar Indonesië te brengen naar een wetenschappelijke stage op de IC in het Dijkzicht naar dan eindelijk de SEAS. Bedenker van dit onderzoek, co-promotor, mentor, collega en bovenal goede vriend zijn woorden die onze relatie slechts beginnen te omschrijven. Coosje, sorry voor alle keren dat ik jullie avonden en weekenden zowel in Veen als in Kasterlee kwam verstoren. Ik ben jullie beiden erg dankbaar voor de enorm leuke, leerzame en intensieve tijd die we samen beleefd hebben. Het wordt tijd dat we weer gezellig gaan eten met z'n allen! Nu ik in Den Haag werk en Djo weer terug is op het oude honk in Rotterdam gaat dat er vast van komen.

Prof. Dr. F.C. Visser, beste Frans. Toen ik als 4^e-jaars student geneeskunde de eerste keer mijn afstudeerscriptie over cardiale effecten bij SABs en het voorstel tot onderzoek aan je gaf vond je het helemaal niks. Gelukkig liet jij je makkelijk overtuigen en kon ik je enthousiasmeren voor de SEASAH. Jij hebt de start van dit onderzoek mogelijk gemaakt door me een baan te geven in het Kennemer Gasthuis en daarna in de VU zodat we het studieprotocol konden schrijven en de logistiek konden opzetten. Met plezier denk ik terug aan onze trips naar de verschillende centra om ze te vragen te participeren in een uniek onderzoek. Ik bewonder je scherpe en analytische geest en denk met erg veel plezier terug aan de vele dagen dat we bij jou thuis aan de meta-analyse werkten. De wasbak was bezaaid met koffie pads en ik denk nog steeds dat we de conceptie van hoofdstuk 2 van dit proefschrift terug kunnen zien in de omzet cijfers van dat bedrijf.

Graag dank ik de leden van de promotiecommissie te weten: prof. dr. M.L. Bots, prof. dr. P.A.F.M. Doevendans, prof. dr. L.J. Kappelle, prof. dr. A.C. van Rossum en prof. dr. A. van der Zwan voor het lezen en beoordelen van mijn proefschrift en om zitting te nemen in de promotie commissie.

Mijn beide paranimfen. Beste Jeroen, het begon op de allereerste introductiedag van de geneeskunde studie aan de VU omdat we in hetzelfde mentorgroepje zaten. Op de een of andere manier komen we elkaar steeds tegen. Kamergenoten in de Meander, samen aan het onderzoek. Samen in opleiding. Ik was jouw paranimf, eindelijk kun jij nu aan mijn zijde staan. Mooi man.

Beste Dilia. Lieve Dilia. Jij vervult twee rollen. Paranimf en echtgenote. Ik kan niemand bedenken die meer voor mij betekend heeft tijdens mijn promotie dan jij. Altijd ondersteunend, altijd bereid om mee te denken. Altijd een opbeurend woord als ik het even niet zag zitten, soms een beetje streng als je vond dat ik aan het zeuren was. Deze promotie is ook voor jou lieve schat en ik ben heel blij dat je altijd maar vooral ook nu naast me staat. Om samen met jou het levenspad te bewandelen en in korte tijd een huis uit de grond te rammen, te trouwen, 2 prachtige kinderen te krijgen was een overweldigende ervaring die ik nog elke dag koester. Soms is dat zwaar en sta je er alleen voor omdat ik in Den Haag ben maar je doet het allemaal geweldig. In de hectiek van alle dag zeg ik het natuurlijk helemaal niet genoeg. Dank je wel voor alles, ik kan niet wachten op wat onze toekomst ons samen gaat brengen. Ik hou van je.

Veel dank ben ik verschuldigd aan de SEASAH investigators welke ook vaak mede-auteur zijn op de artikelen uit dit proefschrift:

Per centrum (alfabetisch):

Academisch Medisch Centrum:

Cardiologie: dr. R.B.A. van den Brink, beste Renee, iedere dokter heeft voorbeelden nodig waar hij(of zij) zich aan kan optrekken. Jij als opleidster cardiologie van het AMC en boegbeeld van de opleiding cardiologie in Nederland bent dat zeker voor mij. Bedankt voor alles. Mijn leukste herinnering is dat we menige zaterdag schouder aan schouder de 1000+(!) echo's van de SEAS zaten te beoordelen. Ik had vrij snel door dat ik de koffie klaar moest hebben als je binnen kwam en dat je na de tweede kop koffie spraakzamer werd en een stuk sneller door die echo's ging. Je hebt me heel veel geleerd (en nog steeds). Ik hoop dat we nog lange tijd kunnen samenwerken op het gebied van echocardiografie, opleiding en het ESC.

Verder dank ik de overige leden van de vakgroep Cardiologie van het AMC voor de mogelijkheden die me geboden zijn om onderzoek te mogen doen en de opleiding tot cardioloog te kunnen volgen.

Uiteraard dank ik alle mede arts-onderzoekers en arts-assistenten. Het zijn er teveel

om op te noemen: B2-115: Pieter Postema, Jonas de Jong. Ik kwam als vreemde eend vanuit de VU naar het AMC met een onderzoek wat nogal buiten de kaders lag. Jullie hebben me fantastisch opgevangen die eerste tijd en ik voelde me op mijn plek. We hebben mooie tijden beleefd met Cardionetworks en daarbuiten. Verder dank ik Marcel Beijk, Imke Christiaans, Hester den Ruijter, Mariëlle Duffels, Annemarie Engstrom, Joost Haeck, Tim van de Hoef, als student begonnen heb je me geholpen met hoofdstuk 6. Je werkte toen al keihard en je bent ook eerder dan ik gepromoveerd! Alexander Hirsch, Wouter Kikkert, Tamara Koopman, Maurice Rummelink, Krishan Sjaauw, Martijn Meuwissen, Niels Verouden, Christian van der Werf, Jacobijne Wiersma, Michiel Winter en nog vele anderen.

En zoals iedere promovendus ben ik Regina en Anita veel dank schuldig voor jullie gouden ondersteuning.

Verder dank ik de echolaboranten. Natuurlijk Rianne, dank voor alle gezelligheid, dank voor het maken van al die SEAS echo's die meestal op een ongelukkig moment kwamen en dank dat je me hebt leren echoën. Dat zelfde geldt natuurlijk ook voor Jim, Hettie en Denise.

Intensive Care: Dr. J. Horn, beste Janneke, dank voor de prettige manier van samenwerken. Zonder jou was de logistiek op de IC van het AMC niet mogelijk geweest. Prof. Dr. M.B. Vroom, dank voor het goedkeuren van het studieprotocol. En natuurlijk de andere leden van de vakgroep Intensive Care voor het meewerken aan de studie.

Neurochirurgie: Prof. Dr. W.P. Vandertop, u bent vanaf het eerste uur betrokken geweest bij het opzetten en het uitvoeren van de SEAS. In eerste instantie alleen in de VU maar omdat u ook naar de afdeling in het AMC ging en zo het Neurochirurgisch Centrum Amsterdam opzette maakte dat de logistiek een stuk makkelijker. Het NCA zal misschien niet primair voor de SEAS zijn gedaan maar het hielp wel... Dank voor het meedenken, het opzetten en het uitvoeren van de SEAS. Zonder uw ondersteuning was de SEAS misschien wel niet mogelijk geweest.

Erasmus Medisch Centrum:

Cardiologie: dr. F.J. Ten Cate, dank voor het dragen van SEAS binnen de vakgroep.

Experimentele Cardiologie: Ook veel dank aan prof. dr. D.J. Duncker voor het meedenken aan de studieopzet en het concept van neurogene stunning.

Intensive Care: prof. dr. J. Bakker, dank voor het meedenken over de studieopzet.

Dr. M. Van der Jagt, beste Mathieu, van elastiekjes schieten in een ruimte zonder ramen zijn we toch best ver gekomen. Jij was altijd al een ras-neuroloog en ik was

een brallerige studentikoze Amsterdammer. We hebben mooie tijden gehad. Van een Stroke congres tot een NVIC bijeenkomst, we waren er samen bij. Menig kroeg hebben we van binnen gezien. Mijn promotie is dan eindelijk klaar, ben jij al klaar voor die volgende stap?...

Neurologie: Prof. Dr. P.J. Koudstaal, dank voor het begeleiden van mijn stage en het meedenken over de SEAS. Dr. F. van Kooten, beste Fop, dank je voor al je input, de logistiek en het beoordelen van al die CT scans!

Pathologie: Prof. Dr. J.M. Kros, dank voor de hulp bij het verzamelen van de coupes van de welke de basis vormen voor hoofdstuk 6.

Echolaboranten: Wim Vletter, dank voor het maken van de echo's.

Datamanager: Naziha Bouyakoub, dank voor de koffie.

Universitair Medisch Centrum Groningen:

Cardiologie: Prof. Dr. M.P. van den Berg, beste Maarten, dank je wel voor het meedenken, het meeschrijven en het mogelijk maken van de SEAS in het UMCG. Het was altijd prettig om naar het hoge noorden af te reizen.

Dank Yoran Hummel voor het maken van echo's.

Intensive Care: Joost Regtien, John Meertens. Beste Joost en John, jullie zijn een van de pijlers van de SEAS. Dank voor de vele inclusies en alle studielogistiek. Jullie hebben ongeveer 35% van alle patiënten van de SEAS aangeleverd. Het was altijd een prettige sfeer om in het apparaten opslaghokje de patiëntendata in mijn database in te kloppen.

Neurochirurgie: Prof. Dr. R.J.M. Groen en dr. J.D.M. Metzemaekers, beste Rob en Jan, dank voor het aanleveren van al de patiënten en het mogelijk maken van SEAS in het UMCG.

Universitair Medisch Centrum Utrecht:

Cardiologie: dr. M.J.M Cramer, beste Maarten-Jan, met jouw enthousiasme was het altijd leuk om een site visit aan Utrecht te maken. We hebben veel echo's samen bekeken en je was bijzonder betrokken bij mij en bij de SEAS. We hebben alleen ons strainproject nog niet af kunnen maken maar dat komt nog. Dank voor de mooie tijd, je optimisme, het meeschrijven aan het protocol en de artikelen. Ik ben blij dat het weer goed met je gaat. We gaan onze samenwerking uitbreiden. Verder dank ik ook Arco Teske voor het maken van vrijwel alle SEAS echo's. Dat zijn er voor het UMCU >300! Misschien heb je nog zin in een paar strain analyses?...

Neurologie: Sanne Dorhout Mees, Walter van den Bergh, dank voor het includeren van vele patiënten. Paut Greebe, dank je wel voor je gastvrijheid op het secretariaat.

Ook dank voor het opvragen van al die statussen en de koffie. Die koffie die jij zette was toch echt veel lekkerder dan die automaat.

Epidemiologie: Prof. Dr. A. Algra, beste Ale, van statistiek en epidemiologie had ik niet veel kaas gegeten toen ik je voor het eerst ontmoette. Maar dat maakte je niks uit. Je ging gewoon zitten en legde me de meest basale zaken van SPSS uit. Je bent natuurlijk op een cardiologisch onderwerp gepromoveerd dus dat hielp ook. Dank je wel voor al je ondersteuning.

VU Medisch Centrum:

Cardiologie: Dr. M.J.W. Götte, beste Marco, jij was in je afrondingsfase van je assistenten bestaan toen ik als AGNIO aankwam. Jij hebt de eerste SEAS echo's gemaakt in het VUMC en hebt daarna veel SEAS echo's geanalyseerd. Toen jij naar het UMCG ging heb je de SEAS daar geïntroduceerd en mede mogelijk gemaakt. Veel dank daarvoor. Maar daar houdt het niet bij op. Jij hebt me ook geïntroduceerd in het Haga en nu zijn we vakgroepgenoten ofwel maten. Ik kijk uit naar onze verdere samenwerking op heel veel vlakken. Vooral als we nu eindelijk die MRI scanner hebben. We gaan volle kracht vooruit en ik heb er zin in. Ik hoop dat jij mij kan bijhouden en ik jou! Dr. O. Kamp, beste Otto, dank voor het meedenken aan het SEAS protocol en het mogelijk maken van de echo's in de VU.

Verder dank ik alle leden van de vakgroep Cardiologie van het VUMC voor de eerste fase van mijn opleiding en promotieonderzoek.

En natuurlijk mijn collega's en arts-onderzoekers met wie ik hele leuke tijden heb beleefd, mijn mede "Meanderthalers": Olga Bondarenko, Pieter Dijkmans, Paul Knaapen, Ramon van Loon. En natuurlijk de magneetjongens van de overkant: Tjeerd Germans en Robin Nijveldt. Eindelijk is die rare SEAS klaar jongens, en die beertender heb ik nog steeds!

Graag dank ik ook de echolaboranten voor het maken van al die SEAS echo's. Vooral in het begin heeft dat veel tijd gekost.

Dank voor alle studenten die hun wetenschappelijke stage bij mij hebben gedaan en me zo geholpen hebben: Tim, Jean-Paul (dank voor al die keren dat je mee bent gegaan om SEAS data in te kloppen en dank voor je hulp bij hoofdstuk 6), Ferlin, Zehlia, Shaan, Amit, Bart, Erik, Karel-Jan.

Dank ook Ankie en Sandra voor de ondersteuning.

Intensive Care: Prof. Dr. J. Groeneveld, beste Johan, ik zet je onder de VU maar je zit nu natuurlijk in het ERMC. Jou ben ik specifieke dank verschuldigd voor de hulp op de IC in het VUMC. Door jou kon ik de logistiek rond krijgen en je tips en ideeën

hebben bijgedragen aan een betere studie. Verder heb je me meerdere malen een hand toe gestoken als ik op een dood punt zat. Je weet het waarschijnlijk niet eens meer maar toen ik op een gegeven moment weer patiëntendata aan het verzamelen was en SPSS niet meewerkte, keek je me aan (over je bril op de wijze die jou zo kenmerkt) en zei: “collega, de aanhouder wint altijd. ALTIJD!”. Die woorden en de wijze van uitspreken zijn me bijgebleven en hebben me vaak over een dood punt heen geholpen. Dank je wel!

Verder dank ik prof. dr. A.R.J. Girbes, voor het mogelijk maken van de SEAS en het meeschrijven aan de artikelen.

Neurochirurgie: Ik dank de vakgroep voor het includeren van patiënten.

Pathologie: Prof. Dr. H.W.M. Niessen, beste Hans, dank je wel dat je je lab ter beschikking hebt gesteld voor het myocarditis onderzoek en voor de prettige samenwerking. Marc Begieneman, dank voor het samenwerken aan hoofdstuk 6 en voor het begeleiden van de studenten.

Datamanager: Evaline Bah, dank je voor de ondersteuning in de studielogistiek.

Neurologie: Marieke Visser, dank voor het meedenken in de eerste fase van de studie.

Mijn ouders. Niet alleen tijdens mijn promotie maar mijn hele leven staan jullie mij bij met een nimmer aflatende steun en liefde. Al snapten jullie niet helemaal waar de promotie nou precies over ging en vooral waarom het nou zo lang duurde....! Toch hebben jullie je altijd ondersteunend en begripvol opgesteld. Dank jullie wel voor alles en deze promotie is ook voor jullie.

Tenslotte Reinout en Aletta van der Bilt. Dank jullie wel voor het hinderen en het affeiden. Typen en nadenken als jullie op willekeurige knoppen op het toetsenbord blijven drukken en dan wegrekken blijf ik irritant vinden. Maar nu dit af is gaan we wel vaker buiten spelen.

Curriculum Vitae

Curriculum Vitae

Ivo Adriaan Cornelis van der Bilt was born on august 1st. 1975 in Bergen op Zoom. He grew up in Kaatsheuvel and Berkel-Enschot and finished secondary school at the Theresialyceum in Tilburg. In 1994 he started to study Chemical Technology at the Technical University in Eindhoven but quickly decided another career would be more suitable. He was accepted for medical school at the Free University in Amsterdam in 1996 and finished his Medical Degree in 2002. From 2001-2002 he was chair of the council of interns (Co-raad). During his medical study his interest in Cardiology started. He chose a cardiovascular profile consisting of a cardiological elective (keuzevak), student internship (wetenschappelijke stage) and elective rotation (keuze co-schap). He did an extended student internship (6 months) on the Intensive Care Unit in the Dijkzigt Hospital (now Erasmus Medical Center Rotterdam) and wrote his final report on Cerebro-cardio-pulmonary interaction after aneurysmal subarachnoid hemorrhage. This paper was the basis for the SEASAH study protocol. After the student internship and before starting rotations, he was a student assistant for 6 months at the department of Anesthesiology of the Dijkzigt hospital in Rotterdam during which he wrote the SEASAH protocol, started with the study logistics and worked on several other protocols such as Xenon anesthesia and high frequency ventilation.

After his Medical Degree, he started working as a resident cardiology (AGNIO) in the Kennemer Gasthuis in Haarlem to gain clinical experience while trying to raise funds for the SEASAH study. In January 2004 he started as a resident cardiology (AGNIO) in the VU University Medical Center (VUMC) and later that year he started as a full time PhD student. Inclusion of patients in the SEASAH started in 2005. Due to funding problems in the VUMC he switched to the Academic Medical Center in 2006 where he started his training in cardiology (AIOS) in 2008.

In 2007 he co-founded the Cardionetworks Foundation. This is a non-profit NGO which launched and maintains several websites (ECGpedia.org, Echopedia.org).

From 2008 to 2010 he did his Internal Medicine residency (trainer prof. dr. P. Speelman and prof. dr. M.M. Levi). From January 2010 until May 2010 he interrupted cardiology training to finish the data inclusion of the SEASAH. From June 2010 until November 2013 he worked as a resident cardiology in the AMC with a short period of 3 months in the Tergooi Hospital in Blaricum. In November 2013 he started his differentiation year in cardiac imaging in the Heart center of the Haga Teaching

Hospital in The Hague (trainer M.J.W. Götte and B. Delemarre). He graduated as a cardiologist in October 2014.

Since December 2014 he works as a staff Cardiologist in the Haga Teaching Hospital in the Hague. He specializes in imaging and is head of the department of Echocardiography.

Since 2012 he is active within the European Society of Cardiology as a question writer and standard setter for the European Examination in General Cardiology. He was elected as a member of the ESC Education Committee 2014-2016.

His hobbies are flying and sailing. He is married with Dilia Ham and has two children, Reinout and Aletta.

List of publications

Publications in this thesis

van der Bilt IA, Vendeville JP, van de Hoef TP, Begieneman MP, Lagrand WK, Kros JM, Wilde AA, Rinkel GJ, Niessen HW. Myocarditis in patients with subarachnoid hemorrhage: A histopathologic study. *J Crit Care*. 2016 Apr;32:196-200

Cremers CH, **van der Bilt IA**, van der Schaaf IC, Vergouwen MD, Dankbaar JW, Cramer MJ, Wilde AA, Rinkel GJ, Velthuis BK. Relationship Between Cardiac Dysfunction and Cerebral Perfusion in Patients with Aneurysmal Subarachnoid Hemorrhage. *Neurocrit Care*. 2015 Aug 12. *Epub ahead of print*

van der Bilt IA, Hasan D, van den Brink RB, Cramer MJ, van der Jagt M, van Kooten F, Regtien JG, van den Berg MP, Groen RJ, Cate FJ, Kamp O, Götte MJ, Horn J, Girbes AR, Vandertop WP, Algra A, Rinkel GJ, Wilde AA; SEASAH (Serial Echocardiography After Subarachnoid Hemorrhage) Investigators. Time course and risk factors for myocardial dysfunction after aneurysmal subarachnoid hemorrhage. *Neurosurgery*. 2015 Jun;76(6):700-5; discussion 705-6

van der Bilt I, Hasan D, van den Brink R, Cramer MJ, van der Jagt M, van Kooten F, Meertens J, van den Berg M, Groen R, Ten Cate F, Kamp O, Götte M, Horn J, Groeneveld J, Vandertop P, Algra A, Visser F, Wilde A, Rinkel G; SEASAH (Serial Echocardiography After Subarachnoid Hemorrhage) Investigators. Cardiac dysfunction after aneurysmal subarachnoid hemorrhage: relationship with outcome. *Neurology*. 2014 Jan 28;82(4):351-8.

van der Bilt IA, Hasan D, Vandertop WP, Wilde AA, Algra A, Visser FC, Rinkel GJ. Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis. *Neurology*. 2009 Feb 17;72(7):635-42.

van der Bilt IA, Hasan D, Rinkel GJ, Wilde AA, Visser FC. Rationale of the SEAS study: Serial Echocardiography After Subarachnoid haemorrhage, a prospective national, multicentre, multidisciplinary, cohort study to evaluate cardiac abnormalities following intracranial haemorrhage. *Neth Heart J*. 2006 Nov;14(11):366-371.

Other publications

Schuuring MJ, Delemarre B, Keyhan-Falsafi AM, **van der Bilt IA**. Mending a Darkened Heart: Alkaptonuria Discovered During Aortic Valve Replacement. *Circulation*. 2016 Mar 22;133(12):e444-5

Tanis W, Budde RP, **van der Bilt IA**, Delemarre B, Hoohenkerk G, van Rooden JK, Scholtens AM, Habets J, Chamuleau S. Novel imaging strategies for the detection of prosthetic heart valve obstruction and endocarditis. *Neth Heart J*. 2016 Feb;24(2):96-107

Milano A, Vermeer AM, Lodder EM, Barc J, Verkerk AO, Postma AV, **van der Bilt IA**, Baars MJ, van Haelst PL, Caliskan K, Hoedemaekers YM, Le Scouarnec S, Redon R, Pinto YM, Christiaans I, Wilde AA, Bezzina CR. HCN4 mutations in multiple families with bradycardia and left ventricular noncompaction cardiomyopathy. *J Am Coll Cardiol*. 2014 Aug 26;64(8):745-56.

Postema PG, Wiersma JJ, **van der Bilt IA**, Dekkers P, van Bergen PF. Takotsubo cardiomyopathy shortly following pacemaker implantation-case report and review of the literature. *Neth Heart J*. 2014 Oct;22(10):456-9.

Schut AFC, **van der Bilt IA**, van der Jagt M. Systemic consequences of neurological catastrophes at the ICU. *Neth J Crit Care*. 2012 Feb;16(1): 6-11

Hasan D, **van der Bilt IA**.

Treat but meanwhile do not do any harm. *Neth J Crit Care*. 2009 Aug;13(4): 175-77

van Bree MD, Roos YB, **van der Bilt IA**, Wilde AA, Sprengers ME, de Gans K, Vergouwen MD. Prevalence and characterization of ECG abnormalities after intracerebral hemorrhage. *Neurocrit Care*. 2010 Feb;12(1):50-5.

van der Bilt IA, van Dijk J, van den Brink RB, Götte MJ, Visser FC. Examining the octopus pot: multimodality imaging of a typical takotsubo cardiomyopathy. *Echocardiography*. 2008 Aug;25(7):794-6.

Postema PG, De Jong JS, **Van der Bilt IA**, Wilde AA. Accurate electrocardiographic assessment of the QT interval: teach the tangent. *Heart Rhythm*. 2008 Jul;5(7):1015-8

van der Jagt M, Bosman RJ, van Schaik IN, **van der Bilt IA**, Dekker LR, Zandstra DF. Differential diagnosis in patients with suspected anoxic-ischaemic coma. *Ned Tijdschr Geneeskd*. 2008 Feb 9;152(6):297-301

Begieneman MP, van de Goot FR, **van der Bilt IA**, Vonk Noordegraaf A, Spreeuwenberg MD, Paulus WJ, van Hinsbergh VW, Visser FC, Niessen HW. Pulmonary embolism causes endomyocarditis in the human heart. *Heart*. 2008 Apr;94(4):450-6.

van der Bilt IA, Raaphorst J, Wouda EJ, Visser FC. Ischemic stroke mimicking acute myocardial infarction, a diagnostic dilemma. *Int J Cardiol*. 2006 Apr 28;109(1):127-8.

Van der Bilt IA, Visser FC. Neurogenic induced myocardial dysfunction. *Heart Metab*. 2004;24:27-30.

